


CRI-CIMT-EATI-AACR

FOURTH INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE: TRANSLATING SCIENCE INTO SURVIVAL

September 30-October 3, 2018
New York Marriott Marquis
New York, NY



POCKET PROGRAM

#CICON18

► Continuing Medical Education Activity-
AMA PRA Category 1 Credits™ available



TABLE OF CONTENTS

2	Welcome
4	Scientific Planning Committee
5	About the Partner Organizers
7	General Information
14	Continuing Medical Education (CME)
17	Site Maps
20	Supporters
21	Conference Schedule
33	Poster Session A
62	Poster Session B
87	Author Index
145	Invited Speaker Index
147	Subject Index

SAVE THE DATE

CRI-CIMT-EATI-AACR

Fifth International Cancer Immunotherapy Conference
September 25-28, 2019, Paris, France

About the Cover Image

Synovial sarcoma primarily strikes adolescents and young adults, with particularly devastating results. Vaccination trials show some promise, which implies that these sarcomas may be immunologically competent. *Cancer Immunology Research*, February 2017; 5(2).

WELCOME

Dear Colleagues,

On behalf of the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR), it is our pleasure to welcome you to New York City for the Fourth International Cancer Immunotherapy Conference: Translating Science into Survival. We are very pleased to continue to join forces in the sponsorship of this important conference series.

We are extremely grateful to the Conference Co-chairs, including Nina Bhardwaj and Elizabeth M. Jaffee, and the twelve members of the Scientific Planning Committee for their thoughtful insights and expert guidance during the past year of planning. The conference program that they have developed features the latest cutting-edge science in the field of cancer immunotherapy and offers time for thought-provoking discussions. The William B. Coley Lecture on Sunday afternoon will be delivered by Padmanee Sharma of the University of Texas MD Anderson Cancer Center, and the keynote address on Monday morning will be delivered by Ignacio Melero of the Universidad de Navarra, University Clinic and CIMA. Eight general scientific sessions throughout the meeting will address all major areas of cancer immunology and immunotherapy.

More than 400 abstracts will be presented during two poster sessions that will be held in the New York Marriott Marquis, and 16 proffered abstracts will be presented as short talks during thematic scientific sessions. We hope you will use the time during the poster sessions, group meals, and receptions to network with colleagues and establish new collaborations.

We extend our profound thanks to the following organizations for their dedication to this growing field and for their financial support of this conference: Silver Supporters: Amgen; Bristol-Myers Squibb; GlaxoSmithKline (conference charging stations); Janssen Research & Development, LLC; Juno Therapeutics; and Lilly Oncology; Supporter: AbbVie (meeting app); and AbbVie; AstraZeneca; Celgene; Lilly; Merck; Novartis; and Pfizer for their professional educational grants.



Thank you for joining us. We look forward to your active participation during the next few days. Please also note the dates of next year's meeting, which will be presented in Paris, France, on September 25-28, 2019.


With best wishes for an outstanding meeting,




Jill O'Donnell-Tormey, PhD
Chief Executive Officer
and Director of
Scientific Affairs
CRI



Christoph Huber, MD
President
CIMT



Guido Kroemer, MD, PhD
Founding Director
EATI



Margaret Foti, PhD, MD (hc)
Chief Executive Officer
AACR



SCIENTIFIC PLANNING COMMITTEE

CONFERENCE COCHAIRS

Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY

Christoph Huber, Association for Cancer Immunotherapy (CIMT), Mainz, Germany

Elizabeth M. Jaffee, Johns Hopkins University School of Medicine, Baltimore, MD

Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France

PLANNING COMMITTEE MEMBERS

Carl G. Figdor, Radboud University Nijmegen, Nijmegen, The Netherlands

Wolf H. Fridman, Centre de Recherche des Cordeliers, Paris, France

Crystal L. Mackall, Stanford University School of Medicine, Stanford, CA

Cornelis J.M. Melief, Leiden University Medical Center & ISA Pharmaceuticals, Leiden, The Netherlands

Drew M. Pardoll, Johns Hopkins University School of Medicine, Baltimore, MD

Ellen Puré, University of Pennsylvania, Philadelphia, PA

Catherine Sautès-Fridman, Université Paris-Descartes, Paris, France

Ton Schumacher, The Netherlands Cancer Institute, Leiden, The Netherlands

Giorgio Trinchieri, National Cancer Institute, Bethesda, MD

Özlem Türeci, Ganymed Pharmaceuticals, Mainz, Germany

Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY

Laurence Zitvogel, Institut Gustave Roussy, Paris, France

ABOUT THE PARTNER ORGANIZERS



CANCER
RESEARCH
INSTITUTE

CANCER RESEARCH
INSTITUTE

Cancer Research Institute (CRI), founded in 1953 to foster the science of cancer immunology, is the world's leading nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. CRI funds the most innovative clinical and laboratory research around the world, supports the next generation of the field's leaders, and serves as the trusted source of information on immunotherapy for cancer patients and their caregivers.



CIMT THE ASSOCIATION FOR
CANCER IMMUNOTHERAPY

The Association for Cancer Immunotherapy (CIMT) is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians, and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent nonprofit organization.

ABOUT THE PARTNER ORGANIZERS



THE EUROPEAN ACADEMY OF TUMOR IMMUNOLOGY

Since 2011 the principal objective of the European Academy of Tumor Immunology (EATI) is to promote tumor immunology at the scientific and clinical levels. EATI promotes all areas of tumor immunology, considered as a continuum between fundamental, translational, and clinical research, as well as the practical implementation of diagnostic and therapeutic procedures in routine clinical practice. EATI strives for excellence, independence, leadership, diversity, and flexibility. Throughout its work, EATI provides independent, authoritative and evidence-based advice to underpin policy for stimulating the implementation of concepts, methods, and procedures inspired by tumor immunology.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is the first and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attracts the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer. The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

GENERAL INFORMATION

LOCATION OF SESSION ROOMS AND OFFICES

New York Marriott Marquis

Conference Office: Cantor (Ninth Floor)

Conference Registration: Westside Ballroom Foyer (Fifth Floor)

General Session Room: Broadway Ballroom (Sixth Floor)

Press Room: Odets (Fourth Floor)

Speaker Preparation Room: O'Neill (Fourth Floor)

Continental Breakfast: Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Lunch: Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Breaks: Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Poster Sessions and Exhibits: Westside Ballroom (Fifth Floor)

CONFERENCE REGISTRATION

Westside Ballroom Foyer (Fifth Floor)

Saturday, September 29	5:00 p.m.-7:00 p.m.
Sunday, September 30	7:00 a.m.-6:15 p.m.
Monday, October 1	7:00 a.m.-6:15 p.m.
Tuesday, October 2	7:00 a.m.-6:15 p.m.
Wednesday, October 3	7:00 a.m.-12:00 p.m.

GENERAL INFORMATION

SPEAKER PREPARATION ROOM O'Neill (Fourth Floor)

Speakers must visit the Speaker Preparation Room at least one day prior to their presentations to confirm presentation order and load presentations. The room will be open on the following schedule:

Saturday, September 29	5:00 p.m.-7:00 p.m.
Sunday, September 30	7:00 a.m.-6:15 p.m.
Monday, October 1	7:00 a.m.-6:15 p.m.
Tuesday, October 2	7:00 a.m.-6:15 p.m.
Wednesday, October 3	7:00 a.m.-12:00 p.m.

CERTIFICATES OF ATTENDANCE AND RECEIPTS

Both certificates of attendance and receipts for conference registration fees are available at the conference Registration Desk. Certificates of attendance will also be sent by email after the conference.

ASSISTANCE FOR PHYSICALLY CHALLENGED REGISTRANTS

Registrants with special requirements should notify a member of the conference staff at the Registration Desk upon arrival at the conference.

INTERNET

Wireless Internet is available in the lobby, public spaces, and session rooms in the New York Marriott Marquis. To ensure everyone has access, please limit your connection time and only connect one device at a time.

BUSINESS CENTER

The New York Marriott Marquis's FedEx Business Center is located on the Eighth Floor, to the left of the check-in counter/front desk. The hours of operation are 7:00 a.m. to 7:00 p.m. Monday-Friday, and 8:00 a.m. to 5:00 p.m. on Saturday-Sunday.

POSTER SESSIONS AND EXHIBITS **Westside Ballroom (Fifth Floor)**

Poster Sessions and Exhibits will be held on the following schedule:

Poster Session A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Poster Set-Up for Session A

7:00 a.m.-11:45 a.m.

(Posters should be removed by 7:00 p.m.)

Poster Session B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Poster Set-Up for Session B

7:00 a.m.-12:45 p.m.

(Posters should be removed by 7:00 p.m.)

We suggest that presenters take the first half hour of the poster session for their lunch. Presenters with an odd number poster board should stand by their poster for the first hour after the half-hour lunch; presenters with an even number should stand by their posters for the second hour after the half-hour lunch.

Exhibits

Sunday, September 30- 10:00 a.m.-5:00 p.m.

Tuesday, October 2

Wednesday, October 3 10:00 a.m.-1:00 p.m.

GENERAL INFORMATION

SATELLITE EDUCATIONAL SYMPOSIA

Two Satellite Educational Symposia will be held in conjunction with the CRI-CIMT-EATI-AACR Fourth International Cancer Immunotherapy Conference. These CME-accredited events are supported by parties other than the meeting organizers and are not part of the official program of the conference. Symposia were evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official scientific program. There is no cost to attend these symposia.

Follow that Biomarker: Biomarker Testing to Optimize Immunotherapies for Cancer

Monday, October 1, 2018

6:00 a.m.-6:30 a.m.	Breakfast and Registration Broadway Ballroom Foyer (Sixth Floor)
6:30 a.m.-8:00 a.m.	Program Broadway Ballroom (Sixth Floor)

Improving Patient Outcomes with Cancer Immunotherapies throughout the Lung Cancer Continuum: State of the Science and Implications for Practice

Tuesday, October 2, 2018

6:00 a.m.-6:30 a.m.	Breakfast and Registration Broadway Ballroom Foyer (Sixth Floor)
6:30 a.m.-8:00 a.m.	Program Broadway Ballroom (Sixth Floor)

To view more information or register for any of these symposia, visit www.cancerimmunotherapyconference.org.



EXHIBITING COMPANIES

(as of 9/5/18)

American Association for Cancer Research

The Association for Cancer Immunotherapy

Bristol-Myers Squibb

Cancer Research Institute

Caprion

Celetrix

The European Academy of Tumor Immunology

Genentech USA, Inc.

Immudex

MBL International Corporation

StemImmune LLC

Studylog Systems, Inc.

BREAKS AND MEALS

Breaks and meals are for registered conference attendees, only. Please wear your conference badge at all times.

Times and locations are subject to change; please look for additional signage.

Continental breakfast for all attendees will be served in the Westside Ballroom (Fifth Floor) and the Broadway Ballroom Foyer (Sixth Floor) on the following schedule:

Sunday, September 30 7:30 a.m.-8:30 a.m.

Monday, October 1-
Wednesday, October 3 7:15 a.m.-8:15 a.m.

On Monday and Tuesday, an early continental breakfast will be available from 6:00 a.m. to 7:15 a.m. in conjunction with the Satellite Educational Symposia.

GENERAL INFORMATION

Lunch and Poster Sessions: Lunch will be served in the Westside Ballroom (Fifth Floor) and the Broadway Ballroom Foyer (Sixth Floor):

Sunday, September 30 11:45 a.m.-2:15 p.m.

Monday, October 1 12:45 p.m.-2:15 p.m.
(Lunch Only)

Tuesday, October 2 12:45 p.m.-3:15 p.m.

Breaks: All breaks will be held in the Westside Ballroom (Fifth Floor) and the Broadway Ballroom Foyer (Sixth Floor) on the following schedule:

Sunday, September 30 9:45 a.m.-10:15 a.m.
 4:15 p.m.-4:45 p.m.

Monday, October 1 10:15 a.m.-10:45 a.m.
 4:15 p.m.-4:45 p.m.

Tuesday, October 2 10:15 a.m.-10:45 a.m.
 4:45 p.m.-5:15 p.m.

Wednesday, October 3 10:15 a.m.-10:45 a.m.

PRESS/MEDIA RELATIONS

There will be a room for media at the conference. It is located in Odets (Fourth Floor) in the Marriott Marquis New York. The media representatives who can assist you are Julia Gunther (770-403-7690, julia.gunther@aacr.org); Rachel Salis-Silverman (267-970-3685, rachel.silverman@aacr.org); Rick Buck (856-562-5668, rick.buck@aacr.org); and Christiana Pascale (215-915-2550, cpascale@w2ogroup.com); and Brian Brewer (917-676-0871, bbrewer@cancerresearch.org).

SOCIAL MEDIA


While we encourage your use of social media in and around the conference, we ask that you be aware of the following guidelines:

- Follow the conference organizers on Twitter (@CancerResearch, @C_IMT, and @AACR) and use the hashtag #cicon18 for this conference.

- Conference attendees may share information from presentations on social media provided that they respect the wishes of presenters. Oral presenters may label any or all slides in their presentations with “DO NOT POST.” Similarly, poster presenters may label their posters with “DO NOT POST.” Attendees must respect the presenters’ requests in these instances and refrain from posting any images from these designated slides or posters on social media.

MEETING POLICIES AND PROCEDURES

- Conference attendees may take photographs during oral or poster presentations provided that the photographs are strictly for personal, noncommercial use and are not to be published in any form. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience.
- The New York Marriott Marquis is 100% smoke-free; smoking within the hotel is prohibited.
- Children under 12 years of age are not permitted in any scientific session or poster session at any time. Children cannot be left unattended or unsupervised.
- Cell phones, pagers, and other electronic devices must be turned off or placed on “silent” mode before entering a session.
- Lost and Found: Attendees may contact the conference Registration Desk for any lost items.
- Poster presenters are solely responsible for placing their poster on the assigned poster board and removing their poster according to the schedule provided. The conference organizers cannot be responsible for any posters that are not removed at the designated time. Posters left in the Poster Hall after that time may be discarded.
- Poster presenters should not leave any items at their poster board unattended, including poster tubes, meeting bags, Programs, personal items, etc. The conference organizers are not responsible for any items left in the Poster Hall.



CONTINUING MEDICAL EDUCATION (CME)

ACCREDITATION STATEMENT

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

CREDIT DESIGNATION STATEMENT

AACR has designated this live activity for a maximum of 23.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

CLAIMING (CME) CREDIT

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Wednesday, November 14, 2018. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.


STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVES

An estimated 1,735,350 new cancer cases will be diagnosed in 2018 in the United States, and 609,640 people will die from the disease. Continued efforts are needed to identify new strategies and therapeutic options to improve patient survival and quality of life.



Immunotherapy is a promising area that takes advantage of the body's natural defenses to fight cancer. Scientists are discovering novel therapeutic strategies to harness the power of the immune system to specifically target tumor cells or to counteract immunosuppressive signals for improved regression and complete remission for cancer patients. New technologies have greatly enhanced our understanding of immune surveillance, vastly contributing to the development of novel immunotherapies. To further improve the prognosis and outcome of subsequent therapies, it is extremely important to understand the interaction of tumor cells with their microenvironment. Adoptive cell therapy (ACT) continues to gain traction, and chimeric antigen receptor (CAR)-modified T cells have shown clinical successes in hematopoietic malignancies. Cancer vaccines are also being developed to both treat and prevent certain cancers. Monoclonal antibodies and checkpoint inhibitors are being used to fight many types of cancer, with 25 monoclonal antibodies and 6 checkpoint inhibitors approved by the FDA. Combination and targeted therapies are promising and active areas of research as researchers learn how to predict an individual's response to treatment. Importantly, as individualized therapy becomes more prevalent, researchers and physicians can utilize technology—to analyze and alter single cells—to aid more patients, faster.

To develop more effective therapies for a broader range of cancer types, it is essential to provide a venue for researchers, physician scientists, and all stakeholders to meet, share novel findings, and have an active exchange of ideas. This joint meeting will provide an unparalleled opportunity for teaching, learning, and networking. The potential of immune-based therapeutics will be fully explored, and successes in clinical trials and clinical trial design will be discussed. This conference will stimulate discussions and an active exchange of scientific ideas for the development of more effective therapies for a broader range of cancer types.



CONTINUING MEDICAL EDUCATION (CME)

After participating in this CME activity, physicians should be able to:

- 1) Describe the principles of cancer immunotherapy, the value of combination therapy, and mechanisms of new immunotherapy drugs
- 2) Articulate how checkpoint blockade is being used in a therapeutic setting
- 3) Assess the contribution of the tumor microenvironment, cancer cell metabolism, and the microbiome in tumor progression, immunosuppression, and growth
- 4) Articulate how recent advances in genetic engineering are contributing to personalized cancer immunotherapy
- 5) Identify mechanisms involved in the biology of vaccination
- 6) Evaluate genomic methods for identifying tumor antigens and predicting response to immunotherapy
- 7) Utilize technology to aid in cancer cell characterization and immunotherapy

DISCLOSURE STATEMENT

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the meeting app and conference website.

ACKNOWLEDGMENT OF FINANCIAL OR OTHER SUPPORT


This activity is supported by grants and will be disclosed at the activity.

QUESTIONS ABOUT CME?

Please contact the Office of CME at 215-440-9300 or cme@aacr.org.


SITE MAPS

FOURTH FLOOR




SITE MAPS

FIFTH FLOOR



SIXTH FLOOR





SUPPORTERS*

SILVER SUPPORTERS

Amgen

Bristol-Myers Squibb

GlaxoSmithKline[†]

Janssen Research & Development, LLC

Juno Therapeutics

Lilly Oncology

SUPPORTER

AbbVie[‡]

PROFESSIONAL EDUCATIONAL GRANTS

AbbVie

AstraZeneca

Celgene

Lilly

Merck

Novartis

Pfizer

*As of September 11, 2018

[†]Charging Stations

[‡]Meeting App

CONFERENCE SCHEDULE

SUNDAY, SEPTEMBER 30, 2018

8:30 a.m.-8:45 a.m.

Welcome

Broadway Ballroom (Sixth Floor)

Jill O'Donnell-Tormey, Cancer Research Institute,
New York, NY

8:45 a.m.-11:45 a.m.

Session 1: Regulating T Cells and Their Response to Cancer

Broadway Ballroom (Sixth Floor)

Session Chair: Christoph Huber, Association for Cancer Immunotherapy (CIMT), Mainz, Germany

8:45 a.m. **T-cell exhaustion and PD-1 therapy**

Rafi Ahmed, Emory University,
Atlanta, GA

9:15 a.m.

Tissue resident memory cells: At the center of tumor control

Christian Ottensmeier, University of Southampton, Southampton, United Kingdom

9:45 a.m.

Refreshment Break

Broadway Ballroom Foyer (Sixth Floor)
and Westside Ballroom (Fifth Floor)

10:15 a.m.

Genetic screens for immunotherapy target discovery

W. Nicholas Haining, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m.

Dysfunction and stemness of tumor-infiltrating T cells are triggered by a common mechanism

Nicholas P. Restifo, National Cancer Institute, NIH, Bethesda, MD

CONFERENCE SCHEDULE

Session 1 (*cont'd*)

11:15 a.m.

PR1 Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients*

Roberta Zappasodi, Memorial Sloan Kettering Cancer Center, New York, NY

11:30 a.m.

PR2 Neoadjuvant immunotherapy precancer surgery relieves tumor-specific CD8+ T-cell dysfunction and restores memory differentiation potential*

Jake S. O'Donnell, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

11:45 a.m.-2:15 p.m.

Lunch and Poster Session A and Exhibits

Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Clinical Trials of Cancer Immunotherapies

Genetically Engineered T Cells

Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Regulating T Cells and Their Response to Cancer

Tackling the Tumor Microenvironment - Beyond T Cells

2:15 p.m.-2:45 p.m.

William B. Coley Lecture

Broadway Ballroom (Sixth Floor)

From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy

Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX

*Short talk from proffered abstract

2:45 p.m.-6:15 p.m.

Session 2: Tackling the Tumor Microenvironment – Beyond T Cells

Broadway Ballroom (Sixth Floor)

Session Cochairs: Wolf H. Friedman, Centre de Recherche des Cordeliers, Paris, France, and **Dmitry Gabrilovich**, The Wistar Institute, Philadelphia, PA

2:45 p.m.	Stromal activation in cancer immunology and immunotherapy Shannon J. Turley, Genentech, South San Francisco, CA
3:15 p.m.	Using matrix protein affinity to modulate the tumor microenvironment Jeffrey A. Hubbell, University of Chicago, Chicago, IL
3:45 p.m.	The tumor myeloid microenvironment Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY
4:15 p.m.	Refreshment Break Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)
4:45 p.m.	Harnessing natural and engineered properties of NKT cells for cancer immunotherapy Leonid S. Metelitsa, Baylor College of Medicine, Houston, TX
5:15 p.m.	PMN-MDSC and neutrophils: Tale of two cells in cancer Dmitry Gabrilovich
5:45 p.m.	PR3 Immune-based classification of soft-tissue sarcoma is associated with clinical outcome and unveils tertiary lymphoid structures as surrogate biomarker for the clinic* Wei-Wu Tom Chen, National Taiwan University Hospital, Taipei, Taiwan

*Short talk from proffered abstract

CONFERENCE SCHEDULE

Session 2 (*cont'd*)

6:00 p.m.

PR4 A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments*

Kevin C. Barry, University of California, San Francisco, San Francisco, CA

MONDAY, OCTOBER 1, 2018

8:15 a.m.-8:45 a.m.

Keynote Address

Broadway Ballroom (Sixth Floor)

The immunotherapy faces of Interleukin-8 and CD137

Ignacio Melero, Universidad de Navarra, University Clinic and CIMA, Pamplona, Spain

8:45 a.m.-12:45 p.m.

Session 3: Genetically Engineered T Cells

Broadway Ballroom (Sixth Floor)

Session Cochairs: Crystal L. Mackall, Stanford University

School of Medicine, Stanford, CA, and **Jedd D. Wolchok**, Memorial Sloan Kettering Cancer Center, New York, NY

8:45 a.m.

CAR T-cell therapy for lymphoma and multiple myeloma

James N. Kochenderfer, National Cancer Institute, NIH, Bethesda, MD

9:15 a.m.

Engineering exhaustion-resistant CAR T cells

Crystal L. Mackall

9:45 a.m.

Cell transfer immunotherapy targeting unique somatic mutations in cancer

Steven A. Rosenberg, National Cancer Institute, NIH, Bethesda, MD

*Short talk from proffered abstract

10:15 a.m.	Refreshment Break Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)
10:45 a.m.	Advancing CAR T cell therapy for the treatment of brain tumors Christine E. Brown, City of Hope National Medical Center, Duarte, CA
11:15 a.m.	Novel approaches to CAR T-cell engineering Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY
11:45 a.m.	Utilizing synthetic biology and high-dimension probing to address therapeutic obstacles and empower engineered T cells with the capacity to eradicate tumors Philip D. Greenberg, Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA
12:15 p.m.	PR5 T cells engineered to overcome death signaling within the tumor microenvironment enhance adoptive cancer immunotherapy* Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, New York, NY
12:30 p.m.	PR6 Dual-specific T cells and an indirect vaccine eradicate large solid tumors* Clare Y. Slaney, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

**12:45 p.m.-2:15 pm.
Lunch and Exhibits**

Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

*Short talk from proffered abstract

CONFERENCE SCHEDULE

2:15 p.m.-5:45 p.m.

Session 4: Maintenance of Immune Balance: Effects of Targeted and Immune Therapies

Broadway Ballroom (Sixth Floor)

Session Cochairs: Catherine Sautès-Fridman, Université Paris-Descartes, Paris, France, and **Ellen Puré**, University of Pennsylvania, Philadelphia, PA

- | | |
|-----------|--|
| 2:15 p.m. | Inactivation of DNA repair to improve immune surveillance
Alberto Bardelli, University of Turin and Candiolo Cancer Institute, Candiolo, Italy |
| 2:45 p.m. | CAR T cells: On the road to a cure
David L. Porter, University of Pennsylvania, Philadelphia, PA |
| 3:15 p.m. | Targeting the immune microenvironment in breast cancer
Peter Savas, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia |
| 3:45 p.m. | RNA-editing derived epitopes function as cancer antigens to elicit immune responses
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 4:15 p.m. | Refreshment break
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor) |
| 4:45 p.m. | Autoimmune rheumatic diseases and cancer
Antony Rosen, Johns Hopkins University School of Medicine, Baltimore, MD |
| 5:15 p.m. | PR7 Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone mice*
Arabella Young, University of California San Francisco, San Francisco, CA |

*Short talk from proffered abstract

5:30 p.m.	PR8 Mechanisms of primary resistance to PD-1 checkpoint blockade* Michelle Krosgaard, NYU School of Medicine, New York, NY
-----------	--

TUESDAY, OCTOBER 2, 2018

8:15 a.m.-12:45 p.m.

Session 5: Novel Vaccine Platforms and Combinations

Broadway Ballroom (Sixth Floor)

Session Cochairs: **Nina Bhardwaj**, Icahn School of Medicine at Mount Sinai, New York, NY, and **Cornelis J.M. Melief**, Leiden University Medical Center and ISA Pharmaceuticals, Leiden, The Netherlands

8:15 a.m.	High-dimensional analysis of effective cancer immunotherapy driven by MHC-I and MHC-II neoepitopes Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO
8:45 a.m.	Personalized cancer immunotherapy Ugur Sahin, BioNTech, Mainz, Germany <i>(not eligible for CME credit)</i>
9:15 a.m.	Targeting tumor neoantigens to drive effective tumor immunity Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA
9:45 a.m.	Combination immunotherapy of cancer caused by human papilloma virus Cornelis J.M. Melief
10:15 a.m.	Refreshment Break Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

*Short talk from proffered abstract

CONFERENCE SCHEDULE

Session 5 (*cont'd*)

10:45 a.m.	Oncolytic viruses: Potential for in situ antitumor vaccination and combination with checkpoint blockade Alan Melcher, The Institute of Cancer Research, London, United Kingdom
11:15 a.m.	Nanodisc platform technology for cancer vaccination James J. Moon, University of Michigan, Ann Arbor, MI
11:45 a.m.	Peptide-TLR-7/8 agonist conjugate vaccines chemically programmed for nanoparticle self-assembly to enhance the magnitude and breadth of anticancer neoantigen CD8 T cell immunity Robert Seder, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
12:15 p.m.	PR9 Intratumoral delivery of engineered modified vaccinia virus Ankara expressing Flt3L and OX40L for in situ therapeutic cancer vaccination* Liang Deng, Memorial Sloan Kettering Cancer Center, New York, NY
12:30 p.m.	PR10 Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy* Elizabeth C. Evans, Vaccinex, Inc., Rochester, NY

12:45 p.m.-3:15 p.m.

Lunch and Poster Session B and Exhibits

Westside Ballroom (Fifth Floor) and Broadway Ballroom Foyer (Sixth Floor)

Convergence of Technology and Cancer Immunotherapy

Microbiome and Metabolism

*Short talk from proffered abstract

Mutational Analysis and Predicting Response to Immunotherapy

Novel Vaccine Platforms and Combinations

Trials in Progress

Other

3:15 p.m.-6:45 p.m.

Session 6: Mutational Analysis and Predicting Response to Immunotherapy

Broadway Ballroom (Sixth Floor)

Session Cochairs: Drew M. Pardoll, Johns Hopkins University School of Medicine, Baltimore, MD, and **Ton N. Schumacher**, Netherlands Cancer Institute, Amsterdam, The Netherlands

3:15 p.m. **T-cell recognition in human cancer**
Ton N. Schumacher

3:45 p.m. **Measuring the emergence of non-self in tumors**
Benjamin D. Greenbaum, Icahn School of Medicine at Mount Sinai, New York, NY

4:15 p.m. **Application of TMB in the clinic to predict response to immunotherapy**
Naiyer Rizvi, Columbia University Medical Center, New York, NY

4:45 p.m. **Refreshment break**
Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

5:15 p.m. **Cancer genetics and response to immunotherapy**
Drew M. Pardoll

5:45 p.m. **Mapping immune recognition of non-self neoantigens in human pancreatic cancer**
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY

CONFERENCE SCHEDULE

Session 6 (cont'd)

6:15 p.m.

PR11 CX3CR1+CD8+ T cells are responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade*

Yiyi Yan, Mayo Clinic College of Medicine, Rochester, MN

6:30 p.m.

PR12 Functional identification and therapeutic targeting of tumor neoantigens*

Stephen Philip Schoenberger, La Jolla Institute for Allergy and Immunology, La Jolla, CA

WEDNESDAY, OCTOBER 3, 2018

8:15 a.m.-10:45 a.m.

Session 7: Convergence of Technology and Cancer Immunotherapy

Broadway Ballroom (Sixth Floor)

Session Cochairs: Carl G. Figdor, Radboud University Nijmegen, Nijmegen, The Netherlands, and **Özlem Türeci**, Ganymed Pharmaceuticals, Mainz, Germany

8:15 a.m.

Determinants of effective tumor immunity

Nir Hacohen, Massachusetts General Hospital and Broad Institute, Cambridge, MA

8:45 a.m.

Microengineered physiologic biomimicry: Human organs-on-chips

Dan Dongeun Huh, University of Pennsylvania, Philadelphia, PA

*Short talk from proffered abstract

9:15 a.m.	Enhancing the function of CAR T cells via a universal vaccine strategy Darrell Irvine, MIT/Koch Institute for Integrative Cancer Research, Cambridge, MA
9:45 a.m.	PR13 A new high-performance HLA ligand identification strategy enables prediction of T-cell tolerance to neoepitopes* Martin G. Klatt, Memorial Sloan Kettering Cancer Center, New York, NY
10:00 a.m.	PR14 Identification of specificity TCR groups of tumor antigen-specific T cells* Liang Chen, Stanford University, Stanford, CA
10:15 a.m.	Refreshment break Broadway Ballroom Foyer (Sixth Floor) and Westside Ballroom (Fifth Floor)

10:45 a.m.-12:45 p.m.

Session 8: Microbiome and Metabolism

Broadway Ballroom (Sixth Floor)

Session Cochairs: Guido Kroemer, Centre de Recherche des Cordeliers, Paris, France, and **Laurence Zitvogel**, Institut Gustave Roussy, Paris, France

10:45 a.m.	Manipulating the gut microbiome to improve immunotherapy of melanoma Hassane M. Zarour, University of Pittsburgh School of Medicine, Pittsburgh, PA
11:15 a.m.	Targeting the gut and tumor microbiome in response and toxicity to cancer therapy Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

*Short talk from proffered abstract

CONFERENCE SCHEDULE

Session 8 (*cont'd*)

11:45 a.m.

Control of tissue immunity and repair by the microbiome

Yasmine Belkaid, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

12:15 p.m.

PR15 The oncometabolite R-2-hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via Aryl Hydrocarbon Receptor signaling*

Mirco Friedrich, German Cancer Research Center (NI), Heidelberg, Germany

12:30 p.m.

PR16 Mucosal-associated invariant T cells respond to the cutaneous microbiota and promote skin immunity*

Michael G. Constantinides, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

12:45 p.m.-1:00 p.m.

Closing Remarks

Broadway Ballroom (Sixth Floor)

Margaret Foti, American Association for Cancer Research, Philadelphia, PA

1:00 p.m.

Meeting Ends

*Short talk from proffered abstract

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A001 Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors. Yu Akazawa, Ako Hosono, Toshiaki Yoshikawa, Hide Kaneda, Junichi Hara, Yoshiaki Kinoshita, Kenichi Kohashi, Atsushi Manabe, Yoko Shioda, Kayoko Shoda, Manami Shimomura, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura.

A002 Autologous T-cells transduced with the affinity enhanced NY-ESO-1c259TCR in patients with synovial sarcoma expressing low levels of the NY-ESO-1 antigen. Dejka Araujo, Sandra P. D'Angelo, George Demetri, Mihaela P. Druta, John Glod, Warren A Chow, William D. Tap, Joana Senra, Rachel Abbott, Erin Van Winkle, Karen Chagin, Miguel Maroto, Elliot Norry, Malini Iyengar, Trupti Trivedi, Andrew Gerry, Rafael Amado, Crystal Mackall.

A003 Safety and preliminary efficacy of ACTR707, autologous T lymphocytes expressing an antibody-coupled T cell receptor, in combination with rituximab in subjects with relapsed or refractory CD20-positive B-cell lymphoma. Veronika Bachanova, Jonathon Cohen, Luke Akard, Samantha Jaglowski, Jessica Sachs, Ann Ranger, Patricia Harris, Kathleen McGinness, Greg Motz, Ian Flinn.

A004 HER2 cancer vaccine phase I clinical trial shows clinical benefit in 45% of evaluable patients. Jay A. Berzofsky, Lauren V. Wood, Hoyoung Maeng, Jane V. Trepel, David Stroncek, John C. Morris.

A005 A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. Ana B. Blazquez, Alex Rubinsteyn, Julia Kodysh, John P. Finnigan, Thomas Marron, Rachel L. Sabado, Marcia Meseck, Timothy J. O'Donnell, Jeffrey Hammerbacher, Michael Donovan, John Holt, Milind Mahajan, John Mandeli, Krysztof Misiukiewicz, Eric M. Genden, Brett A. Milles, Hooman Khorasani, Peter R. Dottino, Hanna Irie, Amy B. Tiersten, Elisa R. Port, Andrea S. Wolf, Hearn J. Cho, Ashutosh Tewari, Samir S. Parekh, Sujit Nair, Matthew D. Galsky, William K. Oh, Sacha Gnjatic, Eric E. Schadt, Phillip A. Friedlander, Nina Bhardwaj.

A006 Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors. Margaret K. Callahan, Kunle Odunsi, Mario Sznol,

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok.

A007 Comparison of pre-treatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T cells in patients with

synovial sarcoma. George Demetri, Dejka Araujo, Brian A. Van Tine, George Demetri, Mihaela Druta, John Glod, Warren A. Chow, Stephan Grupp, Alibiruni Abdul Razak, William D. Tap, Breelyn Wilky, Erin Van Winkle, Elliot Norry, Samik Basu, Karen Chagin, Malini Iyengar, Trupti Trivedi, Rafael Amado, Crystal Mackall.

A008 Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update. Shilpa Gupta, Christopher J. Weight, Neeraj Agarwal, Sumati Gupta, Badrinath Konety, Ewan Gibb, Elai Davicioni, Bharat Thyagarajan, Guru Sonpavde.

A009 Forty-three-week follow-up of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients. Jonathan F. Head, Gregory A. Daniels, Michelle McKinney, Jessica A. Wang-Rodriguez.

A010 Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading. Zhuting Hu, Donna Leet, Siranush Sarkizova, Rebecca Holden, Jing Sun, Susan Klaeger, Karl R. Clouser, Sachet A. Shukla, Wandi Zhang, Steven A. Carr, Edward F Fritsch, Bradley L. Pentelute, Nir Hacohen, Derin B. Keskin, Patrick A. Ott, Catherine J. Wu.

A011 First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors: Safety, activity, and immune responses. Filip Janku, Mrinal Gounder, Abdul Mohammad Pezeshki, Ravi Murthy, Andrea Wang-Gillam, Dale Shepard, David S. Hong, Sarina A. Piha-Paul, Anjali Raina, Alexey A. Leontovich, Gary DeCrescenzo, Brent L. Kreider, David Tung, Mary Varteresian, Halle H. Zhang, Khashayarsha Khazaie.

A012 SV-BR-1-GM, a whole-cell targeted immunotherapy for advanced breast cancer: Pharmacodynamic markers of response. Markus D. Lacher, Sanne Graeve, Vivekananda (Vivek) Sunkari, Daniel L. Adams, Cha-Mei Tang, Charles L. Wiseman, George E. Peoples, and William V. Williams.

A013 Haploididential stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma. Peter Lang, Tim Flaadt, Martin Ebinger, Patrick Schlegel, Holger Lode, Ruth Ladenstein, Anne-Marie Lang, Peter Ambross, Juergen Schaefer, Joerg Fuchs, Hans Loibner, Wolfgang Schwinger, Rupert Handgretinger.

A014 Phase I clinical trial with PD-1/MUC1 CAR-pNK92 immunotherapy. Qiao Li, Yi Wang, Ming Lin, Leiming Xia, Yangyi Bao, Xiang Sun, Lin Yang.

A015 Cellular immunonitoring for personalized adoptive cellular therapy trial ACTolog® (IMA101-101). Regina Mendrzyk, Alexander Ulges, Thorsten Demberg, Geoffrey Stephens, Carsten Reinhardt, Steffen Walter, Dominik Maurer.

A016 PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients. Martin Oft, Aung Naing, Jeffrey R. Infante, Kyriakos Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, John B. Mumm, Matthew Adamow, Scott McCauley, Rakesh Verma, Phillip Wong, Peter VanVlasselaer, Joseph Leveque, Nizar M. Tannir.

A017 Immunologic efficacy of heat shock protein 105 peptide vaccine in patients with advanced colorectal and esophageal cancer. Yasuhiro Shimizu, Toshiaki Yoshikawa, Kojima Takashi, Kayoko Shoda, Kazuto Nosaka, Shoichi Mizuno, Satoshi Wada, Yuki Fujimoto, Tetsuro Sasada, Kenichi Kohashi, Hideaki Bando, Itaru Endo, Tetsuya Nakatsura.

A018 Effects of Toca 511 and Toca FC on tumor microenvironment and peripheral blood populations in patient with advanced malignancies. Jaime Merchan, Jordi Rodon, Derek Ostertag, Shree Venkat, Arthur Donahue, Peder Horner, Dalissa Tijera, Thian Kheoh, Douglas J. Jolly, Harry E. Gruber, Jolene S. Shorr, Gerald S. Falchook.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A019 Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies.

Jun Tang, Laura Pearce, Jill O'Donnell-Tormey, Vanessa Hubbard-Lucey.

A020 Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. Alexander Ulges, Norbert Hilf, Wolfgang Wick, Michael Platten, Pierre-Yves Dietrich, Katrin Frenzel, Arie Admon, Sjoerd S.H. van der Burg, Andreas von Deimling, Per thor Straten, Cecile Gouttefangeas, Judith R. Kroep, Francisco Martínez-Ricarte, Hideo Okada, Christian H. Ottensmeier, Berta Ponsati, Hans S. Poulsen, Stefan Stevanovic, Ghazaleh Tabatabai, Hans-Georg Rammensee, Ugur Sahin, Dominik Maurer, Regina Mendlzyk.

A021 Vaccination with autologous, nonattenuated, live glioblastoma cells induces potent peripheral and intratumoral antitumoral responses: A first-in-human study. Ilan Volovitz, Nati Shapira, Rachel Grossman, Zvi Ram.

A022 Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC). Dmitriy Zamarin, Kunle Odunsi, Brian Slomovitz, Vanessa Hubbard-Lucey, Danielle McCabe, Lisa Shohara, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Anne-Kirsti Aksnes, Lukasz Kuryk, Ralph Venhaus.

A023 Highly-enriched memory stem T cell subsets (TSCM) expressing a novel CAR30 have enhanced antitumor effect in Hodgkin lymphoma. Carmen Alvarez-Fernández, Laura Escribà-Garcia, Ana Carolina Caballero, Jorge Sierra, Javier Briones.

A024 Identifying a T cell receptor for immunotherapy against a leukemia associated self-antigen in an allogeneic setting. Maxi-Lu Böschen, Weiwen Yang, Erlend Strønen, Johanna Olweus.

A025 Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and IL-15. Yuhui Chen, Chuang Sun, Leonid Metelitsa, Gianpietro Dotti, Barbara Savoldo.

A026 Novel electroporation method for quick CAR-T cell manufacture. Jian Chen, Xiaofeng Xia.

A027 Targeted insertion of an HPV-16 E7-specific engineered T cell receptor into the TRAC locus.

Alexandra Croft, Cameron Brandt, Stephen Burleigh, Eric Chadwick, Melissa Chin, Dean Toy, Bailey Donahue, Clay Patton, Stephen Goldfless, Brian Belmont, Ruth Salmon, Grant Welstead, Blythe D. Sather, David J. Huss.

A028 Memory stem T cells expressing an optimized CD30-specific chimeric antigen receptor (CAR) efficiently eradicate peripheral T-cell lymphoma in vivo.

Laura Escribà-Garcia, Carmen Alvarez-Fernández, Ana Carolina Caballero, Rydzek Julian, Einsele Hermann, Jorge Sierra, Michael Hudecek, Javier Briones.

A029 Unexpected antagonism between oncolytic virus derived type I interferon and EGFRvIII CAR T cells. Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, Jill L. Thompson, Timothy Kottke, John Sampson, Luis Sanchez Perez, Richard Vile.

A030 Identification of α -fetoprotein-specific T cell receptors for hepatocellular carcinoma immunotherapy. Yukai He, Wei Zhu, Yibing Peng, Lan Wang, Yuan Hong, Juan Wu, Esteban Celis.

A031 Engineering antigen density sensors for T cell immunotherapy. Rogelio A. Hernandez-Lopez, Wendell A. Lim, Wei Yu.

A032 Chimeric antigen receptor (CAR) targeted epitope determines optimal CAR spacer length for therapy against medulloblastoma. Adam J. Johnson, Cindy A. Chang, Michael L. Baldwin, Jason A. Yokoyama, Michael C.M. Jensen.

A034 High-throughput identification of naturally occurring T cell receptors with therapeutic potential against tumor-associated, viral and neoantigens. Mark Klinger, Peter Ebert, Edward Osborne, Ruth Taniguchi, Joyce Hu, Tim Hayes, Sharon Benzeno, Adria Carbo, Melanie Laur, Erica Eggers, Harlan Robins.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A035 Combinatorial IGK-CD19 CAR primarily targets IgK+ malignant B-cells and is less prone to serum IgG inhibition. Hakan Köksal, Pierre Dillard, Sólrún Melkorka Maggadóttir, Gunnar Kvalheim, Erlend Bremertun Smeland, June Helen Myklebust, Else Marit Inderberg, Sébastien Wälchli.

A036 Multiplex human T-cell engineering by Cas9 base editor technology. Cara Lonetree, Beau R. Webber, Miechaleen D. Diers, Walker R. Lahr, Mitchell Kluesner, Mark J. Osborn, Matthew J. Johnson, Branden S. Moriarity.

A037 A novel pharmacologic “ON/OFF” switch to modulate CAR-T cell function in vitro and in vivo. Katrin Mestermann, Rydzek Julian, Frenz Silke, Einsele Hermann, Michael Hudecek.

A038 Effective rerouting of NK cell cytotoxicity against B-cell malignancies upon TCR gene transfer. Laura T. Morton, Anne K. Wouters, Dennis F. Remst, Renate K. Hagedoorn, Marleen M. Van Loenen, Renate de Boer, J. H.F. Falkenberg, Mirjam H.M. Heemskerk.

A039 FAM49B-specific regulatory T cells recognize and target cancer cells in the context of Qa-1. Hidetoshi Nakagawa, Hye-Jung Kim, Harvey Cantor.

A040 Hijacking CAR19 T cells for use in targeting diverse hematopoietic and solid tumors. Paul Rennert, Fay Dufort, Lihe Su, Lan Wu, Alyssa Birt, Christine Ambrose, Roy Lobb.

A041 Hypoxia-responsive CAR T-cells. Tina Anna Sarén.

A042 A novel nonviral, nonintegrative DNA vector system for T-cell engineering. Patrick Schmidt, Matthias Bozza, Dirk Jaeger, Richard Harbottle.

A043 Anti-CD19 CAR T cells with a CRISPR/Cas9-mediated T-cell receptor knockout show high functionality in the absence of alloreactivity in vitro. Dana Stenger, Tanja Stief, Theresa Käuferle, Semjon Willier, Felicitas Rataj, Kilian Schober, Ramin Lotfi, Beate Wagner, Dirk H. Busch, Sebastian Kobold, Franziska Blaeschke, Tobias Feuchtinger.

A044 Mutated NPM1 as target for immunotherapy of acute myeloid leukemia. Dyantha I. van der Lee, Rogier M. Reijmers, M. Willy Honders, Renate M. Hagedoorn, Rob. M. de Jong, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Christiaan Kweekel, Inge Jedema, Hendrik Veelken, Mirjam M. Heemskerk, Peter A. van Veelen, J.H. Frederik Falkenburg, Marieke Griffioen.

A045 Chlorotoxin redirects T cells for specific and effective targeting against glioblastomas. Dongrui Wang, Vanessa Jonsson, Sarah Wright, Wen-Chung Chang, Xin Yang, Renate Starr, Alfonso Brito, Brenda Aguilar, Aniee Sarkissian, Lihong Weng, Stephen J Forman, Michael E Barish, Christine E. Brown.

A046 Retargeting NK92 cells using an anti-hPSMA specific chimeric antigen receptor. Gaia Zuccolotto.

A047/PR6 Dual-specific T cells and an indirect vaccine eradicate large solid tumors. Clare Y. Slaney, Bianca von Scheidt, Phillip K. Darcy, Michael Kershaw.

This abstract is also being presented as a proffered short talk (PR6) in Session 3.

A048 Targeting the tumor microenvironment to enhance immunotherapy against cancer. Clare Y. Slaney, Amanda J. Oliver, Michael H. Kershaw.

A049 Three-dimensional microfluidic platform mimicking the tumor microenvironment. Andrea Pavesi, Siew Cheng Wong, Roger Kamm, Sharon Wei Ling Lee, Giulia Adirani.

A050 Intratumoral delivery of a novel STING agonist synergizes with checkpoint blockade to regress multifocal pancreatic cancer. Casey R. Ager, Maria E. Di Francesco, Philip Jones, Michael E. Curran.

A051 Melanoma displays an evolutionarily conserved resistance to upregulation of prophagocytic signals and to CD47 blockade. Katie L. Anderson, Kristin M. Snyder, Daisuke Ito, Debra M. Lins, Lauren J. Mills, Kipp Weiskopf, Nan G. Ring, Aaron M Ring, Yoji Shimizu, Matthew F. Mescher, Irving L. Weissman, Jaime F. Modiano.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A052/PR4 A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor

microenvironments. Kevin C. Barry, Matthew F. Krummel.

This abstract is also being presented as a proffered short talk (PR4) in Session 2.

A053 Activated B cells in human primary tumors present antigen and increase antitumor function of CD4 T cells

in tertiary lymphoid structures. Tullia C. Bruno, Ayana T.

Ruffin, Anthony R. Cillo, Robert T. Ferris, Dario A.A. Vignali.

A054 Tumor cell intrinsic factors dictate immune cell infiltration and response to immunotherapy.

Katelyn T. Byrne, Jinyang Li, Robert H. Vonderheide, Ben Stanger.

A055 Lineage-tracing reveals a unique contribution of embryonic macrophages to NSCLC progression.

Maria Casanova.

A056 Incessant ER stress responses promote dendritic cell dysfunction in ovarian cancer.

Chang-Suk Chae.

A057 Imprime PGG, a systemically administered PAMP, mobilizes monocytes in the periphery, facilitates their trafficking to the tumor site and polarizes the tumor microenvironment (TME) to an immuno-active state.

Anissa S.H. Chan, Adria Bykowski Jonas, Nadine C. Ottoson, Xiaohong Qiu, Ben Harrison, Keith Gorden, Jamie Lowe, Mark Uhlik, Jeremy Graff, Nandita Bose.

A059 Tackling the tumor microenvironment with CD38 blockade to enhance cancer immunotherapy.

Limo Chen, Lixia Diao, Xiaohui Yi, Bertha Leticia Rodriguez, Yanli Li, Pamela Villalobos, Tina Cascone, Xi Liu, Lin Tan, Philip Lorenzi, Jared Fradette, David Peng, Ferdinandos Skoulidis, Youhong Fan, Jaime Rodriguez-Canales, Vassiliki Papadimitrakopoulou, Ethan Dmitrovsky, Lauren A Byers, Jing Wang, Ignasio Wistuba, Jim Heymach, Don Gibbons.

A060 Targeting glioma-macrophage interplay via LOX in PTEN-deficient glioblastoma.

Peiwen Chen, Alan Wang, Ronald DePinho.

A061 STING, an immune biomarker for colorectal cancer.

Hongjae Chon, Chan Kim.

A062 TIM-3 plays distinct roles in different immune cells to regulate antitumor immune responses. Jie Dai, Jerry Pei, Markus Mohrs, Gavin Thurston, Ella Ioffe.

A063 Multidimensional cytometric analysis of colorectal cancer reveals novel and diverse mediators of antitumor immunity. Noel F. de Miranda, Natasja L. de Vries, Vincent van Unen, Tamim L. Abdelaal, Marieke E. Ijsselsteijn, Ruud van der Breggen, Arantza Farina-Sarasqueta, Koen C.M.J. Peeters, Thomas Höllt, Boudewijn P.F. Lelieveldt, Frits Koning.

A065 Genome-scale CRISPR screens identify essential genes for tumor sensitivity to NK cells. Olli Dufva, Jay Klievink, Khalid Saeed, Matti Kankainen, Mette Ilander, Tiiina Hannunen, Sonja Lagström, Pekka Ellonen, Dean A Lee, Satu Mustjoki.

A066 Expanding insights into the colorectal cancer tumor proteome: Unbiased protein profiling reveals multiple proteomic-based tumor subtypes. Nicholas Dupuis, Jan Muntel, Roland Bruderer, Lukas Reiter.

A067 Cognate interaction with CD4+ T cells instructs M2-like macrophages to acquire M1-like phenotype. David Eisal, Wolfram Osen, Krishna Das, Franziska Marie-Claire Hoerhold, Rainer König, Stefan B. Eichmüller.

A068/PR10 Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy. Elizabeth E. Evans, Holm Bussler, Crystal Mallow, Christine Reilly, Sebold Torno, Maria Scrivens, Alan Howell, Leslie Balch, John E. Leonard, Terrence L. Fisher, Clint Allen, Paul Clavijo, Gregory Lesinski, Christina Wu, Siwen Hu-Lieskovan, Antoni Ribas, Emily Greengard, Ernest S. Smith, Maurice Zauderer.
This abstract is also being presented as a proffered short talk (PR10) in Session 5.

A069 NIM15 blockade – A new stroma-targeting approach for the treatment of epithelial ovarian cancer. Dyke Ferber, Meggy Suarez-Carmona, Frank Momburg, Marten Meyer, Rebecca Rothenheber, Bénédicte M.A. Lenoir, Sarah Schott, Inka Zoernig, Dirk Jäger, Niels Halama.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A070 Virotherapy eradicates established melanoma by reprogramming the tumor microenvironment and engaging the adaptive immunity. Lukas Flatz, Sandra Ring, David Bomze, Lucas Onder, Jovana Cupovic, Sarah Schmidt, Klaus Orlinger, Andrej Besse, Lenka Besse, Christoph Driessen, Hung-Wei Cheng, Alexander Lercher, Daniel Speiser, Tobias Bald, Andreas Bergthaler, Burkhard Ludewig.

A072 Calreticulin exposures by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Jitka Fucikova.

A073 CODEXTM: A novel platform for spatially-resolved deep antigen profiling of single cells in tissue samples. Maria Elena Gallina, Nadya Nikulina, Jaskirat Singh, Gajalakshmi Dakshinamoorthy, Joseph J Kim, Sejal Mistry, Julia Kennedy-Darling.

A074 Spatially-resolved deep antigen profiling of single cells in FFPE tissue samples through CODEXTM. Maria Elena Gallina, Jaskirat Singh, Nadya Nikulina, Gajalakshmi Dakshinamoorthy, Joseph J Kim, Sejal Mistry, Julia Kennedy-Darling.

A075 A protective role for group 3 innate lymphoid cells in colitis-associated colorectal cancer. Jeremy Goc, Nick Bessman, Sheena Sahota, Flamar Anne Laure, Gregory Putzel, David Withers, Janelle Arthur, Manish Shah, Gregory Sonnenberg.

A076 DSP107 -- A novel SIRP α -4-1BBL dual signaling protein (DSP) for cancer immunotherapy. Yosi M. Gozlan, Susan Hilgendorf, Alexandra Aronin, Yehudit Sagiv, Liat Ben-gigi-Tamir, Shira Amsili, Ami Tamir, Iris Pecker, Shirley Greenwald, Ayelet Chajut, Adam Foley-Comer, Yaron Pereg, Amnon Peled, Michal Dranitzki-Elhalel, Edwin Bremer.

A077 Microenvironmental factors shape resistance patterns to immune checkpoint blockade. Shengquing Stan Gu, Xihao Sherlock Hu, Xiaoqing Shawn Wang, Ziyi Li, Nicole Traugh, Xia Bu, Xiaofang Xing, Gordon Freeman, Myles Brown, Xiaole Shirley Liu.

A078 Dissecting the myeloid lineage in human gliomas.

Claudia Z. Han, Sascha H. Duttkie, Zhengyu Ouyang, Sebastian H. Preissl, Johannes C.M. Schlachetzki, Alexander Nott, Conor Fitzpatrick, Carolyn O'Connor, Nicole G. Coufal, Mihir Gupta, David D. Gonda, Michael L. Levy, Ben-Haim Sharona, Barba David, Joseph D. Ciacci, Alexander A. Khalessi, Clark C. Chen, Bing Ren, Christopher K. Glass.

A079 Secreted IL-12p70 from long-term activated dendritic cells is lost concomitant with their apoptosis and release of IL-10. Morten Hansen, Laura Stentoft Carstensen, Andreas Obers, Inge Marie Stentoft Svane.

A080 Cytokine-induced senescence in neuroblastoma cell lines – therapeutic option or idle wish? Theresa Harmuth, Florian Heubach, Thomas Wieder, Rupert Handgretinger, Peter Lang.

A081 Tumors expressing ACKR1 exhibit a unique signature of tumor-infiltrating immune cells in women with breast cancer. Brittany D. Jenkins, Talina Fleifel, Rachel Martini, Haythem Ali, Lisa Newman, Melissa Davis.

A082 Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance. Livnat Jerby, Parin Shah, Michael S. Cuoco, Christopher Rodman, Mei-Ju Su, Johannes M. Melms, Rachel Leeson, Abhay Kanodia, Shaolin Mei, Jia-Ren Lin, Shu Wang, Bokang Rabasha, David Liu, Gao Zhang, Claire Margolais, Orr Ashenberg, Patrick A Ott, Elizabeth I. Buchbinder, Riz Haq, Stephen Stephen Hodi, Genevieve M. Boland, Ryan J. Sullivan, Dennie Frederick, Benchun Miao, Tabea Moll, Keith Flaherty, Meenhard Herlyn, Russell S. Jenkins, Rohit Thummalapalli, Monika S. Kowalczyk, Israel Canadas, Bastian Schilling, Adam N.R Cartwright, Adrienne M. Luoma, Shruti Malu, Patrick Hwu, Chantale Bernatchez, Marie-Andree Forget, David A. Barbie, Alex K. Shalek, Itay Tirosh, Peter K. Sorger, Kai W. Wucherpfennig, Eliezer M. Van Allen, Dirk Schadendorf, Bruce E. Johnson, Asaf Rotem, Orit Rosenblatt-Rozen, Levi A. Garraway, Charles H. Yoon, Benjamin Izar, Aviv Regev.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A083 Inflammasome-independent IL-1 β release by myeloid cells promotes vessel destabilization and immune suppression in the tumor microenvironment.

Máté Kiss, Lieselotte Vande Walle, Helena Van Damme, Aleksandar Murgaski, Evangelia Bolli, Jiri Keirsse, Maria Solange Martins, Yvon Elkrim, Amelie Fossoul, Jens Serneels, Massimiliano Mazzone, Mohamed Lamkanfi, Jo A. Van Ginderachter, Damya Laoui.

A084 Towards combining androgen deprivation and immunotherapy to prevent progression to castration resistant prostate cancer. John J. Krolewski, Kai Sha, Michalis Mastri, Dean Tang, Kevin Eng, Kent L. Nastiuk.

A085 High infiltration of NK cells expressing elevated LAG-3 in a subgroup of renal cell carcinoma patients.

Moon Hee Lee, Petrus Järvinen, Harry Nisén, Oscar Brück, Mette Ilander, Satu Mustjoki, Kreutzman Anna.

A086 Omental fat in ovarian cancer induces lymphangiogenesis. Bénédicte M.A. Lenoir, Dyke Ferber, Victor Starrach, Meggy Suarez-Carmona, Sarah Schott, Inka Zoernig, Dirk Jäger, Niels Halama.

A087 The immunosuppressive property of mesenchymal stem cell in an apoptotic tumor microenvironment. Anita K.Y. Li, Carmen J.M. Cao, Godfrey C.F. Chan.

A088 Selective blockage of the innate immune checkpoint receptor CD47 on mesothelin (MSLN) positive solid tumor cells via dual targeting bispecific antibodies alters the tumor microenvironment to control tumor growth. Stefano Majocchi, Valéry Moine, Xavier Chauchet, Lucile Broyer, Laura Cons, Laurence Chatel, Eric Hatterer, Vanessa Buatois, Hasnaà Haddouk, Gérard Didelot, Giovanni Magistrelli, Yves Poitevin, Ulla Ravn, Anne Papaioannou, Françoise Richard, Limin Shang, Marie H. Kosco-Vilbois, Nicolas Fischer, Walter G. Ferlin, Krzysztof Masternak.

A089 The effect of lactate dehydrogenase-A (LDH-A) knockdown and human prostate-specific membrane antigen (hPSMA) directed CAR T cell treatment on hPSMA(+) Myc-CaP tumors. Mayuresh M. Mane, Khalid Shalaby, Ivan Cohen, Avi Albeg, Jenny Ijoma, Myat Ko, Masatomo Maeda, Kiranmayi Vemuri, Jaya Satagopan, Anna Moroz, Juan Zurita, Larissa Shenker, Ellen Ackerstaff, Masahiro Shindo, Ekaterina Moroz, Maxim A. Moroz, Inna Serganova, Jason Koutcher, Vladimir Ponomarev, Ronald G. Blasberg.

A090 The Duffy Antigen Receptor for Chemokines (DARC) influences levels of tumor-associated leukocytes in the breast tumor microenvironment. Rachel Martini, Brittany D. Jenkins, Clayton Yates, Lisa D. Newman, Melissa Davis.

A091 IL-33 activates antitumoral toxicity in eosinophils through stimulation of contact-dependent degranulation. Fabrizio Mattei, Carla Buccione, Sara Andreone, Francesca Spadaro, Adele De Ninno, Jacopo Mancini, Cristiana Zanetti, Isabella Parolini, Francesca Iosi, Antonella Tinari, Valeria Lucarini, Annamaria Gerardino, Giovanna Ziccheddu, Luca Businaro, Claudia Afferni, Giovanna Schiavoni.

A092 TAM receptors targeting unleashes antileukemic immunity and enables checkpoint blockade leading to eradication of leukemic cells. Hind Medyouf, Irene Tirado-Gonzalez, Aleksandra Nevmerzhitskaya, Arnaud Descot, Devona Soetopo, Ewelina Czlonka, Maresa Weitmann, Carolin Wachtel, Julia Slotta-Huspenina, Christine Tran-Quang, Katharina Götze, Emily Alberto, Carla Vanina Rothlin, Jacques Ghysdael, Hind Medyouf.

A093 Immune resistance emerges from tumor-initiating stem cells. Yuxuan Miao, Elaine Fuchs.

A094 Characterization of pancreatic cancer endothelial cells: Approaching to enhance immune cell infiltration for immunotherapy. Kosei Nakajima, Yashunori Ino, Toshimitsu Iwasaki, Nobuyoshi Hiraoka.

A095 Discovering the immune profiles of a novel anti-folate receptor alpha IgE antibody associated with monocyte-mediated antitumor functions. Mano Nakamura, Heather J. Bax, James F. Spicer, Katie J. Lacy, Sophia Tsoka, Debra H. Josephs, Sophia Karagiannis.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A096 The potential role of fibroblast activation protein as a natural killer cell immune checkpoint. Allison O'Connell, Shangzi Wang, Louis M. Weiner.

A097 Complement system mutations in cancer: Uncovering new relationships between tumor hypoxia and complement. Monica M. Olcina, Nikolas G. Balanis, Ryan K. Kim, Michael G. Thompson, Thomas G. Graeber, Amato J. Giaccia.

A098 SLC12A2 as a novel “brake” on immunogenic apoptotic cell clearance. Justin Shaun Arnold Perry, Sho Morioka, Christopher Medina, Michael Raymond, Kodi Ravichandran.

A099 Using high-throughput phenotypic screening to identify therapeutic targets for the inhibition of myeloid-derived suppressor cells. Elissaveta Petrova, Sandra Schäffner, Jan-Carsten Pieck, Christian Herhaus, Friedrich Rippmann, Oliver Pöschke, Laura Helming.

A100 ROBO2 is a stroma suppressor gene in the pancreas through regulation of TGF- β . Andreia V. Pinho, Mathias Van Bulck, Lorraine Chantrill, Mehreen Arshi, David Herrmann, Claire Vennin, APGI - Australian Pancreatic Cancer Genome Initiative, Anthony Gill, Paul Timpson, Andrew Biankin, Jianmin Wu, Ilse Rooman.

A101 IDO2 host genetic status influences progression and radiotherapy response in pancreatic ductal adenocarcinoma. George C. Prendergast, Avinoam Nevler, Alexander J. Muller, Erika Sutanto-Ward, James B. DuHadaway, Kei Nagatomo, Eric Londin, Kevin O'Hayer, Joseph A. Cozzitorto, Harish Lavu, Theresa P. Yeo, Mark Curtis, Tatiana Villatoro, Benjamin E. Leiby, Jordan M. Winter, Charles J. Yeo, Jonathan R. Brody.

A102 Rescue of lost skin dendritic cells in melanoma is key for the resuscitation of antitumor T cell responses. Anastasia Prokopi, Christoph H. Tripp, Bart Tummers, Kerstin H. Komenda, Katharina Hutter, Giuseppe Cappellano, Lydia Bellmann, Mirjana Efremova, Zlatko Trajanoski, Suzie Chen, Bjorn E. Clausen, Douglas R. Green, Patrizia Stoitzner.

A103 Allosteric inhibition of SHP2 induces antitumor immunity in PD-1-sensitive tumors through modulation of both innate and adaptive mechanisms. Elsa Quintana, Kasia Mordec, Robert J. Nichols, David Wildes, Chris J. Schulze, Darienne R. Myers, Mallika Singh, Elena Koltun, Adrian Gill, Stephen Kelsey, Mark A Goldsmith, Jan A.M. Smith.

A104 Matrix Metalloproteinase-2 and Toll-Like Receptors modulating immune responses in the tumor microenvironment. Luciana Rebiero Muniz-Bongers, Mansi Saxena, Nina Bhardwaj.

A106 Higher numbers of cancer stem cells in the peripheral blood of children with B-ALL after chemotherapy. Mohamed Labib Salem, Mohamed Attia, Said Abdou, Abdel-Aziz A. Zidan, Mona F. Zidan.

A109 Matrix metalloproteinase-2 stimulates Toll Like Receptor-2 on melanoma cells to induce immunosuppressive inflammation in the tumor microenvironment. Mansi Saxena, Keerthi Caroline Sadanala, Luciana Rebiero Muniz-Bongers, Nina Bhardwaj.

A110 Efficacy of anti-PD1 immune checkpoint blockade involves the cooperative interaction of myeloid and lymphoid subpopulations in the tumor microenvironment. Sjoerd Schetters, Yvette Van Kooyk.

A111 Effects of ionizing radiation on brain metastasis-associated inflammation and its implication for immunotherapy. Michael Schulz, Katja Niesel, Anna Salamero Boix, Woon Hyung Chae, Birgitta Michels, Alexander Schaeffer, Maja Strecker, Tijna Alekseeva, Stefan Stein, Henner Farin, Franz Roedel, Harter Patrick, Karlheinz Plate, Lisa Sevenich.

A112 OncoPeptTUME – A novel computational approach analyzes the tumor microenvironment to predict response to checkpoint inhibitors. Xiaoshan Shi, Malini Manoharan, Nitin Mandloi, Sushri Priyadarshini, Laxman Iyer, Rohit Gupta, Papia Chakraborty, Amitabha Chaudhuri, Ravi Gupta.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A113 Harnessing lymphoid organ neogenesis as a novel prognostic biomarker and therapeutic target. Karina Silina, Alex Soltermann, Chiara Burkhardt, Farkhondeh Movahedian Attar, Ruben Casanova, Alessandra Curioni-Fontecedro, Holger Moch, Florian Posch, Thomas Winder, Nick van Dijk, Charlotte Voskuilen, Michiel van der Heijden, Maries van den Broek.

A114 Omental fat in ovarian cancer induces metabolic and immune alterations. Meggy Suarez-Carmona, Nektarios A. Valous, Pornpimol Charoentong, Jakob A. Kather, Mareike Hampel, Bénédicte M.A. Lenoir, Dyke Ferber, Sarah Schott, Sabine Kess, Inka Zoernig, Dirk Jaeger, Niels Halama.

A115 Use of angiotensin system inhibitors is associated with immune activation and longer survival in pancreatic ductal adenocarcinoma patients. Nilesh P. Talele, Hao Liu, Kamila Naxerova, Matthias Pinter, Joao Incio, Hang Lee, Kohei Shigeta, William W. Ho, Theodoros Michelakos, Theodore S. Hong, Jeffrey W. Clark, Janet E. Murphy, David P. Ryan, Vikram Deshpande, Kieth D. Lillemoe, Carlos Fernandez-del Castillo, Michael Downes, Ronald M. Evans, James Michaelson, Dan G. Duda, Cristina R. Ferrone, Yves Bouches, Rakesh Jain.

A116 Lipid control of DNA-stimulated innate immunity. Xiaojun Tan, Conggang Zhang, Zhijian J. Chen.

A117 Tumor-produced IL-6 and IL-8 are associated with MDSC accumulation and correlate with long-term clinical outcomes in melanoma patients. Richard P. Tobin, Kimberly R. Jordan, Dana Davis, Victoria R. Vorwald, Kasey Couts, Dexiang Gao, Derek E Smith, William A Robinson, Virginia Borges, Martin D McCarter.

A118 Clinical impact of PD-L1 expression and epithelial-mesenchymal transition in the tumor microenvironment of extrahepatic cholangiocarcinoma. Takahiro Tsuchikawa, Takashi Ueno, Osamu Sato, Toru Nakamura, Yoshitsugu Nakanishi, Toshimichi Asano, Takehiro Noji, Keisuke Okamura, Toshiaki Shichinohe, Satoshi Hirano.

A119 Combating primary and secondary checkpoint blockade resistance using immunostimulatory CD40L/4-1BBL-encoding oncolytic virotherapy for melanoma. Jessica Wenthe, Mantas Šilanskas, Emma Eriksson, Angelica Loskog.

A120 Intratumoral dendritic cell dynamics in responsive and non-responsive syngeneic murine tumor models.

Huizhong Xiong, Stephanie Mittman, Ryan Rodriguez, Marina Moskalenko, Patricia Pacheco Sanchez, Yagai Yang, Rafael Cubas.

A121 Single-cell transcriptomic analyses reveal heterogeneity of vascular endothelial cells in cancer models. Yu Zhu, Nicole Salazar, Kevin Brulois, Eugene Butcher.

A122 Self-recognition of Alu duplex RNAs is the basis for MDA5-mediated interferonopathies. Sadeem Ahmad, Xin Mu, Sun Hur.

A123 Skewed CD4 and CD8 T cell differentiation in pancreatic cancer patients. Cecile Alanio, Bertram Bengsch, Josephine R. Giles, Sarah Henrickson, Nan Ping Weng, Janae A Ritz-Romeo, Mark O'Hara, Joseph J Melenhorst, Simon Lacey, Regina M Young, Carl H June, E. John Wherry.

A124 Preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapies. Amy E. Anderson, Annette Becker, FangFang Yin, Hema Singh, Xiaoning Zhao, Lisa Seitz, Rick Stanton, Nigel P.C. Walker, Joanne B.L. Tan.

A125 Pulsatile MEK inhibition improves antitumor immunity and T cell function in Kras mutant lung cancer. Hyejin Choi, Jiehui Deng, Shuai Li, Tarik Silk, Elliott J. Brea, Jonathan Boiarsky, Esra A. Akbay, Paul D. Smith, Taha D. Merghoub, Kwok-Kin Wong, Jedd D. Wolchok.

A126 Approaches to increase the therapeutic window of agonistic anti-CD40 antibodies. Rony Dahan.

A127 Role of macrophage subsets in liver metastasis. Zihou Deng.

A128 Tumor endothelial say IDO to CD40-stimulating immunotherapy. Anna Dimberg, Alexandros Karampatzakis, Sander Tuit, Mohanraj Ramachandran, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Kaunisto Aura, Peter Ellmark, Sara M Mangsbo, Joachim L. Schultze, Magnus Essand, Maria Georganaki.

A129 Augmenting T cell priming to noninflamed tumors. Stephanie K. Dougan.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A130 Metastatic melanoma patients responding to PD1 therapy have higher proportion of peripheral blood NKT cells. Henna H.E. Hakanen, Micaela Hernberg, Siru Mäkelä, Bhagwan Yadav, Oscar Brück, Susanna Juteau, Laura Kohtamäki, Mette Ilander, Satu Mustjoki, Kreutzman Anna.

A131 Targeting B7-H3 (CD276) in neuroblastoma: In vitro evaluation of Fc-optimized antibodies and immunocytokines. Florian Heubach, Patrick Schlegel, Latifa Zekri, Timo Manz, Sabine Schleicher, Armin Rabsteyn, Gundram Jung, Hans-Jörg Bühring, Stephen D. Gillies, Rupert Handgretinger, Peter Lang.

A132 Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D. Jun Hu, Xing Liu, Jingxia Zhao, Shiyu Xia, Jianbin Ruan, Xuemei Luo, Justin Kim, Judy Lieberman, Hao Wu.

A133 APOBEC3 confers resistance to oncolytic VSV therapy. Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, Jill Thompson, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Reuben S. Harris, Amy Molan, Jose S. Pulido, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Laura Evgin, Richard Vile.

A134 Single-cell roadmap of the evolution of T cell response during anti-LAG3 and anti-PD1 combination treatment in metastatic melanoma patients. Jani Huuhwanen, Henna H.E. Hakanen, Tapio Lönnberg, Olli H.E. Dufva, Katriina Peltola, Siru Mäkelä, Micaela Hernberg, Petri Bono, Kreutzman Anna, Satu Mustjoki.

A135 Combining low-dose chemotherapy with an NK cell-based immunotherapy as a treatment for triple negative breast cancer. Sarra Idri, Graham Pawelec, Yvonne Barnett, Graham Pockley.

A136 AST-008, a novel TLR9 agonist SNA, induces abscopal antitumor effects in mouse tumor models. Ekambar R. Kandimalla, SubbaRao Nallagatla, Bart R. Anderson, Richard Kang.

A137 The innate/adaptive immune response triggered in response to local immunotherapy of orthotopically growing bladder cancer tumors. Iliana Kyriaki Kerzeli, Sara M. Mangsbo.

A138 CD39 increase on cytotoxic T cell induced by myeloid-derived suppressor cell correlated with poor prognosis in patients with non-small cell lung cancer.

Jiae Koh, Kyung Young Lee, Boram Kim, Mi Soon Kim, Hee Jin Cho, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn.

A140 A T-cell utilizing bispecific anti-CD3/GD2 construct mediates superior in vitro efficacy compared to CH14.18 mAb in neuroblastoma patients after allogeneic SCT.

Anne-Marie Lang, Gundram Jung, Ursula Seidel, Florian Heubach, Armin Rabsteyn, Patrick Schlegel, Christian Seitz, Emmanuelle Moraes Ribeiro, Rupert Handgretinger, Peter Lang.

A141 Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy induces anti-tumoral immune responses. Heung Kyu Lee, Dong Sun Oh.

A142 Anti-mesothelin immunotoxins induce markers of immunogenic cell death and when injected locally into AE17M mesothelioma tumors enhance the effect of CTLA-4 blockade. Yasmin Leshem, Emily King, Yoram Reiter, Ira Pastan.

A143 Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRP α axis and target for immunotherapy. Meike Emma Willemijn Logtenberg.

A144 The transcriptomic profile of peripheral T cells that maintain dormant state of melanoma cells in patients treated with allogenic melanoma vaccine. Andrzej A. Mackiewicz, Partycja Czerwinska, Marcin Rucinski, Katarzyna Gryska, Iga Grzadzielewska, Anna Jaworska, Jacek Mackiewicz.

A145 Study of mechanisms of immune evasion of oncogenic KRAS in NSCLC. Edurne Mugarza, Febe van Maldegem, Miriam Llorian Sopena, Miriam Molina Arcas, Julian Downward.

A146 Systematic discovery of immune regulatory mechanisms in tumor cells. Deng Pan, Aya Kobayashi, Peng Jiang, Guo-Cheng Yuan, X. Shirley Liu, John Doench, Xintao Qiu, Prakash Rao, Henry Long, Myles A. Brown, Kai W. Wucherpfennig, Lucas Ferrari de Andrade, Rong En Tay, Adrienne M. Luoma, Daphne Tsoucas, Klothilda Lim.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A147 AO-176, a next generation anti-CD47 antibody, induces immunogenic cell death. Daniel S. Pereira, Benjamin J. Capoccia, Ronald R. Hiebsch, Michael J. Donio, Alun J. Carter, Robyn J. Puro, W. Casey Wilson, Pamela T. Manning, Robert W. Carr.

A148 A hydrogel platform for the delivery of specialized pro-resolving mediators to treat chronic inflammatory disease. Padmini Sushila Pillai, Jamie Webster, Robert Langer.

A149 E μ Tel-Jak2 T-ALL mouse model is dependent upon Myb function and susceptible to immune checkpoint therapy. Sara Roth, Shienny Sampurno, Michaela Waibel, Leonie Cluse, Lloyd A. Pereira, Ricky W. Johnstone, Robert G. Ramsay.

A150 Enhancing abscopal responses to radiation therapy by manipulating autophagy. Marissa Rybstein, Takahiro Yamazaki, Aitziber Buque Martinez, Lorenzo Galluzzi.

A151 Immunotherapy against cancer using iNKT ligands in combination with an attenuated *Listeria monocytogenes* in humanized mouse models. Noemi Alejandra Saavedra-Avila, Shalu Sharma, Christopher T. Johndrow, Tony Ng, Claudia Gravekamp, Steven A. Porcelli.

A152 Investigating metabolic basis of neurotoxicity during CAR-T therapies. Darin Salloum, Bianca Santomasso, Renier J. Brentjens, Hans-Guido Wendel.

A153 Targeting DNA damage response upregulates PD-L1 level and promotes antitumor immunity in small cell lung cancer. Triparna Sen, Bertha Leticia Rodriguez, Limo Chen, Naoto Morikawa, Junya Fujimoto, Lixia Diao, Youhong Fan, Jing Wang, Bonnie S. Glisson, Ignasio Wistuba, Julien Sage, John V. Heymach, Don L. Gibbons, Lauren A. Byers.

A154 Flow cytometric analysis of immune responses in the melanoma tissue biopsies before or during anti-PD1 immunotherapy. Elena Shklovskaya, Jenny Lee, Su Yin Lim, Sara Alavi, John Thompson, Robyn Saw, Matteo Carlino, Richard Scolyer, Alexander Menzies, Georgina Long, Richard Kefford, Helen Rizos.

A155 Antibody-dependent cancer cell phagocytosis in macrophages induces immune escape by upregulating PD-L1 and IDO. Shicheng Su.

A156 PDA tumor cell death as following combination anti-PD-1 blockade and CXCR4 blockade is a direct effect of CD8+ T cells. Kevin M. Sullivan, Yongwoo David Seo, Xiuyun Jiang, Teresa David Kim, Raymond S.W. Yeung, Venu G. Pillarisetty.

A157 Preclinical pharmacokinetic and pharmacodynamic characterization of AB680, a small-molecule CD73 inhibitor for cancer immunotherapy. Joanne B.L. Tan, Jie Chen, Elaine Ginn, Devika Ashok, Amy E Anderson, Jesus Banuelos, Kristen Zhang, Amber Pham, Timothy Park, Ada Chen, Xiaoning Zhao, Kenneth K.V. Lawson, Jenna Jeffreys, Jarek Kalisiak, Manmohan R. Leleti, Matthew J. Walters, Jay P. Powers.

A158 Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. Jan H. Tavernier.

A159 Agonistic CD40 antibody therapy induces formation of tertiary lymphoid structures in glioma and inhibits the response to immune-checkpoint blockade. Luuk van Hooren, Alessandra Vaccaro, Maria Georganaki, Mohanraj Ramachandran, Hua Huang, Joey Lau, Anja Smits, Magnus Essand, Anna Dimberg.

A160 Deep immunoprofiling of mouse lung cancer models in steady state and upon drug treatment. Febe van Maldegem, Karishma Valand, Victoria Tsang, Edurne Mugarza, Deborah Caswell, Philip Hobson, Julian Downward.

A161 Targeting gastrointestinal tumors with constant region engineered anti-glycan antibodies. Mireille Vankemmelbeke, Thomas Kirk, Jia X. Chua, Richard McIntosh, Lindy G. Durrant.

A162 AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression. Daniel DiRenzo, Dana Piovesan, Joanne Tan, Dillon H. Miles, Manmohan R. Leleti, Timothy Park, Ferdie Soriano, Bryan Handlos, Jenna L. Jeffrey, Ehsan U. Sharif, Brandon R. Rosen, Ulrike Schindler, Jay P. Powers, Matthew J. Walters.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A163/PR7 Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone mice. Arabella Young, Vinh Nguyen, Jee Hye Kang, Sadaf Mehdizadeh, Amy Mei, Kathleen C. F. Sheehan, David V. Serreze, Yi-Guang Chen, Robert D. Schreiber, Jeffrey A. Bluestone.

This abstract is also being presented as a proffered short talk (PR7) in Session 4.

A164 Specifically targeting PD-L1 in the tumor-draining lymph node unmasks its spatiotemporal role in perturbing anti-tumor immunity and survival. Floris F. Dammeijer, Mandy van Gulijk, Melanie M. Lukkes, Menno van Nimwegen, Rudi W. Hendriks, Thorbald T. van Hall, Heleen H. Vroman, Joachim J.G.J.V. Aerts.

A165 Depletion of macrophages in the tumor draining lymph node enhances dendritic cell-induced anti-tumor immunity and survival. Floris F. Dammeijer, Mandy van Gulijk, Melanie M. Lukkes, Menno van Nimwegen, Rudi W. Hendriks, Thorbald T. van Hall, Heleen H. Vroman, Joachim J.G.J.V. Aerts.

A166 Reprogramming of exhausted T cells following cure of chronic viral infection. Mohamed S. Abdel-Hakeem, Jean-Christophe Beltra, Zeyu Chen, John Johnson, Saskinath Manne, Mohammed-Alkhatim Ali, E. John Wherry.

A167 Prevalence of TREG cells and effects of their inhibition on growth of oral cancer cells. Sadhna Aggarwal, Suresh C. Sharma, Satya N. Das.

A168 Quiescent stem cells evade immune surveillance. Judith Agudo, Miriam Merad, Brian D. Brown.

A169 Macrophage targeted zoledronic acid conjugated biomineral nanoparticles for $\gamma\delta$ T cell based cancer immunotherapy. Anusha Ashokan, Minu Anoop, Siju Surendran, Aparna Balakrishnan, Ida M. Anna, Anjana Ramkumar, Girish Chundayil Madathil, Vijay Harish, Manzoor Koyakutty.

A170 Transient microbiota depletion enhances mucosal CD8 T cell responses. Simone Becattini, Alexander Louie, Ingrd M. Leiner, Eric Pamer.

A171 A fully human tissue-based ex vivo cell migration analysis model to study T cell infiltration and distribution in colorectal cancer liver metastases. Anna Berthel, Meggy Suarez-Carmona, Jakob N. Kather, Rodrigo Rojas-Moraleda, Pornpimol Chaorenpong, Nektarios A. Valous, Fee Klupp, Martin Schneider, Alexis Ulrich, Markus Buechler, Inka Zoernig, Dirk Jaeger, Niels Halama.

A172 Cxcr6-deficiency impairs cancer vaccine efficacy and resident memory CD8+ T cells recruitment in tumor. Soumaya Karaki, Charlotte Blanc, Thi Tran, Isabelle Galy-Fauroux, Marie Anson, Rachel Golub, Eric Tartour.

A173 The extracellular ATP receptor P2RX7 is required for CD8+ T cells to maintain and respond to chronic virus and melanoma tumors. Henrique Borges da Silva, Stephen C. Jameson.

A174 The anti-LAG-3 antibody REGN3767 promotes immune activation in the tumor microenvironment and enhances antitumor activity of anti-PD-1 antibody REGN2810 in PD-1/LAG-3 humanized mice. Elena Burova, Gabor Halls, Omaira Allbritton, Wen Zhang, William Olson, Markus Mohrs, Gavin Thurston, Ella Ioffe.

A175 Memory T cells targeting unique and shared oncogenic mutations detected in peripheral blood of epithelial cancer patients. Gal Cafri, Rami Yossef, Anna Pasetto, Drew Deniger, Jared J. Gartner, Todd Prickett, Paul F. Robbins, Steven A. Rosenberg.

A176 Overcoming CD8 T cell suppression in the tumor microenvironment. Adam N.R Cartwright, Peng Jiang, Assieh Saadatpour, Guo-Cheng Yuan, Shirley X. Liu, Kai W. Wucherpfennig.

A177 Impact of regulatory T cells on carcinogenesis of oral squamous cell carcinoma. Jaime L. Chao, Peter A. Savage.

A178 Nr4a transcription factors limit CAR T cell function in solid tumors. Joyce Chen, James P. Scott-Browne, Isaac F. Lopez-Moyado, Laura P. Hempleman, Hyungseok Seo, Takashi Sekiya, Akihiko Yoshimura, Anjana Rao.

A179 Targeting UCP2 pathway in melanoma cells reprograms the tumor microenvironment and initiates anti-tumor immune cycle. Wan-Chen Cheng.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A180 HHLA2 is a novel tumor-expressed member of the B7 immune checkpoint family. Jordan Manek Chinai, Hao Wang, Xudong Tang, Murali Janakiram, Haiying Chen, Xingxing Zang.

A181 Origin of tumor-elicited cytotoxic innate-like T cell responses. Chun Chou, Saida Dadi, Briana G. Nixon, Ming Li.

A182 T cell exhaustion assessment using a fully automated sequential chromogenic multiplex assay. Aurélie Collignon, Assil Benchaaben, Anna Martirosyan, Matthieu Duval, Emilie Bonzom, Emmanuel Prestat, Christophe Haond, Jacques Fieschi.

A183 ATOR-1017: A 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy. Eva Dahlén, Anna Rosén, Karin Barchan, Anna Dahlman, Peter Ellmark, Tina Furebring, Karin Enell Smith.

A184 T-cell rejuvenation is associated with vorinostat-induced immune response in combination with immune checkpoint blockade. Nur P. Damayanti, Justin A. Budka, Josue D. Ordaz, Ashley A. Orillion, Khunsha Ahmed, Xioana Chu, Yue Wang, Yunlong Liu, Roberto Pili.

A185 Effective expansion of poly-functional tumor-reactive TILs from NSCLC correlates with an immune-engaged T cell profile in tumor tissues. Rosa De Groot, Marleen M. van Loenen, Aurélie Guislain, Derk M. Amsen, John B.A.G. Haanen, Kim Monkhorst, Koen J. Hartemink, Monika C. Wolkers.

A186 A new strategy to identify and expand tumor-reactive CD8 TILs in human solid tumors. Thomas Duhen, Rebekka Duhen, Ryan Montler, Tarsem Moudgil, Jitske van den Bulk, Bernard A. Fox, Shu-Ching Chang, Gary Grunkemeier, Els M.E. Verdegaal, Noel F. de Miranda, Rom Leidner, Richard B. Bell, Andrew D. Weinberg

A187 RIG-I agonists reinforce antitumor adaptive immunity and decrease Treg activity in breast cancer. David L. Elion, Max E. Jacobson, Donna J. Hicks, Bushra E. Rahman, Violeta Sanchez, Paula I Gonzales-Ericsson, Olga Fedorova, Anna M. Pyle, John T. Wilson, Rebecca S. Cook.

A188 T cell priming with Deep IL-15 improves preclinical safety compared to systemic IL-15, and increases in vivo persistence and activity. Elena Geretti, Philip Bardwell, Xiaoyan Liang, Santina Caruso, De-Kuan Chang, Jesse Lyons, Austin Boesch, Aaron Handler, Carlos Tassa, Sanelia Bilic, Janice Lancita, Becker Hawes, Jonathan Fitzgerald, Thomas Andresen.

A189 Targeting T cell epigenetic programs to enhance the efficacy of immune checkpoint blockade. Hazem E. Ghoneim, Yiping Fan, Ardiana Moustaki, Hossam Abdelsamed, Pradyot Dash, Pranay Dogra, Robert Carter, Walid Awad, Geoff Neale, Paul Thomas, Ben Youngblood.

A190 Mechanisms governing Foxp3-dependent and -independent gene expression in regulatory T cells in evolutionary distant mice. Ariella Glasner, Yi Zhong, Joris Van Der Veeken, Alexander Rudensky.

A191 Novel approaches to the study of NK cell exhaustion in humans. Elena Gonzalez-Gugel, Keerthi Caroline Sadanala, Adeeb Rahman, Richard Stephen Blumberg, Amir Horowitz, Nina Bhardwaj.

A192 Non-IL-2 blocking anti-CD25-targeting antibodies: Depletion of regulatory T cells driving optimal effector response for rejection of established tumors. Anne Goubier, Isabelle Solomon, Frederick Arce Vargas, Dimitrios Zervas, Chen Qing, Josephine Salimu, Mark Brown, Pascal Merchiers, Karl S. Peggs, Sergio A. Quezada.

A195 Mechanosensory mechanisms and in vivo tissue topology contribute to rheology of circulating leukocytes resulting in efficient post-capillary vessel wall adhesion and recruitment. Alex Y. Y. Huang, Bryan L. Benson, Luis Correa, Lucy L. Li, Jay T Myers, Umut A Gurkan, Richard Ransohoff.

A196 Systematic identification of markers and drug targets on exhausted CD8+ T cells. Will H. Hudson, Julia L. Gensheimer, Haydn T. Kissick, Rafi L. Ahmed.

A197 The HMG transcription factor TOX induces a transcriptional and epigenetic program of CD8+ T cell exhaustion in chronic infection and cancer. Omar Khan, Josephine R. Giles, Sierra McDonald, E. John R. Wherry.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A198 The inhibitory checkpoint molecule NKG2A is upregulated on tumor infiltrating NK cells and CD8 T cells in human head and neck tumors. Michael J. Korrer, Young Kim.

A199 TNFR2-targeted elimination of Tregs and tumor-residing T cells in a murine colon cancer model. Russell LaMontagne.

A200 Targeting ICOS receptor for development of cancer immunotherapy. Yu-Hsun Lo, Cheng-Chou Yu, Shu-Han Yu, Tsung-Hang Hsieh, Mei-Chi Chan, Tsai Shih-Chong.

A201 Single-cell resolution profiling of tumor-reactive CD4 T-cells reveals immune landscape alterations. Assaf Magen, Jia Nie, Thomas Ciucci, Yongmei Zhao, Monika Mehta, Bao Tran, Sridhar Hannenhalli, Rémy Bosselut.

A202 Lysophosphatidic acid impedes the effector function of CD8+ T cells through LPA5R. Divij Mathew, Pamela Strauch, Roberta Pelanda, Raul Torres.

A203 Role of nonimmune functions of regulatory T cells in inflammation and tissue homeostasis. Alejandra Mendoza.

A204 A protective GD3-based vaccine increases NKT cells in a C57BL/6 murine model. Rowan J. Milner, Bikash Sahay, Matthew Cascio, Marc Salute.

A205 Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse. Stephen Mok, Colm R. Duffy, Nana-Ama A.S. Anang, James R. Allison.

A206 Extracellular matrix anchoring of locally administered cytokines safely potentiates systemic cancer immunotherapy. Noor Momin.

A207 PD-1-functionality and CD28 molecule expression in CD8+ T cells of cancer patients. Belinda Palermo, Ornella Franzese, Mariangela Panetta, Virginia Ferraresi, Gabriele Alessandrini, Franco Facciolo, Gennaro Ciliberto, Paola Nistico.

A208/PR2 Neoadjuvant immunotherapy pre-cancer surgery relieves tumor-specific CD8+ T cell dysfunction and restores memory differentiation potential . Jake S. O'Donnell, Jing Liu, Stacey Allen, Scott Mueller, Mark J Smyth, Michele W.L. Teng.

This abstract is also being presented as a proffered short talk (PR2) in Session 1.

A209 Targeting immune cell-specific sphingosine-1-phosphate receptor 4 to restore anti-tumor immunity resulting in improved therapy response. Catherine Olesch, Evelyn Sirait-Fischer, Bernhard Brüne, Andreas Weigert.

A210 Tumor-associated ADAM10 and ADAM17 produce soluble PD-L1 (sPD-L1, sB7-H1) and affect downstream tumor immunity – a resistance mechanism to PD-1 checkpoint blockade in melanoma. Jacob J. Orme, Khalid Jazieh, Susan Harrington, Matthew Ball, Tariq U. Azam, Xin (Cindy) Liu, Tiancheng Xie, Aaron Mansfield, Roxana S. Dronca, Haidong Dong.

A211 Requirement of Treg-intrinsic CTLA4-PKC ϵ ta signaling pathway for suppressing tumor immunity. Christophe Pedros, Hsin-Yu Liu, Ann J. Canonigo-Balancio, Kok-Fai Kong, Amnon Altman.

A212 expanded CD8+PD-1+ T cell and TCR repertoire signatured clinical response of adoptive T cell immunotherapy in advanced pancreatic cancers. Guoliang Qiao.

A213 Exploit the zebrafish to study lymphocyte infiltration in MYCN-amplified neuroblastoma. Xiaodan Qin, Andrew Lam, Hui Feng.

A214 An in vitro preclinical package to assess the safety and efficacy of ImmTAC™ molecules. Ana Ribeiro, Tomasz Dobrzycki, Jane Harper, Giovanna Bossi, Debbie Wright, Andrea Stacey, Nicole Bedke, Ruth Martinez-Hague, Dan Blat, Laure Humbert, Zoe Donellan, Samantha Paston, Luise Weigand, Martina Canestraro, Sophie Botta Gordon-Smith, Bent K. Jakobsen, Joseph Dukes.

POSTER SESSION A

Sunday, September 30 • 11:45 a.m.-2:15 p.m.

Westside Ballroom (Fifth Floor)

A215 Thymocyte selection-associated HMG box protein TOX is a master regulator of tumor-specific T cell dysfunction.

Andrew C. Scott, Steven Camara, Peter Lauer, Alexandra Synder, Dmitriy Zamarin, Tyler Walther, Olivier Levy, Michael Glickman, Jonathan Kaye, Mary Philip, Andrea Schietinger.

A216 Functionally specialized subsets of exhausted CD8+ T cells mediate tumor control and response to checkpoint blockade.

Debattama R. Sen, Brian C. Miller, Rose Al Abosy, Kevin C. Bi, Martin W. LaFleur, Kathleen B. Yates, Ana Lako, Kristen D. Felt, Girish S. Naik, Michael Manos, Evisa Gjini, Yamini V. Virkud, Stephen Hodin, Scott J. Rodig, Arlene H. Sharpe, W. Nicholas Haining.

A217 TCR affinity determines the fate of T cells in tumors.

Mojdeh Shakiba.

A218 Modulating glucocorticoid receptor-mediated signaling for enhancement of cancer immunotherapy.

Qin Tang, Myles A. Brown.

A219 Using poxvirus to improve immunotherapy for brain glioma.

Bingtao Tang, Claire Schane, Joanna Shisler, Edward Roy.

A220 Destabilizing domain technology facilitates exogenous regulation of IL15 and IL12 for adaptive

T-cell therapy. Karen Tran, Kutlu Elpek, Tucker Ezell, Scott Heller, Mara Inniss, Abhishek Kulkarni, Dan Jun Li, Grace Olinger, Michelle Ols, Christopher Reardon, Dexue Sun, Tariq Kassum, Michael Briskin, Celeste Richardson, Vipin Suri, Steven Shamah, Michael Gilman.

A221 Epigenetic therapy restores polyfunctionality of malignant pleural effusion T cells in patients with non-small cell lung cancer without downregulation of PD-1.

Hsing-Chen Tsai, Yi-Chieh Wu, Shu-Yung Lin, I-Yu Chen, Jih-Hsiang Lee, Kuang-Hua Cheng, Ping-Huai Wang, Huan-Jang Ko, Wen-Chien Huang, Yi-Jhen Huang, Kai-Lin Wei, Chong-Jen Yu, Yen-Ling Chiu.

A222 Exploiting mTORC1-independent protein synthesis in Tregs to boost antitumor immune response.

Viviana Volta, Amanda Ernlund, Columba De la Parra, Abilash Gadi, Amanda Valeta-Magara, Robert J. Schneider.

A223 CD36-mediated metabolic adaptation guides

regulatory T cells in tumors. Haiping Wang, Ping-Chih Ho.

A224 Bone marrow T cells are tumor infiltrating T cells in pediatric patients with acute leukemia and their phenotype reflects immune evasion of leukemic blasts. Semjon Manuel Willier, Paula Rothaemel, Jonas Wilhelm, Dana Stenger, Theresa Käuferle, Irene Schmid, Michael H. Albert, Vera Binder, Franziska Blaeschke, Tobias Feuchtinger.

A225/PR1 Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients. Roberta Zappasodi, Cynthia Sirard, Yanyun Li, Sadna Budhu, Moshen Abu-Akeel, Cailian Liu, Xia Yang, Hong Zhong, Walter Newman, Jinjin Qi, Phillip Wong, David Schaer, Henry Koon, Vamsidhar Velcheti, Michael Postow, Margaret K Callahan, Jedd D. Wolchok, Taha D. Merghoub. *This abstract is also being presented as a proffered short talk (PR1) in Session 1.*

A226 Cell-free membrane reconstitution system for cis and trans interaction of T cell co-receptors and ligands. Yunlong Zhao, Enfu Hui.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B001 Generation of ImmTACTM molecules: Engineering high-affinity soluble T cell receptors for the treatment of cancer. Izabela Bombik, Alessio Bortoluzzi, Nicole Mai, Andrew Preston, Annelise Vuidepot, Bent K. Jakobsen, Nathaniel Liddy.

B002 Computational design of hyperstable, modular protein inhibitors targeting PD-1. Cassie M. Bryan.

B003 IL23 secreted by myeloid cells drives castration resistant prostate cancer. Arianna Calcinotto, Clarissa Spataro, Elena Zagaro, Johann de Bono, Andrea Alimonti.

B004/PR14 Identification of specificity TCR groups of tumor antigen specific T cells. Liang Chen, Chunlin Wang, Mark Davis.

This abstract is also being presented as a proffered short talk (PR14) in Session 7.

B005 Linking transcriptomic and imaging features of the melanoma tumor microenvironment. Andrew X. Chen, Robyn Gartrell, Douglas K. Marks, Thomas Hart, Emanuelle Rizk, Anthea Monod, Raul Rabadan, Yvonne Saenger.

B006 Gridded tissue profiling strategy with digital spatial profiling for unbiased tissue sampling. Sarah Church, Chris Merritt, Giang Ong, Andrew White, Kristi Zevin, Sarah Warren, Joseph M. Beechem.

B007 Identification of prostate cancer stem cell antigens for T cell immunotherapy by HLA ligandome analysis. Amy S. Codd, Saly Al-Taei, Serina Tokita, Emi Mizushima, Pierre J Rizkallah, Tom Whalley, Barbara Szomolay, Kristin Ladell, James E McLaren, Sian Llewellyn-Lacey, David A Price, Takayuki Kanaseki, Toshihiko Torigoe, Stephen Man, Zsuzsanna Tabi.

B008 Treatment of IDO1 and TDO2 positive tumors with a kynurenine-degrading enzyme: A highly differentiated approach from IDO1 inhibition. Silvia Coma, Jillian Cavanaugh, James Nolan, Jeremy Tchaicha, Karen McGovern, Everett Stone, John Blazeck, Candice Lamb, George Georgiou, Mark G Manfredi, Michelle Zhang.

B009 New development of monoclonal antibodies targeting TRAIL agonist receptors. Agathe Dubuisson.

B010 A survey of circulating biomarkers in subjects with NSCLC using library-based data independent acquisition mass spectrometry reveals host immune response mechanisms. Nicholas Dupuis, Jakob Vowinckel, Daniel Heinzmann, Claudia Escher.

B011 Inhibition of G9a reestablishes the MHC class I loss due to EMT in lung cancer cells. Heidge Fukumasu, Pedro R.L. Pires, Pedro L.P. Xavier.

B012 Characterizing tumor-induced exhaustion in melanoma patients treated with neo-adjuvant pembrolizumab. Josephine R. Giles, Alexander C. Huang, Sashinath Manne, Jorge C. Henao-Meji, E. John Wherry.

B013 Site specific conjugation of engineered non-native amino acids in an anti-CD3 Fab-folate bispecific antibody significantly enhances its anti-tumor properties in gynecologic cancers. Michael J. Gray, Wisam Barkho, Barbara Tipton, Prathap Shastri, Hyun-Bae Jie, Jeff Steen, Rik Frank, Feng Tian, Dowdy Jackson, Shawn Zhang.

B014 T cell Elispot Proficiency Panel 2017/2018: Evaluating routine T cell Elispot assays. Stephen T. Haley, Charlotte Halgreen, Katrine Frederiksen, Rikke Brogaard, Liselotte Brix.

B015 T cell recognition profiling of CD8+ T cells in tumor-infiltrating lymphocytes expanded for adoptive cell transfer. Christina Heeke, Anne-Mette Bjerregaard, Amalie Kai Bentzen, Marco Donia, Rikke Andersen, Inge Marie Stentoft Svane, Sine Reker Hadrup.

B016 Automated ex vivo expansion of low numbers of tumor-reactive T cells on the CliniMACS Prodigy®. Bianca Heemskerk, Christina Maeder, Elvira Criado-Moronati, Lisa Boettcher, Andrew Kaiser, Mario Assenmacher, Andrzej Dzionek.

B017 Multifunctional immunomodulator capable of hypoxia-sensitive adjuvant delivery and photodynamical assistance for DC antigen presentation for cancer immunotherapy. Sooseok Im, Won Jong Kim.

B018 Landscape of natural HLA class I ligand peptides of cancer cells. Yasuhiro Kikuchi, Takayuki Kanaseki, Ayumi Hongo, Serina Tokita, Toshihiko Torigoe, Kochin Vitaly.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B019/PR13 A new high-performance HLA ligand identification strategy enables prediction of T cell tolerance to neoepitopes. Martin G. Klatt, Ron S. Gejman, Sung S. Moon, Tatyana S. Korontsvit, Tao Dao, David A. Scheinberg.

This abstract is also being presented as a proffered short talk (PR13) in Session 7.

B020 T cell recognition of large T and small T antigen in Merkel cell polyomavirus-associated cancer. Ulla Kring Hansen, Rikke Lyngaa, Per Thor Stratén, Jürgen C. Becker, Candice D Church, Paul Nghiem, Sine Reker Hadrup.

B021 Imaging immunotherapy in the tumor microenvironment in 3D. Stephen J. Kron, Steve Seung-Young Lee, David Scholten, Vytautas Seung-Young Bindokas, Jacqueline Brinkman.

B022 Properties of T cell recognized neoantigens. Pia Kvistborg, Marit M. van Buuren, Daisy Philips, Nienke M. van Rooij, Arno Velds, Sam Behjati, Marlous van den Braber, Mireille Toebe, Lorenzo Fanchi, Maarten Slagter, Inge Marie Stentoft Svane, Patrick Hwu, Joost van den Berg, Michael Stratton, Christian Blank, John B.A.G. Haanen, Can Kesmir, Ton N.M. Schumacher.

B023 Protein logic for ultraspecific T cell targeting and immunostimulation. Marc J. Lajoie, Scott E. Boyken, Alfredo Quijano Rubio, Robert E. Langan, Daniel Adriano Silva Manzano, Umut Y. Ulge, Alexander I. Salter, Anusha Rajan, Isabel Leung, Mesfin M. Gewe, Colin E. Correnti, Stanley R. Riddell, David A. Baker.

B024 Using single cell paired sequencing to isolate cancer-specific T cell receptors for cancer immunotherapy. Karolina Lech, Lucia Correia, Max Beckmann, Maria Busz, Sean Collison, Sterenn Davis, Paraskevi Mallini, Sarah Scaife, Joseph Dukes, Bent K. Jakobsen, Luke Williams, Michelle Teng.

B025 Multiplex three-dimensional mapping of mRNA and protein in the tumor microenvironment. Steve Seung-Young Lee, David Scholten, Vytautas P. Bindokas, Stephen Kron.

B026 Development of tumor-targeted agonistic immunomodulators using the DARPin® Technology Platform. Victor Levitsky, Alexand Link, Michael T. Stump, Elmar vom Baur.

B027 Antitumor effects of the programmed death receptor-1 and the programmed death-ligand 1 blockade in human colorectal carcinoma in a humanized orthotopic mouse model. Li Li, Xin Zhang, Grace Maresh, Linh Hellmers, Avi Patel, Ravan Moret, Sarah Cohen, David Margolin.

B028 Label free Raman signatures of immune cells: A new tool for artificial intelligence in immunotherapy.

Girish Chundayil Madathil, Raveena Nagareddy, Anjana Ramkumar, Manu Krishnan, Vijay Harish, Anusha Ashokan, Shanti Kumar Nair, Manzoor Koyakutty.

B029 A novel media supplementation strategy for improved T cell culture and preservation of naivety.

Alyssa Master, Roddy S. O'Connor, Saba Ghassemi, Dina S. Schneider, Lisa Karimi-Naser.

B030 Predicting the response of uveal melanoma to immunotherapy with MRI assessments. Alvaro Moreira, Marc Saake, Gerold Schuler, Lucie Heinzerling.

B031 Development of anti-myeloma immunotherapy by exploiting modified antibodies specific for A2/NY-ESO-1. Toshiki Ochi, Masaki Maruta, Kazushi Tanimoto, Hiroaki Asai, Takashi Saitou, Yoshihiro Yakushijin, Hiroshi Fujiwara, Takeshi Imamura, Katsuto Takenaka, Masaki Yasukawa.

B032 PhIP-seq assessment of the serum antibody repertoire before and after immune-related adverse events in four melanoma patients treated with checkpoint blockade immunotherapy. Timothy J. O'Donnell, Meimi Shan, Elliott Merritt, Elena Gonzalez Gugel, Ana B. Blasquez, Marcia Meseck, Phillip A. Friedlander, Alexander Rubinsteyn, Amir Horowitz, Nina Bhardwaj, Uri Laserson.

B033 T cell-induced tumor vulnerability discovery in an IFN γ -independent genomic landscape. Daniel S. Peeper, David Vredevoogd, Thomas Kuilman.

B034 A novel immunomodulatory strategy of targeting glyco-immune checkpoints with EAGLE technology.

Li Peng.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B035 Enhancing antitumoral activity of cell based immunotherapies by modulating the JAK-STAT axis.

Luis Alberto Perez-Quintero, Kelly Anne Pike, Penafuerte Claudia, Michel Tremblay.

B036 T cell recognition of breast cancer antigens. Nadia Viborg Petersen, Sofie Ramskov, Rikke Sick Andersen, Özcan Met, Per thor Straten, Amalie Kai Kai Bentzen, Sine Reker Hadrup.

B037 Tunable thermal bioswitches for control of cell-based therapeutics. Dan Ilya Piraner, Mikhail G. Shapiro.

B038 A unified genome-wide analysis of dysfunctional T cell states in cancer and chronic viral infection. Yuri Pritykin, Christina Leslie.

B039 Peptide-MHC-directed expansion of multifunctional antigen-responsive T cells. Vibeke Mindahl Rafa, Mona Bodenhöfer, Amalie Kai Bentzen, Tripti Tamhane, Marco Donia, Inge Marie Stentoft Svane, Søren Nyboe Jakobsen, Christian Schmess, Sine Reker Hadrup.

B040 Electrospun implantable anticancer device comprising immune adjuvant photoresponsive nanoparticles with checkpoint blockade for effective cancer therapy. Afeesh Rajan Unnithan, Arathyram Ramachandra Kururp Sasikala, Chan Hee Park, Cheol Sang Kim.

B041 An injectable magnetic nanogel system for filling surgical residual cavity with effective cancer immunotherapy combined hyperthermic capability. Arathyram Ramachandra Kururp Sasikala, Afeesh Rajan Unnithan, Chan Hee Park, Cheol Sang Kim.

B042 Broad analysis and more accurate predictions of HLA class I epitope binding in 92 common HLA alleles profiled by mono-allelic mass spectrometry. Siranush Sarkizova, Susan Klaeger, Derin B. Keskin, Karl Clauser, Hasmik Keshishian, Christina R. Hartigan, Nir Hacohen, Steven A. Carr, Catherine J. Wu.

B043 Enhanced T-cell immunity *in vivo* using injectable bioengineered scaffolds. Nisarg Shah, David J. Mooney.

B044 Engineering CAR NK cells for antigen-dependent autocrine expansion. Avishai Shemesh, Kole T. Roybal, Lewis L. Lanier.

B045 Antigen-free cancer vaccine to treat poorly immunogenic tumors. Miguel C. Sobral, Hua Wang, Alexander J. Najibi, Aileen Li, Catia S. Verbeke, David J. Mooney.

B046 Immune repertoire sequencing enables complete B-cell and T-cell clonality determination and minimal residual disease assessment. Chen Song, Luo Sun, Pingfang Liu, Bradley Langhorst, Andrew Barry, Theodore B. Davis, Eileen T. Dimalanta.

B047 Next-generation gene expression enables tumor-focused immuno-oncology therapies. Patrick Stern.

B048 Proteomic approaches for the identification of druggable protein and epigenetic targets to complement melanoma immunotherapy. Alan Tackett.

B049 Empty MHC class I molecules for improved detection of antigen-specific T cells. Tripti Tamhane, Sunil Kumar Saini, Raghavendra Anjanappa, Ankur Saikia, Sofie Ramskov, Marco Donia, Inge Marie Stentoft Svane, Søren Nyboe Jakobsen, Maria Garcia-Alai, Martin Zacharias, Rob Meijers, Sebastian Springer, Sine Reker Hadrup.

B050 Identification of PD-1T TILs and CXCL13 as determinants for response to anti-PD-1 treatment using human tumor explants. Daniela S. Thommen, Viktor H. Koelzer, Petra Herzig, Marjolein H. de Brujin, Paula Voabil, Marlous van den Braber, Karlijn Hummelink, Kim Monkhorst, Kirsten D. Mertz, Alfred Zippelius, John B.A.G. Haanen, Ton N.M. Schumacher.

B051 Facilitating translational research with interactive tools for immuno-oncology data. Vesteinn Thorsson, James A. Eddy, Andrew Lamb, David A. Gibbs, Ilya Shmulevich, Justin Guinney.

B052 Immunotherapy for melanoma by adenovirus-mediated full-length antibody, nivolumab. Xuchen Wang.

B053 In vivo metabolic labeling and targeted modulation of dendritic cells for enhanced cancer immunotherapy. Hua Wang, David J. Mooney.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B054 Single-cell analysis illuminates the gradients of immune cell functional states within human melanoma tumors, and facilitates characterization of tumor reactive T cells. Ido Yofe, Hanjie Li, Anne van der Leun, Yaniv Lubling, Dikla Gelbard, Alexander C. J. van Akkooi, Amos Tanay, Ton N.M. Schumacher, Ido Amit.

B055 Enhanced detection of T cells targeting unique neoantigens and shared mutated oncogenes for personalized cancer immunotherapy. Rami Yossef, Eric Tran, Alena Gros, Drew Deniger, Gal Cafri, Steven A. Rosenberg.

B057 Enhancing immunotherapy for triple-negative and HER2+ breast cancer using EpCAM aptamer-siRNA mediated gene knockdown. Ying Zhang, Judy Lieberman.

B058 Rapid and controlled T cell expansion using scaffolds that mimic antigen presenting cells. David K.Y. Zhang, Anna Vaynrub, David J. Mooney.

B059 Synergistic activation of antitumor immunity by an oncolytic virus VG161 armed with multiple immune stimulating genes. Ronghua Zhao, Jun Ding, Dmitry Choujenko, Yanal Murad, Erica Lee, Guoyu Liu, Luke Bu, William Jia.

B060 Commensal bacteria Bifidobacterium stimulates an antitumor response via cross-reactivity. Catherine Ami Bessell.

B062 Investigate the role of T lymphocytes in the regulation of energy expenditure and obesity. Bo Hu, Chengcheng Jin, Xing Zeng, Mark Jedrychowski, Chen Zhao, Alex Banks, Steven Gigi, Diane Mathis, Bruce Spiegelman.

B063 Leveraging gut microbiota networks to impact tumor immunotherapy. Lata Jayaraman, Jaclyn Sceneay, Srimathi Srinivasan, Keith Halley, Meghna Bist, Kathleen Cieciuch, George Marnellos, Christopher Desjardins, Jennifer Wortman, Matthew Henn, David Cook.

B064 Chemical biology studies of anti-inflammatory lipids. Qiang Li, Howard Hang.

B065 Tracking adipose-tissue Treg provenance, dependencies, and activities via T cell receptor transgenic mice. Chaoran Li, Joanna R. DiSpirito, David Zemmour, Raul R. Spallanzani, Wilson Kuswanto, Christophe Benoist, Diane Mathis.

B066 Identifying novel effectors of the gut microbiota that modulate cancer cell killing by CTLs using functional metagenomics. Lior Lobel, Wendy S. Garrett.

B067 Distinct necessity of mitochondrial complex I and III for regulatory T cell function. Elizabeth M. Steinert, Samuel E. Weinberg, Navdeep S. Chandel.

B068 Vitiligo and melanoma: The role of cutaneous human commensal bacteria in anti-melanocyte immune responses. Ivan Vujkovic-Cvijin.

B069 Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells. Vito Amodio, Giovanni Germano, Ludovic Barault, Simona Lamba, Giuseppe Rospo, Alessandro Magrì, Federica Maione, Giovanni Crisafulli, Carlotta Cancelliere, Giulia Lerda, Alice Bartolini, Giulia Siravegna, Benedetta Mussolin, Roberta Frappolli, Monica Montone, Giovanni Randon, Filippo de Braud, Nabil Amrourchene Angelozzi, Silvia Marsoni, Maurizio D'Incalci, Armando Orlandi, Enrico Giraudo, Andrea Sartore-Bianchi, Salvatore Siena, Filippo Pietrantonio, Federica Di Nicolantonio, Alberto Bardelli.

B070 Neoepitope and mutation load as a biomarker in a broad cohort of cancer patients treated with immunotherapy. Anne-Mette Bjerregaard, Vinicius Araujo Barbosa de Lima, Annie Borch, Olga Araujo Barbosa de Oestrup, Ulrik Lassen, Sine Reker Hadrup.

B071 Validating sequence similarity-driven neoepitope fitness models via immunogenomics on TCGA and multiregional tumor data. Adrian Bubie, Nicholas Akers, Augusto Villanueva, Bojan Losic.

B072 Immune checkpoint blockade enhances mutated calreticulin-induced T cell immunity in myeloproliferative neoplasms. Cansu Cimen Bozkus, Vladimir Roudko, John P. Finnigan, John Mascarenhas, Ronald Hoffman, Camelia Iancu-Rubin, Nina Bhardwaj.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B073 A pan-HLA predictor of neoantigen processing and presentation to the tumor cell surface. Trevor Clancy, Richard Stratford.

B074 A recall antigen-based potency assay for immunomodulatory biologics that could discriminate responders from non-responders. Marc Delecommene, Wushouer Ouerkaxi, Pirouz Daftarian.

B075 Modelling response and resistance to immune checkpoint blockade in syngeneic mouse glioma.

Katrin Deumelandt, Jens Blobner, Jana K. Sonner, Mirco Friedrich, Edward Green, Michael O. Breckwoldt, Manuel Fischer, Jochen Meyer, Felix Sahm, Daniel Schrimpf, Andreas von Deimling, Michael Platten.

B076 Pan-cancer analysis to identify which cancers may benefit most from LAG-3 blockade. Shridar Ganeshan, Anshuman Panda, Gyan Bhanot.

B077 Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response. Peng Jiang, Shengqing Gu, Deng Pan, Jingxin Fu, Avinash Sahu, Xihao Hu, Ziyi Li, Nicole Traugh, Xia Bu, Bo Li, Jun Liu, Gordon J Freeman, Myles A Brown, Kai W. Wucherpfennig, Xiaole Shirley Liu.

B078 Unbiased identification of CD4+ T-cell epitopes using novel MHC-based chimeric receptors. Jan Kisielow, Franz-Josef Obermair, Manfred Kopf.

B079 Evaluation of tools for predicting mutated tumor antigens from exome and RNA sequencing. Julia Kodysh, John P. Finnigan, Alex Rubinsteyn.

B080 Improved neoantigen vaccine selection by combining prediction of pMHC presentation and T-cell epitopes. Julia Kodysh, Tim O'Donnell, Ana B. Blazquez, John Finnigan, Nina Bhardwaj, Alex Rubinsteyn.

B081 Serum antibody against NY-ESO-1 and XAGE1 predicts clinical responses to anti-PD-1 therapy in non-small-cell lung cancer. Koji Kurose, Yoshihiro Ohue, Takahiro Karasaki, Junichiro Futami, Isao Irei, Takeshi Masuda, Masaaki Fukuda, Akitoshi Kinoshita, Hirokazu Matsushita, Katsuhiko Shimizu, Hiroyuki Yamaguchi, Minoru Fukuda, Kazuhiro Kakimi, Mikio Oka.

B082 PD-1 to CD8 ratio on tumor infiltrating lymphocytes and peripheral blood mononuclear cells as a predictor for determining response of glioblastoma patients to radiation-induced ICD-based DC vaccine therapy. Fang-Yu Lin, Chia-Ing Jan, Wan-Chen Tsai, Horng-Jyh Harn, Hsin-Man Lu, Ming-Chao Liu, Shao-Chih Chiu, Der-Yang Cho.

B083 Defective transcription elongation in a subset of cancers confers immunotherapy resistance. Vishnu Modur.

B084 Methylation landscape of tumors associated with antitumor immune signature. Chan-Young Ock, Changhee Park, Kyeonghun Jeong, Sohee Jung, Jeong Mo Bae, Kwangsoo Kim.

B085 High mutation burden and response to immune checkpoint inhibitors in angiosarcomas of the scalp and face. Corrie Painter, Esha Jain, Michael Dunphy, Elana Anastasio, Mary McGillicuddy, Rachel Stoddard, Beena Thomas, Sara Balch, Kristin Anderka, Katie Larkin, Niall Lennon, Yen-Lin Chen, Andrew Zimmer, Esme O. Baker, Simone Maiwald, Jen Lapan, Jason L. Hornick, Chandrajit Raut, George Demetri, Eric S. Lander, Todd Golub.

B086 Exploiting large-scale HLA peptidomics to generate novel immunotherapies: A data-driven approach to true neoantigen prioritization. Alex S. Powlesland, Geert P.M. Mommen, Ricardo J. Carreira, Jacob P.M. Hurst, Michael J. Cundell, David Lowne, Floriana Capuano, Bent K. Jakobsen.

B087 MHC class II on cancer cells -- role in response to BCG therapy of bladder cancer. Gil Redelman-Sidi, Michael Glickman, Anna Binyamin, Anthony Antonelli.

B088 Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma. Paula Restrepo, Raymund Yong, Ilaria Laface, Nadejda Tsankova, Sacha Gnjatic, Adilia Hormigo, Bojan Losic.

B089 Application of precision cancer immunotherapy design tools to bladder cancer: Non-self-like neoepitopes as a prognostic biomarker. Guilhem Richard, Randy F. Sweis, Leonard Moise, Matthew F. Ardito, William A. Martin, Gad Berdugo, Gary D. Steinberg, Anne S. De Groot.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B090/PR12 Functional identification and therapeutic targeting of tumor neoantigens. Stephen Phillip Schoenberger, Aaron M. Miller, Luise A. Sternberg, Leslie M. Montero Cuencac, Milad Bahmanof, Zeynep Koasaloglu-Yalcin, Manasa Lanka, Ashmitaa Premlal, Pandurangan Vijayanand, Jason Greenbaum, Allesandro Seatte, Ezra E.W. Cohen, Bjoern Peters.

This abstract is also being presented as a proffered short talk (PR12) in Session 6.

B091 Platinoid-chemotherapy upregulation of MHC-I machinery in tumor cells determines the response to checkpoint inhibitors. Shabnam Shalapour, Ingmar Niels Bastian, Weihua Li, Kathleen Niels Fisch, Michael Karin.

B092 Tumor-infiltrating T-cells from renal cell carcinoma patients recognize neoantigens derived from point and frameshift mutations. Sofie Sofie Ramskov, Ulla Kring Hansen, Anne-Mette Bjerregaard, Amalie Kai Bentzen, Marco Donia, Rikke Andersen, Zoltan Szallasi, Inge Marie Stentoft Svane, Aron Charles Eklund, Sine Reker Hadrup.

B093 Development of prediction software PrDx, trained on peptide-MHC stability assays, show new important positions in the binding patterns of the peptides-MHC I&II complexes. Stephan Thorgrimsen, Sune Justesen, Nicolas Rapin.

B094 Successful identification of neo-antigen-specific T cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development. Jitske van den Bulk, Dina Ruano, Marieke E. Ijsselsteijn, Marten Visser, Ruud van der Breggen, Koen C.M.J. Peeters, Thomas Duhen, Rebekka Duhen, Andrew D Weinberg, Sjoerd S.H. van der Burg, Els M.E. Verdegaal, Noel F. de Miranda.

B095 Mapping the genetic features of immune checkpoint responsiveness using AAV-CRISPR mediated in vivo screen. Guangchuan Wang, Ryan Chow, Zhigang Bai, Lupeng Ye, Sidi Chen.

B096 Dissecting the flames from the fire: Distribution of immune checkpoints in hot and cold tumors. Sarah Warren, Tressa Hood, Patrick Danaher, Alessandra Cesano.

B097/PR11 CX3CR1+CD8+ T cells are responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade. Yiyi Yan, Haidong Dong, Roxana Dronca, Svetomir Markovic.

This abstract is also being presented as a proffered short talk (PR11) in Session 6.

B098 A novel engineered oncolytic virus as an optimal viro-immunotherapeutic platform for solid tumors.

Jennifer Altomonte, Sarah Abdullahi, Teresa Krabbe, Katja Steiger, Roland M. Schmid, Oliver Ebert.

B099 Elucidating the mechanisms that underpin RAG chromatin scanning in V(D)J recombination at antigen receptor gene loci. Zhaoqing Ba, Suvi Jain, Jiazhi Hu, Frederick Alt.

B100 Development of targeted multiple myeloma cancer vaccine and antigen-specific T-cell immunotherapy using novel immunogenic engineered heteroclitic BCMA peptides. Jooeun Bae, Teru Hideshima, Yu-Tzu Tai, Nikhil Munshi, Kenneth Anderson.

B101 Novel oncolytic vaccinia virus platform for systemic delivery of immunotherapeutic payloads. John C. Bell, Adrian Pelin, Michael Huh, Matthew Tang, Fabrice Le Boeuf, Brian Keller, Jessie Duong, Katherine Clark-Knowles, Julia Petryk, Victoria A. Jennings, Alan Melcher, Mathieu Crupi, Larissa Pikor, Caroline Breitbach, Steven Bernstein, Michael Burgess.

B102 Pre-existing citrulline specific CD4 T cells can be efficiently harnessed for tumor therapy. Victoria A. Brentville, Peter Symonds, Katherine W. Cook, Ian Daniels, Suha Atabani, Ruhul Choudhury, Poonam Vaghela, Rachael L. Metheringham, Mohamed Gijon, Wei Xue, Lindy G. Durrant.

B103 Altering the mevalonate pathway to enhance CD8+ T cell responses. Olivia K. Burn, Astrid Authier-Hall, Collin Brooks, Regan Anderson, Andrew Marshall, Gavin Painter, Robert Weinkove, Ian Hermans.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B104 Post translationally modified homocitrulline induced by MDSCs can be an effective anti-tumour target for CD4 T cells. Katherine W. Cook, Wei Xue, Peter Symonds, Mohamed Gijon, Sabaria Shah, Suha Atabani, Poonam Vaghela, Ruhul Choudhury, Rachael L. Metheringham, Ian Daniels, Victoria Brentville, Lindy Durrant.

B105 A cancer vaccine targeting many neoantigens is required for effective eradication of large tumors. Anna Morena D'Alise, Guido Leoni, Gabriella Cotugno, Francesca Langone, Imma Fichera, Maria De Lucia, Rosa Vitale, Adriano Leuzzi, Veronica Bignone, Elena Di Matteo, Fabio Giovanni Tucci, Lidia Avalle, Valeria Poli, Armin Lahm, Maria Teresa Catanese, Antonella Folgori, Stefano Colloca, Alfredo Nicosia, Elisa Scarselli.

B106/PR9 Intratumoral delivery of engineered modified vaccinia virus Ankara expressing Flt3L and OX40L for “in situ” therapeutic cancer vaccination. Liang Deng, Ning Yang, Yi Wang, Wei Yan, Jiahua Wang, John Choi, Stewart Shuman, Taha D. Merghoub, Jedd D. Wolchok.

This abstract is also being presented as a proffered short talk (PR9) in Session 5.

B107 Next generation of poxvirus-based immunotherapeutics. Laetitia Fend.

B108 Molecular and cellular properties of neoantigen-specific CD8+ T cells on interaction with B16F10 melanoma in situ. John P. Finnigan, Andrew S. Ishizuka, Geoffrey M. Lynn, Alex S. Rubenstein, Robert A Seder, Nina Bhardwaj.

B109 Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design. Andrew I. Flyak, Stormy Ruiz, Michelle Colbert, Tiffany Luong, James E. Crowe, Jr., Justin R. Bailey, Pamela J. Bjorkman.

B110 Pro-inflammatory allogeneic dendritic cells promote activation of bystander immune cells and indirectly license antigen-specific T cells. Grammatiki Fotaki, Chuan Jin, Iliana Kyriaki Kerzeli, Mohanraj Ramachandran, Alex Karlsson-Parra, Di Yu, Magnus Essand.

B111 Vaccination against TAP downregulation-induced neoantigens to prevent future tumor development in the setting of recurrence or premalignancy. Greta Garrido

Hidalgo, Brett Schrand, Ailem Rabasa, Agata Levay, Tal Gefen, Giri Bhawan Bhawan, Anthony R. Ferrantella, Vikas Dudeja, Koen Marijt, Thorbald T. van Hall, Eli Gilboa.

B112 Combined therapy with an autologous tumor cells/bacillus Calmette-Guérin/formalin-based vaccine plus anti-PD-1 inhibitor enhances the antitumor response in a 4T1 breast cancer model. Maria Jose Godoy Calderon, Eglys González Marcano, Ana Federica Convit.

B113 Protective serum responses by CRISPR/Cas9 edited primary B cells expressing antibodies of choice. Harald Hartweger, Mila Jankovic, Michel C. Nussenzweig.

B114 Cancer immunotherapy combining oral vaccination of recombinant *Bifidobacterium longum* displaying human Wilms' tumor 1 protein and anti-PD-1 checkpoint blockade for solid tumors in mice experimental model.

Koichi Kitagawa, Maho Tatsumi, Mako Kato, Shota Komai, Yoshiko Hashii, Takane Katayama, Toshiro Shirakawa.

B115 Optimization of cancer vaccine development by using Multiplexed Identification of T-cell Receptor Antigen specificity (MIRA). Peter Ebert, Mark Klinger, Edward Osborne, Ruth Taniguchi, Joyce Hu, Tim Hayes, Sharon Benzeno, Adria Carbo, Melanie Laur, Erica Eggers, Harlan Robins.

B116 Nano-neo-mRNA Vaccine: A novel platform technology for cancer-immunotherapy. Manzoor Koyakutty Koyakutty, Navyashree A Ramesh, Ashwathy Nambiar, Najuma Nujum Ambili Anna, Manju C Abraham, Minu Anoop, Anjana Ramkumar, Nair Shanti, Vijay Harish Harish, Anusha Ashokan.

B117 Allogeneic tumor-lysate loaded dendritic cells induce antitumor immunity and tumor responses in preclinical models of pancreatic adenocarcinoma: Towards clinical trials. Sai Ping S. Lau, Priscilla P. Kinderman, Melanie M. Lukkes, Floris P. Dammeijer, Heleen H. Vroman, Menno M. van Nimwegen, Thorbald T. van Hall, Sjoerd S.H. van der Burg, Joachim J.G.J.V. Aerts, Nadine A.G. Pronk-van Montfoort, Casper C.H.J. van Eijck.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B118 Development of a novel prostatic acid phosphatase-derived vaccine for the treatment of advanced prostate cancer. Pauline Le Vu, Jayakumar Vadakekolathu, Dennis Christensen, Lindy Durrant, Graham Pockley, Stephanie E.B. McArdle.

B119 DC-recruiting biomaterial vaccine to enhance antitumor immunity. Aileen W. Li, Maxence O. Dellacherie, Miguel Sobral, Omar O. Ali, Jaeyun Kim, David J. Mooney.

B120 TIPE2 regulates apoptosis and autophagy to inhibit tumorigenesis in colon cancer. Jun Li, Xiaoli Xia.

B121 Checkpoint inhibitor vaccine stimulates antitumor T cells that block tumor growth. Takuya Tada, Nathaniel R. Landau, Thomas David Norton.

B122 Development of a new immunotherapy treatment for glioblastoma multiforme. Joshua R. D. Pearson, Lindy G. Durrant, Victoria A. Brentville, Graham G. Pockley, Stephanie E.B. McArdle.

B123 Local treatment with PeptiCRAd-1, a novel cancer immunotherapy approach, mediates a systemic anti-tumour CD8+ T-cell response and infiltration of CD8+ and CD4+ T-cells into distant untreated tumours in a clinically relevant humanised mouse melanoma model. Erkko Ylosmaki, Tuuli Ranki, Petri Priha, Charlotta Backman, Matthew Vaughn, Vincenzo Cerullo, Sari Pesonen.

B124 Personalized peptide vaccination based on patient-individual tumor-specific variants induces T cell responses in pediatric patients. Armin Rabsteyn, Christina Kyzirakos, Christopher Schroeder, Marc Sturm, Christopher Mohr, Jakob Matthes, Magdalena Feldhahn, Nicolas Casadei, Martin Ebinger, Stefan Stevanovic, Peter Bauer, Oliver Kohlbacher, Cecile Gouttefangeas, Juergen Schaefer, Hans-Georg Rammensee, Rupert Handgretinger, Peter Lang.

B125 Targeting human CD141+ DC using CLEC9A antibodies for cancer immunotherapy. Kristen Radford, Frances Pearson, Kelly-Anne Masterman, Kirsteen Tullett, Oscar Haigh, Carina Walpole, Ghazal Daraj, Ingrid Leal Rojas, Mireille Lahoud.

B126 Degradation-regulatable architected implantable macroporous scaffold for the spatiotemporal modulation of immunosuppressive microenvironment and enhanced combination cancer immunotherapy. Long Ren, Il Woo Shin, Chanyoung Song, Yong Taik Lim.

B127 NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders. Hadas Reuveni, Izhak Haviv, Lana Kupershmidt.

B128 Timing and sequence of CpG and anti-OX40 is critical for in situ vaccination. Idit Sagiv-Barfi, Debra K. Czerwinski, Ronald Levy.

B129 Human endogenous retroviruses as a potential reservoir for T-cell mediated cancer immunotherapy. Sunil Kumar Saini, Anne-Mette Bjerregaard, Andreas D. Ørskov, Ashwin Unnikrishnan, Staffan Holmberg, Govardhan Anande, Amalie Kai Bentzen, Zoltan Szallasi, Aron C. Eklund, Kirsten Grønbæk, Sine Reker Hadrup.

B130 Induced lymphangiogenesis enhances antigen-specific T cell response in anticancer vaccination. Maria Stella Sasso, Sylvie Hauert, Priscilla Briquet, Yue Wang, Jun Ishihara, Jeffrey A. Hubbell, Melody A. Swartz.

B131 Live-attenuated LCMV-based vector for active immunotherapy of HPV16+ cancer. Sarah Schmidt, Ahmed ElGazzar, Welyd V. Bonilla, Mindaugas Pauzuolis, Andrea Reiter, Theresa Kleissner, Daniel Oeler, Felix Stemeseder, Ursula Berka, Bettina Kieffmann, Sophie Schulha, Igor Matushansky, Doron Merkler, Daniel Pinschewer, Klaus Orlinger.

B132 A new concept of cancer immunotherapy by targeting pancreatic ductal adenocarcinoma through a childhood recall antigen. Benson C. Selvanesan, Dinesh Chandra, Wilber Quispe, Ankur Patel, Kiran Meena, Steven K. Libutti, Ziqiang Yuan, Jennifer Chuy, Claudia Gravekamp

B133 Implantable synthetic immune hydrogel for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity. Chanyoung Song, Il Woo Shin, Long Ren, Yong Taik Lim.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B134 Use of p19Arf/interferon- β immunotherapy in association with chemotherapy permits reduced drug dosage and avoids cardiotoxicity associated with doxorubicin. Bryan E. Strauss, Ruan F.V. Medrano, Rodrigo Tamura, Samir F.V. Mendonça, Valker A. Feitosa, Rafael Dariolli, Thiago A. Salles, Aline Hunger, João P.P. Catani, Elaine G. Rodrigues.

B135 Novel immunotherapeutic strategy based on the immunopathologic properties of cancer stem cells.
Toshihiko Torigoe, Yoshihiko Hirohashi.

B136 Optimized messenger RNA immunolipoplexes for cancer immunotherapy: Balancing immunogenicity and adjuvancy. Rein Verbeke, Ine Lentacker, Karine Breckpot, Serge Van Calenbergh, Stefaan C. De Smedt, Heleen Dewitte.

B137 Preclinical evaluation of a Wilms' tumor protein 1-targeted interleukin-15 dendritic cell vaccine: T cell activity and batch production. Maarten Versteven, David Damoiseaux, Diana Campillo-Davo, Heleen Van Acker, Hans De Reu, Sébastien Anguille, Zwi N. Berneman, Evelien L. Smits, Viggo F. Van Tendeloo, Eva Lion.

B138 Cancer immunotherapy with APOBEC3B-induced heteroclitic library tumor cell vaccines and immune checkpoint blockade. Richard Vile, Laura Evgin, Timothy Kottke, Matthew Schuelke, Christopher B. Driscoll, Amanda L. Huff, Jill Thompson, Amy Molan, Reuben S. Harris, Jose S. Pulido, Phonphimon Wongthida.

B139 Plant viral particle vaccine induces a potent antitumor response through by induction of antigen specific T-cells and overcoming an immunosuppressive tumor microenvironment. Chuan Wang, Yidao Wang, Alex J. Allen, Jantipa Jobsri, Gareth J. Thomas, Christian H. Ottensmeier, Natalia Savelyeva.

B140 Positron emission tomography-guided photodynamic therapy with biodegradable silica nanoparticles for personalized cancer immunotherapy.
Cheng Xu, James Moon.

B141 Antitumor immune responses elicited by mesothelin virus-like particles vaccine effectively controls pancreatic cancer in animal models. Qizhi Cathy Yao, Ethen Poteet, Zhengdong Liang, Phoebe Lewis, Zhiyin Yu, Changyi Chen.

B142 Activation of endogenous anergic self-specific CD8+ T cells by polymeric nanoparticles for enhanced cancer immunotherapy. Qian Yin.

B143 Lace molecular vaccine with adjuvant booster to enhance immunogenicity. Chunson Yu, Haipeng Liu.

B144 Morphologic consequences for non-capsular lymphoid tissue in the case of malignancy of GERD (Barrett's esophagus). Bakhtiyar Talgatuly Azhken.

B145 Identification of tumor cell intrinsic immune evasion mechanisms. Carmen Ballesteros Reviriego, Anneliese O. Speak, Gemma Turner, Vivek O. Iyer, Leopold Parts, David J. Adams.

B146 The tumor necrosis factor superfamily member RANKL suppresses effector cytokine production in group 3 innate lymphoid cells. Jennifer Kaoru Bando, Susan Gilfillan, Christina Song, Keely McDonald, Stanley C-C. Huang, Rodney D. Newberry, Yasuhiro Kobayashi, David S.J. Allan, James R. Carlyle, Marina Celli, Marco Colonna.

B147 From bioactive small molecule to an identified protein target: A new method combining stochastic photomodification with a synthetic antibody mimetic. Kristyna Blazkova, Petr Šimon, Tomáš Knedlík, Petra Dvořáková, Anna Březinová, Libor Kostka, Vladimír Šubr, Jan Konvalinka, Pavel Šácha.

B148 Microvilli enable efficient T cell antigen search and ligand detection. En Cai, Kyle Marchuk, Casey Beppler, Matthew Krummel.

B149 Real-time analysis of cell membrane protein and virus internalization using site-specific conjugation of protease-sensitive probes. Ross W. Cheloha, Zeyang Li, Djenet Bousbaine, Andrew Woodham, Priscillia Perrin, Jana Volaric, Hidde L. Ploegh.

B150 STING acquired species-specific motifs to control alternative immune responses. Carina C. de Oliveira Mann, David S. King, Philip J. Kranzusch.

B151 Exploring the induction of immunogenic cell death (ICD) by high intensity focused ultrasound (HIFU). Heleen Dewitte, Yanou Engelen, Guillaume Lajoinie, Lígia Gomes-da-Silva, Michel Versluis, Stefaan C. De Smedt, Guido Kroemer, Karine Breckpot, Ine Lentacker.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B152 Generation of monoclonal antibodies against a newly identified target for invasive prostate cancer and their use in the development of an antibody-based targeting therapy. Anna Di Biase, Tarik Regad, Jayakumar Vadakekolathu, Desmond Powe, Hans-Martin Jäck, Edith Roth.

B153 Human NK cell distribution memory and residence in tissue sites. Pranay Dogra, Takashi Senda, Peter Szabo, Dustin Carpenter, Marta Toth, Puspa Thapa, Mark Snyder, Michelle Miron, Brahma Kumar, Donna L. Farber.

B154 Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses – implications for the management of irAEs. Marco Donia, Troels H. Borch, Haja D. Radic, Christopher H. Chamberlain, Aishwarya Gokuldass, Inge Marie Stentoft Svane, Arianna Draghi.

B155 Impact of transcription initiation on translation regulation by the mTOR pathway. Sascha H. Duttke, Max Chang, Christopher K. Glass, Andrea Berman, Christopher Benner.

B156 Characterization and role of CCR8+ regulatory T-cells in mouse models of malignant melanoma. Andrew K. Edwards, Mihaela Skobe, Anita Rogic, Marcus Bosenberg.

B157 Modulation of Natural Killer cell dysfunction in human bladder cancer. Adam M. Farkas, Francois Audenet, Harry Anastos, Matthew Galsky, John P. Sfakianos, Nina Bhardwaj.

B158 Clinical features and management of mantle cell lymphoma. Fatiha Grifi, Soraya Bougerira, Amel Djenouni.

B159 Investigating the neuroimmune interaction between nociceptive neurons and dendritic cells. Pavel Hanc, Siyi Huang, Ulrich H. von Andrian.

B160 Comparative analysis of pharmacokinetics and antitumor effect between anti-PD-1 and anti-PD-L1 in mice models. Hiroto Hatakeyama, Taiki Kurino, Hiroyuki Suzuki, Ayu Terui, Tomoya Uehara, Yasushi Arano, Akihiro Hisaka.

B161 Pseudoprogression of metastatic abdominal wall nodules in a patient with lung carcinoma treated with pembrolizumab. Tiffany Hennedige, Daniel Tan, Narayanan Gopalakrishna Iyer, Amit Jain.

B162 Developmental programming of long-term immunity of CD8 T cells by perinatal glucocorticoids. Jun Young Hong, Bharat Vaidyanathan, Jen Young Cho, Ruslan Medzhitov.

B163 Regulation of translation by the interferon-induced antiviral protein viperin. Chun-Chieh Hsu, Maudry Laurent-Rolle, Peter Cresswell.

B164 Inhibiting glycolysis enhances imiquimod-induced immunogenic cell death and the antitumor immune response. Shi-Wei Hunag, Jeng-Jer Shieh, Sin-Ting Wang, Der-Yang Cho, Shao-Chih Chiu.

B165 Investigating in vivo synergistic effect of checkpoint blockade and radiation therapy against chordomas in a humanized mouse model. Wataru Ishida, Kyle L. McCormick, Aayushi Mahajan, Eric L. Feldstein, Michael Lim, Jeffrey N. Bruce, Peter D. Canoll, Sheng-fu L. Lo.

B166 Mass spectrometric characterisation of MHC peptides on therapeutic EBV transformed primary lymphoblastoid cells from HLA A*11 patients. Amit Jain.

B167 Antigen presenting cells as coordinators of T cell responses to gut microbiota. Ranit Kedmi, Kai Mesa, Dan Littman.

B168 A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with glioblastoma multiforme in The Cancer Genome Atlas Dataset. Inah Kim, Bum Sup Jang.

B169 Engineering phase separation of multivalent signaling proteins through the solubility of folded protein domains. Jonggul Kim, Jonathon Ditlev, Michael K. Rosen.

B170 Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases. Julie Leca.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B171 Elucidating the mechanism of RAG tracking and its impacts on V(D)J recombination. Cheng-Sheng Lee, Jiazhi Hu, Frederick W. Alt.

B172 Molecular mechanisms of Dual-Specificity Phosphatase 22 (DUSP22) in suppression of tumorigenesis: The potential involvement of the EGFR/PD-L1 axis. Wen-Jye Lin, Cheng-Wei Chang, Hsiu-Ping Lin, Hui-Min Ho.

B173 G protein coupling signaling as regulators of dendritic cell maintenance and function in immune responses. Dan Liu, Jason G. Cyster.

B174 Co-expression of stimulators and inhibitors of T-cell activation in melanoma. Rachana Maniyar, Robert Freund, Aryan Malhotra, Sanjukta Chakraborty, Jan Geliebter, Marc Wallack, Raj K. Tiwari.

B175 Semliki Forest virus-mediated oncolytic immunotherapy in mouse GL261 glioblastoma model. Miika Martikainen, Di Yu, Mohanraj Ramachandran, Grammatiki Fotaki, Minttu-Maria Martikainen, Andres Merits, Magnus Essand.

B176 Sequential immunotherapy and association with clinical outcomes in advanced stage cancer patients. Mehmet Bilen, Dylan Martini, Yuan Liu, Colleen Lewis, Hannah Collins, Julie Shabto, Mehmet Akce, Haydn Kissick, Bradley Carthon, Walid Shaib, Olatunji Alese, Rathi Pillai, Conor Steuer, Christina Wu, David Lawson, Ragini Kudchadkar, Bassel El-Rayes, Viraj Master, Suresh Ramalingam, Taofeek Owonikoko, R. Donald Harvey.

B177 Analysis of immunogenic cell death (ICD) induced in multiple myeloma cells. Maiko Matsushita, Sho Kashiwazaki, Satoshi Kamiko, Ryo Uozaki, Daiju Ichikawa, Yutaka Hattori.

B178 Development and pre-clinical efficacy characterization of a systemically administered multiple Toll-like receptor (TLR) agonist for antitumor immunotherapy. Michael J. Newman.

B179 The regulation of silent apoptotic cell-clearance in tissue-resident macrophages. Kathleen Pestal, Gregory M. Barton.

B180 Effects of EMT process under MHC class I and TAP1 gene expression related to antigen presentation. Pedro Ratto Lisboa Pires, Pedro L.P. Xavier, Heidge Fukumasu.

B181 Adenovirus, Semliki Forest virus and Vaccinia virus-induced immunogenic cell death augments oncolytic virus immunotherapy. Mohanraj Ramachandran, Magnus Essand.

B182 Repurposing antiviral T cells to fight tumors.

Pamela C. Rosato, Sathi Wijeyesinghe, J. Michael Stolley, Christine Nelson, Rachel L. Davis, Luke S. Manlove, Christopher A. Pennell, Bruce R. Blazar, Clark C. Chen, Melissa A. Geller, Vaiva Vezys, David Masopust.

B183 LFA-1 signals via Crk adapter proteins to induce actin-dependent T cell migration and mechanosensing.

Nathan H. Roy, Joanna L. MacKay, Alexander Buffone Jr, Krista L. Newell, Tanner F Robertson, Sangya Agarwal, Mobin Karimi, Daniel A Hammer, Janis K Burkhardt.

B184 Modulating antigen flow to control immune tolerance. Megan K. Ruhland, Edward W. Roberts, Matthew F. Krummel.

B185 Epithelial cancer cell expressed genes contribute to clinically relevant immune-based classifications of breast cancer. Jonathan Shepherd, Charles Perou.

B186 Tumor cell-derived proteases contribute to antigen processing and enhance cross-presentation.

Nicholas J. Shields, Katie A. Young, Christopher Jackson, Sarah A. Young.

B187 Origins of neoantigens for the major histocompatibility complex class I pathway. Ewa Maria Sroka, Rodrigo Prado Martins, Chrysoula Daskalogianni, Sebastien Apcher, Robin Fahraeus.

B188 CMTM6, beyond a regulator of PD-L1 expression.

Chong Sun, Riccardo Mezzadra, Raquel Gomez-Eerland, Ingrid Hofland, Dennis Peters, Annegien Broeks, Hugo M. Horlings, Wei Wu, Albert J. R. Heck, Ton N.M. Schumacher.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B189 Recognition of cytosolic DNA in tumor cells

depends on cGAS and STING. Manuel Adrian Suter,

Wendy Ya Ling Zhang, Muznah Bte Nazar Khan Khatoo,

Nikki Ya Ling Tan, Chien Tei Too, Shubhita Tripathi, Paul A.

MacAry, Veronique Angeli, Stephan Gasser.

B190 WASP-dependent actin protrusions mechanically

potentiate killing by cytotoxic T cells. Fella Tamzalit,

Mitchell S. Wang, Weiyang Jin, Vitaly S. Boyko, John M.

Heddleston, Charles T. Black, Lance C. Kam, Morgan Huse.

B191 The impact of postoperative myeloid-derived

suppressor cells on prognosis of gastric cancer patients.

Shinya Urakawa, Hisashi Wada, Masaki Mori, Yuichiro Doki.

B192 CD56 participation in immune effector cell

activation and tumor cell eradication: A role for

interleukin-15. Heleen H. Van Acker, Maarten Versteven,

Hans De Reu, Peter Ponsaerts, Zwi N Berneman, Viggo F.

Van Tendeloo, Evelien L. Smits.

B193 PD-L1 somatic alterations predict sensitivity of

advanced prostate cancer patients to platinum-based

chemotherapy. Panagiotis J. Vlachostergios, Aileen

Lee, Charlene Thomas, Priyanka Patel, Amy L. Hackett,

Naureen Rashid, Ana M. Molina, David M. Nanus, Himisha

Beltran, Scott T. Tagawa.

B194 Quantifying the interaction between macrophages

and deformable microparticles with cell-like mechanical

properties. Daan Vorselen, Yifan Wang, Matt Footer, Wei

Cai, Julie Theriot.

B195 Chemical probes for exploring muropeptide-

pattern recognition receptor interactions in cells. Yen-

Chih Wang.

B196 Examining proteasome sensitivity of lymphoid

malignancy: Ubiquilin 1 (Ubqln1) is required for BCR-

induced proliferation of B cells. Alexandra M. Whiteley,

Eric Brown, Daniel Finley.

B197 Translational control in macrophages during

inflammatory response. Kehui Xiang, David P. Bartel.

B198 Dissection of ROR γ t functions in lymphoid cell fate

determination and differentiation. Hao Xu, Dan Littman,

Wendy Huang.

B199 Potent induction of immunogenic cell death by PT-112. Takahiro Yamazaki, Tyler David Ames, Lorenzo Galluzzi.

B200 Single-cell RNA-sequencing (ScRNA-seq) reveals broad heterogeneity among CD8 T cells during chronic viral infection and identifies a critical role for CD4 help in promoting the differentiation of a potent cytotoxic CD8 T cell subset. Ryan Zander, David Schauder, Gang Xin, Christine Nguyen, Xiaopeng Wu, Weigu Cui.

B201 Exploration and exploitation of macrophage death pathways: Infection by Mycobacterium tuberculosis as a model. Li Zhang, Carl Nathan.

B202 Defining the role of IL-27 signaling on responses to metastatic melanoma. Anthony T. Phan, Christopher A. Hunter.

B203 Chemokine modulation to enhance the effectiveness of pembrolizumab in patients with metastatic triple negative breast cancer. Yara Abdou, Paweł Kalinski, Mateusz Opyrchal.

B204 Collimator design and simulation for preclinical radiotherapy applications using a clinical cell irradiator. Jessica Benitez, Davide Fontanarosa, Robert Mazzieri, Davide Moi.

B205 Adoptive transfer of autologous T cells, modified with a MART-1 specific TCR and cultured in IL-7/IL-15, for the treatment of metastatic melanoma patients.

Raquel Gomez-Eerland, Maartje Rohaan, Joost van den Berg, Maaike van Zon, Renate de Boer, Noor Bakker, Bastiaan Nijnen, Ton N.M. Schumacher, John B.A.G. Haanen.

B206 Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab. Niels Halama, Ulrike Prüfer, Anna Froemming, Diana Beyer, Dirk Eulberg, Jarl Ulf Jungnelius, Aram Mangasarian.

POSTER SESSION B

Tuesday, October 2 • 12:45 p.m.-3:15 p.m.

Westside Ballroom (Fifth Floor)

B207 Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE. Naiyer

Rizvi, Patricia Tang, Nina Bhardwaj, Timothy A. Chan, Jeffrey S. Weber, Michael Vickers, Sofya Pintova, Holger Hirte, Neil H. Segal, Neesha Dhani, Daniel Cho, Stephen Chia, Caitlin Burns, Donsheng Tu, Laura Pearce, Alison Urton, Martin Smoragiewicz, Janet Dancey.

B208 APAVAC®, a very simple autologous vaccine (AV) process with clinical efficacy in advanced cancers (C): Results of a pilot study including 55 patients. Jean-François Rossi, Nicole Rouquet, Patrick Frayssinet.

B209 Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Joshua Sabari, Kristen Aufiero Ramirez, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus.

AUTHOR INDEX

A

Abbott, Rachel	A002
Abdel-Hakeem, Mohamed S.	A166
Abdelaal, Tamim	A063
Abdelsamed, Hossam.....	A189
Abdou, Said M.	A106
Abdou, Yara.....	B203
Abdul Razak, Alibiruni	A007
Abdullahi, Sarah.....	B098
Abraham, Manju C.....	B116
Abu-Akeel, Moshen.....	A225
Ackerstaff, Ellen	A089
Adamow, Matthew	A016
Adams, Daniel L.	A012
Adams, David J.	B145
Adams, Erin J.....	PR16
Admon, Arie	A020
Adriani, Giulia	A049
Adriano Silva Manzano, Daniel	B023
Aerts, Joachim J.G.J.V.....	A164, A165, B117
Afferni, Claudia.....	A091
Agarwal, Neeraj.....	A008
Agarwal, Sangya.....	B183
Ager, Casey R.	A050
Aggarwal, Sadhna	A167
Agudo, Judith	A168
Aguilar, Brenda.....	A045
Ahmad, Sadeem	A122
Ahmed, Khunsha	A184
Ahmed, Rafi.....	A196
Ahn, Jin Seok	A138
Ahn, Myung-Ju	A138
Akard, Luke	A003
Akazawa, Yu.....	A001
Akbay, Esra A.....	A125
Akce, Mehmet.....	B176
Akers, Nicholas.....	B071
Aksnes, Anne-Kirsti.....	A022
Al Abosy, Rose	A216
Al-Taei, Saly	B007
Alanio, Cecile	A123
Alavi, Sara	A154
Albeg, Avi S.....	A089
Albert, Michael H.	A224
Alberto, Emily.....	A092
Alekseeva, Tijna.....	A111
Alese, Olatunji.....	B176

AUTHOR INDEX

Alessandrini, Gabriele	A207
Ali, Haythem.....	A081
Ali, Mohammed-Alkhatim	A166
Ali, Omar A.....	B119
Alimonti, Andrea.....	B003
Allan, David S.J.	B146
Allbritton, Omaira.....	A174
Allen, Alex J.	B139
Allen, Clint	A068
Allen, Stacey	A208
Allison, James P.	A205
Alt, Frederick W.	B099, B171
Altman, Amnon.....	A211
Altomonte, Jennifer	B098
Alvarez Fernandez, Carmen.....	A023, A028
Amado, Rafael.....	A002, A007
Amanda, Huff L.....	A029, A133, B138
Ambrose, Christine.....	A040
Ambross, Peter.....	A013
Ames, Tyler David	B199
Amirouchene Angelozzi, Nabil	B069
Amit, Ido.....	B054
Amodio, Vito	B069
Amsen, Derk.....	A185
Amsili, Shira.....	A076
Amstutz, Pete	A012
Anande, Govardhan	B129
Anang, Nana-Ama A.S.....	A205
Anastasio, Elana.....	B085
Anastos, Harry	B157
Anderka, Kristin	B085
Andersen, Rikke Sick	B015, B036, B092
Anderson, Amy E.	A124, A157
Anderson, Bart R.....	A136
Anderson, Katie L.....	A051
Anderson, Kenneth	B100
Anderson, Regan	B103
Andreone, Sara.....	A091
Andresen, Thomas	A188
Angeli, Veronique	B189
Anguille, Sébastien	B137
Anjanappa, Raghavendra.....	B049
Anna, Ida M.	A169
Anna, Kreutzman.....	A085, A130, A134
Anna, Najuma Nujum Ambili.....	B116
Anne Laure, Flamar.....	A075
Anoop, Minu.....	A169, B116

Anson, Marie	A172
Antonelli, Anthony	B087
Apcher, Sebastien.....	B187
Arano, Yasushi	B160
Araujo, Dejka.....	A002, A007
Arce Vargas, Frederick.....	A192
Ardito, Matthew	B089
Aronin, Alexandra.....	A076
Arshi, Mehreen.....	A100
Arthur, Janelle	A075
Asai, Hiroaki	B031
Asano, Toshimichi.....	A118
Ashenberg, Orr.....	A082
Ashok, Devika	A157
Ashokan, Anusha.....	A169, B028, B116
Assenmacher, Mario.....	B016
Atabani, Suha.....	B102, B104
Attia, Mohamed.....	A106
Audenet, Francois	B157
Aufiero Ramirez, Kristen.....	B209
Aura, Kaunisto	A128
Australian Pancreatic Cancer Genome Initiative, APGI -	A100
Authier-Hall, Astrid	B103
Autio, Karen A.....	A016
Avalle, Lidia	B105
Awad, Walid	A189
Azam, Tariq U.	A210
Azhken, Bakhtiyor Talgatuly.....	B144

B

Ba, Zhaoqing.....	B099
Bachanova, Veronika	A003
Backman, Charlotta	B123
Bae, Jeong Mo.....	B084
Bae, Jooeun.....	B100
Bahmanof, Milad	B090
Bai, Zhigang	B095
Bailey, Justin R.	B109
Baker, David A.....	B023
Baker, Esme O.	B085
Bakker, Noor.....	B205
Balakrishnan, Aparna	A169
Balanis, Nikolas G.....	A097
Balch, Leslie.....	A068
Balch, Sara	B085
Bald, Tobias	A070

AUTHOR INDEX

Baldwin, Michael L.	A032
Ball, Matthew K.	A210
Ballesteros Reviriego, Carmen	B145
Bando, Hideaki	A017
Bando, Jennifer Kaoru	B146
Banks, Alex	B062
Banuelos, Jesus	A157
Bao, Yangyi	A014
Barault, Ludovic	B069
Barbie, David A.	A082
Barchan, Karin	A183
Bardelli, Alberto	B069
Bardwell, Philip	A188
Barish, Michael E.	A045
Barkho, Wisam	B013
Barnett, Yvonne	A135
Barry, Andrew	B046
Barry, Kevin C.	A052/PR4
Bartel, David P.P.	B197
Bartolini, Alice	B069
Barton, Gregory M.	B179
Bastian, Ingmar Niels	B091
Basu, Samik	A007
Bauer, Peter	B124
Bax, Heather J.	A095
Becattini, Simone	A170
Becker, Annette	A124
Becker, Jürgen C.	B020
Beckmann, Max	B024
Bedke, Nicole	A214
Beechem, Joseph M.	B006
Behjati, Sam	B022
Belkaid, Yasmine	PR16
Bell, John C.	B101
Bell, Richard B.	A186
Bellmann, Lydia	A102
Belmont, Brian	A027
Beltra, Jean-Christophe	A166
Beltran, Himisha	B193
Ben-gigi-Tamir, Liat	A076
Benchaaben, Assil	A182
Bengsch, Bertram	A123
Benitez, Jessica	B204
Benner, Christopher	B155
Benoist, Christophe	B065
Benson, Bryan L.	A195
Benzeno, Sharon	A034, B115

Beppler, Casey	B148
Berdugo, Gad.....	B089
Berghaler, Andreas	A070
Berka, Ursula.....	B131
Berman, Andrea J.....	B155
Bernatchez, Chantale	A082
Berneman, Zwi N.....	B137, B192
Bernstein, Steve	B101
Berthel, Anna.....	A171
Berzofsky, Jay A.	A004
Besse, Andrej	A070
Besse, Lenka.....	A070
Bessell, Catherine Ami	B060
Bessman, Nick	A075
Beyer, Diana	B206
Bhanot, Gyan	B076
Bhardwaj, Nina	A005, A104, A109, A191, B032, B072, B080, B108, B157, B207
Bhuwan, Giri.....	B111
Bi, Kevin.....	A216
Biankin, Andrew	A100
Bignone, Veronica	B105
Bilen, Mehmet.....	B176
Bilic, Sanela	A188
Binder, Vera	A224
Bindokas, Vytautas P.....	B021, B025
Binyamin, Anna	B087
Birt, Alyssa.....	A040
Bist, Meghna.....	B063
Bjerregaard, Anne-Mette.....	B015, B070, B092, B129
Bjorkman, Pamela J.....	B109
Black, Charles T.....	B190
Blaeschke, Franziska.....	A043, A224
Blanc, Charlotte.....	A172
Blank, Christian	B022
Blasberg, Ronald G.	A089
Blat, Dan.....	A214
Blazar, Bruce R.	B182
Blazeck, John.....	B008
Blazkova, Kristyna	B147
Blazquez, Ana B.....	A005, B032, B080
Blobner, Jens.....	B075
Bluestone, Jeffrey A.	A163
Blumberg, Richard Steven	A191
Bodenhöfer, Mona	B039
Boesch, Austin.....	A188
Boettcher, Lisa.....	B016

AUTHOR INDEX

Boiarsky, Jonathan	A125
Boland, Genevieve M.....	A082
Bolli, Evangelia	A083
Bombik, Izabela.....	B001
Bomze, David.....	A070
Bonilla, Weldy V.....	B131
Bono, Petri.....	A134
Bonzom, Emilie	A182
Borch, Annie.....	B070
Borch, Troels H.....	B154
Borges, Virginia.....	A117
Borges da Silva, Henrique.....	A173
Bortoluzzi, Alessio.....	B001
Böschen, Maxi-Lu	A024
Bose, Nandita.....	A057
Bosenberg, Marcus W.	B156
Bosselut, Rémy.....	A201
Bossi, Giovanna	A214
Botta Gordon-Smith, Sophie.....	A214
Bouches, Yves.....	A115
Bougherira, Soraya.....	B158
Bousbaine, Djenet	B149
Boyken, Scott E.....	B023
Boyko, Vitaly	B190
Bozza, Matthias.....	A042
Brandt, Cameron.....	A027
Brea, Elliott J.....	A125
Breckpot, Karine	B136, B151
Breckwoldt, Michael O.	B075
Breitbach, Caroline	B101
Bremer, Edwin	A076
Brentjens, Renier J.	A152
Brentville, Victoria A.....	B102, B104, B122
Březinová, Anna	B147
Brinkman, Jacqueline	B021
Briones, Javier	A023, A028
Briquez, Priscilla.....	B130
Briskin, Michael.....	A220
Brito, Alfonso	A045
Brix, Liselotte	B014
Brody, Jonathan R.....	A101
Broeks, Annegien	B188
Brogaard, Rikke.....	B014
Brooks, Collin	B103
Brown, Brian D.	A168
Brown, Christine E.....	A045
Brown, Eric	B196

Brown, Mark	A192
Brown, Myles.....	A077, A146, A218, B077
Broyer, Lucile	A088
Bruce, Jeffrey N.	B165
Brück, Oscar.....	A085, A130
Bruderer, Roland.....	A066
Brulais, Kevin	A121
Brüne, Bernhard.....	A209
Bruno, Tullia C.	A053
Bryan, Cassie M.	B002
Bu, Luke.....	B059
Bu, Xia.....	A077, B077
Buatois, Vanessa.....	A088
Bubie, Adrian P.....	B071
Buccione, Carla.....	A091
Buchbinder, Elizabeth I.....	A082
Budhu, Sadna.....	A225
Budka, Justin A.	A184
Buechler, Markus.....	A171
Buffone Jr, Alexander.....	B183
Bühring, Hans-Jörg	A131
Bunse, Lukas	PR15
Bunse, Theresa	A071
Buque Martinez, Aitziber.....	A150
Burgess, Michael	B101
Burkhardt, Chiara.....	A113
Burkhardt, Janis K.	B183
Burleigh, Stephen	A027
Burn, Olivia Kelsen	B103
Burns, Caitlin.....	B207
Burova, Elena.....	A174
Busch, Dirk H.	A043
Businaro, Luca	A091
Bussler, Holm	A068
Busz, Maria	B024
Butcher, Eugene.....	A121
Byers, Lauren A.....	A059, A153
Bykowski Jonas, Adria	A057
Byrne, Katelyn T.....	A054

C

Caballero Gonzalez, Ana Carolina	A023, A028
Cafri, Gal.....	A175, B055
Cai, En	B148
Cai, Wei.....	B194
Calcinotto, Arianna	B003
Callahan, Margaret K.	A006, A225

AUTHOR INDEX

Camara, Steven	A215
Campillo-Davo, Diana.....	B137
Canadas, Israel.....	A082
Cancelliere, Carlotta.....	B069
Canestraro, Martina.....	A214
Canoll, Peter D.....	B165
Canonigo-Balencio, Ann J.	A211
Cantor, Harvey	A039
Cao, Carmen J.M.....	A087
Capoccia, Benjamin J.	A147
Cappellano, Giuseppe	A102
Capuano, Floriana	B086
Carbo, Adria	A034, B115
Carlino, Matteo S.	A154
Carlyle, James R.	B146
Carpenter, Dustin.....	B153
Carr, Robert W.....	A147
Carr, Steven A.....	A010, B042
Carreira, Ricardo J.....	B086
Carretero, Rafael.....	PR15
Carstensen, Laura Stentoft	A079
Carter, Alun J.	A147
Carter, Robert	A189
Carthon, Bradley	B176
Cartwright, Adam N.R.	A082, A176
Caruso, Santina	A188
Casadei, Nicolas	B124
Casanova, Maria	A055
Casanova, Ruben	A113
Cascio, Matthew.....	A204
Cascone, Tina	A059
Caswell, Deborah.....	A160
Catanese, Maria Teresa	B105
Catani, João P.P.....	B134
Cavanaugh, Jillian.....	B008
Celis, Esteban.....	A030
Cella, Marina.....	B146
Cerullo, Vincenzo.....	B123
Cesano, Alessandra.....	B096
Chadwick, Eric	A027
Chae, Chang-Suk	A056
Chae, Woon Hyung	A111
Chagin, Karen	A002, A007
Chajut, Ayelet	A076
Chakraborty, Papia.....	A112
Chakraborty, Sanjukta	B174
Chamberlain, Christopher A.....	B154

Chan, Ivan H.....	A016
Chan, Anissa S.H.....	A057
Chan, Godfrey C.F.	A087
Chan, Mei-Chi.....	A200
Chan, Timothy A.....	B207
Chandel, Navdeep S.	B067
Chandra, Dinesh.....	B132
Chang, Cindy A.	A032
Chang, Wen-Chung.....	A045
Chang, Shu-Ching.....	A186
Chang, De-Kuan.....	A188
Chang, Max.....	B155
Chang, Cheng-Wei	B172
Chantrill, Lorraine	A100
Chao, Jaime L.....	A177
Chaorentong, Pornpimol	A171
Charles Eklund, Aron.....	B092
Charoentong, Pornpimol	A114
Chatel, Laurence	A088
Chauchet, Xavier.....	A088
Chaudhuri, Amitabha	A112
Cheloha, Ross W.	B149
Chen, Ada	A157
Chen, Andrew X.	B005
Chen, Changyi.....	B141
Chen, Clark C.	A078, B182
Chen, Haiying.....	A180
Chen, I-Yu.....	A221
Chen, Jian	A026
Chen, Jie.....	A157
Chen, Joyce	A178
Chen, Liang.....	B004/PR14
Chen, Limo.....	A059, A153
Chen, Peiwen	A060
Chen, Sidi	B095
Chen, Suzie.....	A102
Chen, Wei-Wu Tom	PR3
Chen, Yen-Lin.....	B085
Chen, Yi-Guang	A163
Chen, Yuhui	A025
Chen, Zeyu.....	A166
Chen, Zhijian J.	A116
Cheng, Hung-Wei	A070
Cheng, Kuang-Hua.....	A221
Cheng, Wan-Chen	A179
Chia, Stephen.....	B207
Chin, Melissa.....	A027

AUTHOR INDEX

Chinai, Jordan Manek	A180
Chiu, Yen-Ling	A221
Chiu, Shao-Chih.....	B082, B164
Cho, Daniel	B207
Cho, Der-Yang.....	B082, B164
Cho, Hearn J.....	A005
Cho, Hee Jin	A138
Cho, Jen Young	B162
Choi, Hyejin	A125
Choi, John.....	B106
Chon, Hongjae.....	A061
Chou, Chun	A181
Choudhury, Ruhul.....	B102, B014
Choujenko, Dmitry	B059
Chow, Ryan.....	B095
Chow, Warren A.....	A002, A007
Christensen, Dennis	B118
Chu, Xiaona	A184
Chua, Jia X.....	A161
Chundayil Madathil, Girish	A169, B028, B006
Church, Candice D.....	B020
Chuy, Jennifer	B132
Ciacci, Joseph D.....	A078
Cieciuch, Kathleen.....	B063
Ciliberto, Gennaro	A207
Cillo, Anthony R.....	A053
Cimen Bozkus, Cansu	B072
Ciucci, Thomas	A201
Clancy, Trevor	B073
Clark, Jeffrey W.....	A115
Clark-Knowles, Katherine.....	B101
Claudia, Penafuerte.....	B035
Clausen, Bjorn E.....	A102
Clauser, Karl R.	A010, B042
Clavijo, Paul	A068
Cluse, Leonie A.	A149
Codd, Amy S.....	B007
Cohen, Ezra E.W.....	B090
Cohen, Ivan.....	A089
Cohen, Jonathon.....	A003
Cohen, Sarah.....	B027
Colbert, Michelle	B109
Collignon, Aurélie	A182
Collins, Hannah.....	B176
Collison, Sean.....	B024
Colloca, Stefano	B105
Colonna, Marco.....	B146

Coma, Silvia.....	B008
Cons, Laura.....	A088
Constantinides, Michael G.....	PR16
Convit, Ana Federica	B112
Cook, David	B063
Cook, Katherine W.	B102, B104
Cook, Rebecca S.	A187
Correa, Luis.....	A195
Correia, Lucia.....	B024
Correnti, Colin E.....	B023
Cotugno, Gabriella	B105
Coufal, Nicole G.	A078
Couts, Kasey.....	A117
Cozzitorto, Joseph A.	A101
Cresswell, Peter	B163
Criado-Moronati, Elvira.....	B016
Crisafulli, Giovanni.....	B069
Croft, Alexandra	A027
Crowe, Jr., James E.....	B109
Crupi, Mathieu	B101
Cubas, Rafael.....	A120
Cui, Weiguo	B200
Cundell, Michael J.....	B086
Cuoco, Michael S.	A082
Cupovic, Jovana.....	A070
Curioni-Fontecedro, Alessandra	A113
Curran, Michael A.	A050
Curtis, Mark	A101
Cyster, Jason G.....	B173
Czerwinska, Partycja.....	A144
Czerwinski, Debra KB	KB128
Czonka, Ewelina	A092

D

D'Alise, Anna Morena.....	B105
D'Angelo, Sandra P.....	A002, A007
D'Incalfi, Maurizio.....	B069
Dadi, Saida.....	A181
Daftarian, Pirouz M.	B074
Dahan, Rony.....	A126
Dahlén, Eva.....	A183
Dahlman, Anna.....	A183
Dai, Jie	A062
Dakshinamoorthy, Gajalakshmi.....	A073, A074
Damayanti, Nur P.....	A184
Dammeijer, Floris F.	A164, A165, B117
Damoiseaux, David	B137

AUTHOR INDEX

Danaher, Patrick.....	B096
Dancey, Janet.....	B207
Daniels, Gregory A.....	A009
Daniels, Ian	B102, B104
Dao, Tao.....	B019
Daraj, Ghazal	B125
Darcy, Phillip K.	A047
Dariolli, Rafael.....	B134
Das, Krishna.....	A067
Das, Satya N.....	A167
Dash, Pradyot	A189
Daskalogianni, Chrysoula.....	B187
Davicioni, Elai.....	A008
David, Barba.....	A078
Davis, Dana.....	A117
Davis, Mark	B004
Davis, Melissa.....	A081, A090
Davis, Rachel L.....	B182
Davis, Sterenn.....	B024
Davis, Theodore B.	B046
de Boer, Reante.....	A038, B205
de Bono, Johann.....	B003
de Braud, Filippo	B069
de Bruijn, Marjolein	B050
De Groot, Anne S.	B089
De Groot, Rosa	A185
de Jong, Rob M.	A044
De la Parra, Columba.....	A222
De Lucia, Maria.....	B105
de Miranda, Noel F.	A063, B186, B094
De Ninno, Adele	A091
de Oliveira Mann, Carina C.	B150
De Reu, Hans.....	B137, B192
de Reyniès, Aurélien	PR3
de Ru, Arnoud H.	A044
De Smedt, Stefaan C.	B136, B151
de Vries, Natasja L.	A063
DeCrescenzo, Gary	A011
Delcommenne, Marc	B074
Dellacherie, Maxence O.	B119
Demberg, Thorsten	A015
Demetri, George	A002, A007, B085
Deng, Jiehui.....	A125
Deng, Liang	B106/PR9
Deng, Zihou.....	A127
Deniger, Drew C.	A175, B055
DePinho, Ronald	A060

Descot, Arnaud	A092
Deshpande, Vikram.....	A115
Desjardins, Christopher.....	B063
Deumelandt, Katrin.....	PR15, B075
Dewitte, Heleen.....	B136, B151
Dhani, Neesha.....	B207
Di Biase, Anna	B152
Di Francesco, Maria E.	A050
Di Matteo, Elena.....	B105
Di Nicolantonio, Federica.....	B069
Diao, Lixia	A059, A153
Didelot, Gérard.....	A088
Diers, Miechaleen D.	A036
Dietrich, Pierre-Yves	A020
Dillard, Pierre	A035
Dillon, Patrick.....	A006
Dimalanta, Eileen T.	B046
Dimberg, Anna	A128, A159
Ding, Jun	B059
DiRenzo, Daniel.....	A162
DiSpirito, Joanna R.	B065
Ditlev, Jonathon	B169
Djenouni, Amel.....	B158
Dmitrovsky, Ethan	A059
Dobrzycki, Tomasz	A214
Doench, John.....	A146
Dogra, Pranay	A189, B153
Doki, Yuichiro.....	B191
Donahue, Arthur	A018
Donahue, Bailey	A027
Donellan, Zoe.....	A214
Dong, Haidong	A210, B097
Donia, Marco	B015, B039, B049, B092, B154
Donio, Michael J.....	A147
Donovan, Michael	A005
Dotti, Gianpietro	A025
Dottino, Peter R.	A005
Dougan, Stephanie K.....	A129
Downes, Michael.....	A115
Downward, Julian	A145, A160
Draghi, Arianna	B154
Dranitzki-Elhalel, Michal	A076
Driessens, Christoph.....	A070
Driscoll, Christopher B.	A133, B138
Dronca, Roxana S.	A210, B097
Druta, Mihaela.....	A002, A007
Dubuisson, Agathe.....	B009

AUTHOR INDEX

Duda, Dan G.....	A115
Dudeja, Vikas	B111
Duffy, Colm R.....	A205
Dufort, Fay.....	A040
Dufva, Olli	A065, A134
DuHadaway, James B.....	A101
Duhen, Rebekka.....	A186, B094
Duhen, Thomas	A186, B094
Dukes, Joseph.....	A214, B024
Dunphy, Michael.....	B085
Duong, Jessie.....	B101
Dupuis, Nicholas	A066, B010
Durrant, Lindy G.	A161, B102, B104, B118, B122
Duttke, Sascha H.	A078, B155
Duval, Matthieu	A182
Dvořáková, Petra.....	B147
Dzionek, Andrzej.....	B016

E

Ebert, Oliver	B098
Ebert, Peter	A034, B115
Ebinger, Martin	A013, B124
Eddy, James A.....	B051
Edwards, Andrew K.	B156
Efremova, Mirjana.....	A102
Eggers, Erica	A034, B115
Eichmüller, Stefan B.	A067
Eisel, David	A067
Eklund, Aron C.	B129
El-Rayes, Bassel	B176
ElGazzar, Ahmed	B131
Elion, David L.....	A187
Elkrim, Yvon	A083
Ellmark, Peter	A128, A183
Ellonen, Pekka	A065
Elpek, Kutlu	A220
Endo, Itaru	A017
Enell Smith, Karin	A183
Eng, Kevin.....	A084
Engelen, Yanou.....	B151
Eriksson, Emma.....	A119
Ernlund, Amanda.....	A222
Escher, Claudia	B010
Escribà-Garcia, Laura	A023, A028
Essand, Magnus.....	A128, A159, B110, B175, B181
Eulberg, Dirk	B206
Evans, Elizabeth E.....	A068/PR10

Evans, Ronald M.....	A115
Evgin, Laura.....	A029, A133, B138
Ezell, Tucker	A220

F

Facciolo, Franco	A207
Fahraeus, Robin	B187
Falchook, Gerald S.	A016, A018
Falkenberg, J. H.F.....	A038, A044
Fan, Youhong.....	A059, A153
Fan, Yiping.....	A189
Fanchi, Lorenzo.....	B022
Farber, Donna L.	B153
Farin, Henner.....	A111
Farina-Sarasqueta, Arantza.....	A063
Farkas, Adam M.	B157
Fedorova, Olga.....	A187
Feitosa, Valker A.....	B134
Feldhahn, Magdalena	B124
Feldstein, Eric M.....	B165
Felt, Kristen D.	A216
Fend, Laetitia.....	B107
Feng, Hui.....	A213
Ferber, Dyke.....	A069, A086, A114
Ferlin, Walter G.	A088
Fernandez-del Castillo, Carlos.....	A115
Ferrantella, Anthony R.	B111
Ferraresi, Virginia.....	A207
Ferrari de Andrade, Lucas.....	A146
Ferris, Robert L.	A053
Ferrone, Cristina R.	A115
Feuchtinger, Tobias.....	A043, A224
Fichera, Imma	B105
Fieschi, Jacques	A182
Finley, Daniel.....	B196
Finnigan, John P.....	A005, B072, B079, B080, B108
Fisch, Kathleen	B091
Fischer, Manuel.....	B075
Fischer, Nicolas.....	A088
Fisher, Terrence L.	A068
Fitzgerald, Jonathan.....	A188
Fitzpatrick, Conor	A078
Flaadt, Tim.....	A013
Flaherty, Keith.....	A082
Flatz, Lukas.....	A070
Fleifel, Talina	A081
Flinn, Ian.....	A003

AUTHOR INDEX

Flyak, Andrew I.	B109
Foley-Comer, Adam	A076
Folgori, Antonella	B105
Fontanarosa, Davide	B204
Footer, Matt	B194
Forget, Marie-Andree	A082
Forman, Stephen J.	A045
Fossoul, Amelie	A083
Fotaki, Grammatiki	A128, B110, B175
Fox, Bernard A.	A186
Fradette, Jared	A059
Frank, Rik	B013
Franzese, Ornella	A207
Frappolli, Roberta	B069
Frayssinet, Patrick	B208
Frederick, Dennie T.	A082
Frederiksen, Katrine	B014
Freeman, Gordon	A077, B077
Frenzel, Katrin	A020
Freund, Robert	B174
Fridman, Wolf Herve	PR3
Friedlander, Philip A.	A005, B032
Friedrich, Mirco	PR15, B075
Fritsch, Edward F.	A010
Froemming, Anna	B206
Fu, Jingxin	B077
Fuchs, Elaine	A093
Fuchs, Joerg	A013
Fucikova, Jitka	A072
Fujimoto, Junya	A153
Fujimoto, Yuki	A017
Fujiwara, Hiroshi	B031
Fukuda, Masaaki	B081
Fukuda, Minoru	B081
Fukumasu, Heidge	B011, B180
Furebring, Tina	A183
Futami, Junichiro	B081

G

Gadi, Abilash	A222
Gallina, Maria	A073, A074
Galluzzi, Lorenzo	A150, B199
Galsky, Matthew D.	A005, B157
Galy-Fauroux, Isabelle	A172
Ganesan, Shridar	B076
Gao, Dexiang	A117
Garcia-Alai, Maria	B049

Garraway, Levi A.....	A082
Garrett, Wendy S.....	B066
Garrido Hidalgo, Greta	B111
Gartner, Jared J.....	A175
Gartrell, Robyn	B005
Gasser, Stephan.....	B189
Gefen, Tal	B111
Gejman, Ron S.....	B019
Gelbard, Dikla	B054
Gelieberter, Jan.....	B174
Geller, Melissa A.....	B182
Genden, Eric M.....	A005
Gensheimer, Julia L.....	A196
Georgiou, George	B008
Gerardino, Annamaria	A091
Geretti, Elena	A188
Germano, Giovanni.....	B069
Gerry, Andrew.....	A002
Gewe, Mesfin M.	B023
Ghassemi, Saba.....	B029
Ghoneim, Hazem E.	A189
Ghysdael, Jacques.....	A092
Giaccia, Amato J.....	A097
Gibb, Ewan.....	A008
Gibbons, Don	A059, A153
Gibbs, David L.	B051
Gigi, Steven	B062
Gijon, Mohamed	B102, B104
Gilboa, Eli	B111
Giles, Josephine R.	A123, A197, B012
Gilfillan, Susan	B146
Gill, Adrian	A103
Gill, Anthony	A100
Gillies, Stephen D.....	A131
Gilman, Michael.....	A220
Ginn, Elaine.....	A157
Giraudo, Enrico.....	B069
Gjini, Evisa.....	A216
Glasner, Ariella.....	A190
Glass, Christopher K.	A078, B155
Glickman, Michael.....	A215, B087
Glisson, Bonnie S.	A153
Glod, John.....	A002, A007
Gnjatic, Sacha	A005, B088
Goc, Jeremy	A075
Godoy, Maria Jose.....	B112
Gokuldass, Aishwarya	B154

AUTHOR INDEX

Goldfless, Stephen	A027
Goldsmith, Mark A.	A103
Golub, Rachel.....	A172
Golub, Todd.....	B085
Gomes-da-Silva, Lígia C.	B151
Gomez-Eerland, Raquel.....	B188, B205
Gonda, David D.	A078
Gonzales-Ericsson, Paula I.	A187
Gonzalez, Eglyss	B112
Gonzalez Gugel, Elena	A191, B032
Gorden, Keith.....	A057
Götze, Katharina	A092
Goubier, Anne	A192
Gounder, Mrinal.....	A011
Gouttefangeas, Cecile	A020, B124
Gozlan, Yosi M.	A076
Graeber, Thomas G.	A097
Graeve, Sanne.....	A012
Graff, Jeremy.....	A057
Gravekamp, Claudia.....	A151, B132
Gray, Mike J.	B013
Green, Douglas R.	A102
Green, Edward.....	PR15, B075
Greenbaum, Jason	B090
Greengard, Emily	A068
Greenwald, Shirley	A076
Griffioen, Marieke	A044
Grifi, Fatiha	B158
Grønbæk, Kirsten.....	B129
Gros, Alena	B055
Grossman, Rachel	A021
Gruber, Harry E.	A018
Grunkemeier, Gary	A186
Grupp, Stephan	A007
Gryska, Katarzyna	A144
Grzadzielewska, Iga	A144
Gu, Shengqing Stan.....	A077, B077
Guinney, Justin	B051
Guislain, Aurélie	A185
Gupta, Mihir	A078
Gupta, Ravi.....	A112
Gupta, Rohit	A112
Gupta, Shilpa.....	A008
Gupta, Sumati.....	A008
Gurkan, Umut A.	A195

H

Haanen, John B.A.G.....	A185, B022, B050, B205
Hackett, Amy L.....	B193
Hacohen, Nir.....	A010, B042
Haddouk, Hasnaà.....	A088
Hadrup, Sine Reker.	B070
Hagedoorn, Renate S.	A038, A044
Haigh, Oscar.....	B125
Haining, W. Nicholas.....	A216
Hakanen, Henna H.E.....	A130, A134
Halama, Niels	A069, A086, A114, A171
Haley, Stephen T.	B014
Halgreen, Charlotte.....	B014
Halley, Keith.....	B063
Halls, Gabor.....	A174
Hammer, Daniel A.	B183
Hammerbacher, Jeffrey	A005
Hampel, Mareike	A114
Han, Claudia Z.	A078
Hanc, Pavel	B159
Handgretinger, Rupert	A013, A080, A131, A140, B124
Handler, Aaron.....	A188
Handlos, Bryan	A162
Hang, Howard.....	B064
Hannenhalli, Sridhar.....	A201
Hannunen, Tiiina	A065
Hansen, Morten	A079
Haond, Christophe	A182
Haq, Riz	A082
Hara, Junichi.....	A001
Harbottle, Richard	A042
Harish, Vijay.....	A169, B028, B116
Harmuth, Theresa	A080
Harn, Horng-Jyh	B082
Harper, Jane	A214
Harrington, Kevin J.	A133
Harrington, Susan.....	A210
Harris, Patricia	A003
Harris, Reuben S.	A133, B138
Harrison, Ben	A057
Hart, Thomas D.	B005
Hartemink, Koen J.....	A185
Hartigan, Christina R.	B042
Hartweger, Harald	B113
Harvey, R. Donald.....	B176
Hashii, Yoshiko.....	B114
Hatakeyama, Hiroto	B160

AUTHOR INDEX

Hatterer, Eric	A088
Hattori, Yutaka.....	B177
Hauert, Sylvie.....	B130
Haviv, Izhak.....	B127
Hawes, Becker	A188
Hayes, Tim	A034, B115
He, Yukai.....	A030
Head, Jonathan F.....	A009
Heck, Albert J. R.....	B188
Heddleston, John M.....	B190
Heeke, Christina	B015
Heemskerk, Bianca.....	B016
Heemskerk, Mirjam H.M.....	A038, A044
Heinzerling, Lucie	B030
Heinzmann, Daniel	B010
Heller, Scott	A220
Hellmers, Linh.....	B027
Helming, Laura	A099
Hempleman, Laura J.....	A178
Henao-Meji, Jorge	B012
Hendriks, Rudi W.....	A164, A165
Henn, Matthew	B063
Hennedige, Tiffany	B161
Henrickson, Sarah.....	A123
Herhaus, Christian	A099
Herlyn, Meenhard	A082
Hermann, Einsele.....	A028, A037
Hermans, Ian	B103
Hernandez-Lopez, Rogelio A.....	A031
Hernberg, Micaela.....	A130, A134
Herrmann, David	A100
Herzig, Petra	B050
Heubach, Florian.....	A080, A131, A140
Heymach, John V.....	A059, A153
Hicks, Donna J.....	A187
Hideshima, Teru.....	B100
Hiebsch, Ronald R.....	A147
Hilf, Norbert.....	A020
Hilgendorf, Susan	A076
Hirano, Satoshi	A118
Hiraoka, Nobuyoshi.....	A094
Hirohashi, Yoshihiko	B135
Hirte, Holger.....	B207
Hisaka, Akihiro.....	B160
Ho, Hui-Min.....	B172
Ho, Ping-Chih.....	A223
Ho, William W.....	A115

Hobson, Philip.....	A160
Hodi, Stephen.....	A082, A216
Hoerhold, Franziska Marie-Claire.....	A067
Hoffman, Ronald.....	B072
Hofland, Ingrid.....	B188
Holden, Rebecca.....	A010
Höllt, Thomas.....	A063
Holmberg, Staffan	B129
Holt, John.....	A005
Honders, M. Willy	A044
Hong, David S.....	A011
Hong, Jun Young	B162
Hong, Theodore S.	A115
Hong, Yuan	A030
Hongo, Ayumi.....	B018
Hood, Tressa.....	B096
Horlings, Hugo M.....	B188
Hormigo, Adilia	B088
Horner, Peder.....	A018
Hornick, Jason L.	B085
Horowitz, Amir	A191, B032
Hosono, Ako.....	A001
Howell, Alan	A068
Hsieh, Tsung-Han.....	A200
Hsu, Chun-Chieh	B163
Hu, Bo.....	B062
Hu, Jiazhi.....	B099
Hu, Jiazhi.....	B171
Hu, Joyce.....	A034, B115
Hu, Jun	A132
Hu, Xihao.....	B077
Hu, Xihao Sherlock.....	A077
Hu, Zhuting.....	A010
Hu-Lieskovan, Siwen.....	A068
Huang, Alex Y.	A195
Huang, Alexander C.....	B012
Huang, Hua.....	A128, A159
Huang, Siyi.....	B159
Huang, Stanley C.C.	B146
Huang, Wen-Chien	A221
Huang, Wendy.....	B198
Huang, Yi-Jhen.....	A221
Hubbell, Jeffrey A.....	B130
Hudecek, Michael.....	A028, A037
Hudson, Will H.....	A196
Huh, Michael.....	B101
Hui, Enfu.....	A226

AUTHOR INDEX

Humbert, Laure	A214
Hummelink, Karlijn	B050
Hunag, Shi-Wei.....	B164
Hung, Annie.....	A016
Hunger, Aline	B134
Hunter, Christopher A.	B202
Hur, Sun	A122
Hurst, Jacob	B086
Huse, Morgan	B190
Huss, David J.	A027
Hutter, Katharina.....	A102
Huuhtanen, Jani	A134
Hwu, Patrick	A082, B022

I

Iancu-Rubin, Camelia	B072
Ichikawa, Daiju.....	B177
Idri, Sarra.....	A135
Ijoma, Jenny	A089
Ijsselsteijn, Marieke E.....	A063, B094
Ilander, Mette	A065, A085, A130
Im, Sooseok.....	B017
Imamura, Takeshi.....	B031
Incio, Joao.....	A115
Inderberg, Else Marit.....	A035
Infante, Jeffrey R.	A016
Inniss, Mara	A220
Ino, Yashunori	A094
Ioffe, Ella.....	A062, A174
Iosi, Francesca	A091
Irei, Isao	B081
Irie, Hanna.....	A005
Ishida, Wataru.....	B165
Ishihara, Jun	B130
Ishizuka, Andrew S.....	B108
Italiano, Antoine.....	PR3
Ito, Daisuke	A051
Iwasaki, Toshimitsu	A094
Iyengar, Malini.....	A002, A007
Iyer, Laxman.....	A112
Iyer, Vivek.....	B145
Iyer, Narayanan Gopalakrishna.....	B161
Izar, Benjamin	A082

J

Jäck, Hans-Martin	B152
Jackson, Dowdy	B013

Jackson, Christopher.....	B186
Jacobson, Max E.....	A187
Jaeger, Dirk.....	A042, A069, A086, A114, A171
Jaglowski, Samantha.....	A003
Jain, Amit.....	B161, B166
Jain, Esha	B085
Jain, Rakesh K	A115
Jain, Suvi.....	B099
Jakobsen, Bent K.....	A214, B001, B024, B086
Jakobsen, Søren Nyboe.....	B039, B049
Jameson, Stephen C.....	A173
Jan, Chia-Ing	B082
Janakiram, Murali.....	A180
Jang, Bum Sup	B168
Jankovic, Mila.....	B113
Janku, Filip.....	A011
Järvinen, Petrus	A085
Jaworska, Anna.....	A144
Jayaraman, Lata.....	B063
Jazieh, Khalid.....	A210
Jedema, Inge	A044
Jedrychowski, Mark	B062
Jeffrey, Jenna L.....	A162
Jeffreys, Jenna.....	A157
Jenkins, Brittany D.....	A081, A090
Jenkins, Russell S	A082
Jennings, Victoria A.....	B101
Jensen, Michael C.....	A032
Jeong, Kyeonghun	B084
Jerby, Livnat.....	A082
Jia, William	B059
Jiang, Peng.....	A146, A176
Jiang, Peng.....	B077
Jiang, Xiuyun	A156
Jie, Hyun-Bae.....	B013
Jin, Chengcheng	B062
Jin, Chuan	B110
Jin, Weiyang.....	B190
Jobsri, Jantipa	B139
Johndrow, Christopher T.....	A151
Johnson, Adam J.....	A032
Johnson, Bruce E.....	A082
Johnson, John L.....	A166
Johnson, Matthew J.....	A036
Johnstone, Ricky W.....	A149
Jolly, Douglas J	A018
Jones, Philip	A050

AUTHOR INDEX

Jonsson, Vanessa.....	A045
Jordan, Kimberly R.	A117
Josephs, Debra H.	A095
Julian, Rydzek.....	A028, A037
June, Carl H.	A123
Jung, Gundram.....	A131, A140
Jung, Sohee.....	B084
Jungnelius, Jarl Ulf.....	B206
Justesen, Sune.....	B093
Juteau, Susanna.....	A130

K

Kai Bentzen, Amalie.....	B015, B036, B039, B092, B129
Kaiser, Andrew.....	B016
Kakimi, Kazuhiro	B081
Kalinski, Pawel.....	B203
Kalisiak, Jarek	A157
Kam, Lance C.....	B190
Kamiko, Satoshi.....	B177
Kamm, Roger Dale.....	A049
Kanaseki, Takayuki	B007, B018
Kandimalla, Ekambar R.	A136
Kaneda, Hide.....	A001
Kang, Jee Hye.....	A163
Kang, Richard	A136
Kankainen, Matti	A065
Kanodia, Abhay.....	A082
Karagiannis, Sophia	A095
Karaki, Soumaya	A172
Karampatzakis, Alexandros	A128
Karasaki, Takahiro	B081
Karimi, Mobin.....	B183
Karimi-Naser, Lisa.....	B029
Karin, Michael	B091
Karlsson-Parra, Alex	B110
Kashiwazaki, Sho	B177
Kassum, Tariq.....	A220
Katayama, Takane	B114
Kather, Jakob N.....	A114, A172
Kato, Mako.....	B114
Käuferle, Theresa	A043, A224
Kaye, Jonathan.....	A215
Kedmi, Ranit.....	B167
Kefford, Richard F.....	A154
Keirsse, Jiri.....	A083
Keller, Brian	B101
Kelsey, Stephen.....	A103

Kennedy-Darling, Julia.....	A073, A074
Kershaw, Michael H.....	A047, A048
Kerzeli, Iliana Kyriaki.....	A137 B110
Keshishian, Hasmik.....	B042
Keskin, Derin B.....	A010, B042
Kesmir, Can.....	B022
Kess, Sabine	A114
Kessler, Tobias	PR15
Kester, Michel G.D.	A044
Khalessi, Alexander A.	A078
Khan, Omar	A197
Khatoon, Muznah Bte Nazar Khan.....	B189
Khazaie, Khashayarsha	A011
Kheoh, Thian	A018
Khorasani, Hooman.....	A005
Kiefmann, Bettina.....	B131
Kikuchi, Yasuhiro.....	B018
Kim, Boram.....	A138
Kim, Chan.....	A061
Kim, Cheol Sang.....	B040, B041
Kim, Hye-Jung	A039
Kim, Inah	B168
Kim, Jaeyun.....	B119
Kim, Jonggul.....	B169
Kim, Joseph J.	A073, A074
Kim, Justin	A132
Kim, Kwangsoo.....	B084
Kim, Mi Soon	A138
Kim, Ryan K.....	A097
Kim, Teresa	A156
Kim, Won Jong.....	B017
Kim, Young	A198
Kinderman, Priscilla P.	B117
King, Emily.....	A142
King, David S.	B150
Kinoshita, Yoshiaki	A001
Kinoshita, Akitoshi.....	B081
Kirk, Thomas	A161
Kisielow, Jan.....	B078
Kiss, Máté	A083
Kissick, Haydn T.	A196, B176
Kitagawa, Koichi	B114
Klaeger, Susan	A010, B042
Klatt, Martin G.	B019/PR13
Klebanoff, Christopher A.....	PR5
Kleissner, Theresa	B131
Klievink, Jay.....	A065

AUTHOR INDEX

Klinger, Mark	A034, B115
Kluesner, Michell	A036
Klupp, Fee.....	A171
Knedlík, Tomáš	B147
Ko, Myat.....	A089
Ko, Huan-Jang	A221
Koasaloglu-Yalcin, Zeynep.....	B090
Kobayashi, Aya	A146
Kobayashi, Yasuhiro	B146
Kobold, Sebastian.....	A043
Kodysh, Julia	A005, B079, B080
Koelzer, Viktor H.	B050
Koh, Jiae	A138
Kohashi, Kenichi.....	A001, A017
Kohlbacher, Oliver	B124
Kohtamäki, Laura.....	A130
Köksal, Hakan	A035
Koltun, Elena	A103
Komai, Shota.....	B114
Komenda, Kerstin	A102
Konety, Badrinath	A008
Kong, Kok-Fai	A211
König, Rainer.....	A067
Koning, Frits	A063
Konvalinka, Jan	B147
Koon, Henry.....	A225
Kopf, Manfred	B078
Korontsvit, Tatyana	B019
Korrer, Michael J.M.....	A198
Kosco-Vilbois, Marie H.	A088
Kostka, Libor	B147
Kottke, Timothy.....	A029, A133, B138
Koutcher, Jason.....	A089
Kowalczyk, Monika S.	A082
Koyakutty, Manzoor	A169, B116, B028
Krabbe, Teresa	B098
Kranzusch, Philip J.	B150
Kreider, Brent L.	A011
Kring Hansen, Ulla.....	B020, B092
Krishnan, Manu.....	B028
Kroemer, Guido	B151
Kroep, Judith R.	A020
Krogsgaard, Michelle	PR8
Krolewski, John J.	A084
Kron, Stephen J.....	B021, B025
Krummel, Matthew F.	A052, B148, B186
Kudchadkar, Ragini	B176

Kuilman, Thomas	B033
Kulkarni, Abhishek.....	A220
Kumar, Brahma.....	B153
Kupershmidt, Lana.....	B127
Kurino, Taiki.....	B160
Kurose, Koji.....	B081
Kuryk, Lukasz.....	A022
Kuswanto, Wilson	B065
Kvalheim, Gunnar	A035
Kvistborg, Pia.....	B022
Kweekel, Christiaan.....	A044
Kyzirakos, Christina.....	B124

L

Lacey, Simon	A123
Lacher, Markus D.	A012
Lacroix, Laetitia.....	PR3
Lacy, Katie E.....	A095
Ladell, Kristin	B007
Ladenstein, Ruth.....	A013
Laface, Ilaria	B088
LaFleur, Martin W.	A216
Lagström, Sonja	A065
Lahm, Armin.....	B105
Lahoud, Mireille.....	B125
Lahr, Walker S.....	A036
Laizet, Yec'han.....	PR3
Lajoie, Marc J.	B023
Lajoinie, Guillaume	B151
Lako, Ana	A216
Lam, Andrew.....	A213
Lamb, Andrew	B051
Lamb, Candice.....	B008
Lamba, Simona.....	B069
Lamkanfi, Mohamed	A083
LaMontagne, Russell.....	A199
Lancita, Janice.....	A188
Landau, Nathaniel R.	B121
Lander, Eric S.....	B085
Lang, Anne-Marie	A013, A140
Lang, Peter	A013, A080, A131, A140, B124
Langan, Robert A.	B023
Langer, Robert.....	A148
Langhorst, Bradley	B046
Langone, Francesca.....	B105
Lanier, Lewis L.....	B044
Lanka, Manasa	B090

AUTHOR INDEX

Laoui, Damya	A083
Lapan, Jen.....	B085
Larkin, Katie	B085
Laserson, Uri	B032
Lassen, Ulrik	B070
Lau, Joey	A159
Lau, Sai Ping S.....	B117
Lauer, Peter	A215
Laur, Melanie	A034, B115
Laurent-Rolle, Maudry.....	B163
Lavu, Harish.....	A101
Lawson, Kenneth K.V.....	A157
Lawson, David H.....	B176
Le Boeuf, Fabrice.....	B101
Le Vu, Pauline	B118
Leal Rojas, Ingrid	B125
Leca, Julie	B170
Lech, Karolina	B024
Lee, Aileen	B193
Lee, Cheng-Sheng.....	B171
Lee, Dean A.....	A065
Lee, Erica.....	B059
Lee, Hang	A115
Lee, Heung Kyu	A141
Lee, Jenny H.	A154
Lee, Jih-Hsiang.....	A221
Lee, Kyung Young.....	A138
Lee, Moon Hee.....	A085
Lee, Sharon Wei Ling.	A049
Lee, Steve Seung-Young.	B021, B025
Leeson, Rachel	A082
Leet, Donna	A010
Leiby, Benjamin E.	A101
Leidner, Rom	A186
Leiner, Ingrd M.....	A170
Leleti, Manmohan R.	A157, A162
Lelieveldt, Boudewijn P.F.	A063
Lennon, Niall	B085
Lenoir, Bénédicte M.A.....	A069, A086, A114
Lentacker, Ine.....	B136, B151
Leonard, John E.	A068
Leoni, Guido	B105
Leontovich, Alexey A.....	A011
Lercher, Alexander	A070
Lerda, Giulia	B069
Leshem, Yasmin	A142
Lesinski, Gregory	A068

Leslie, Christina	B038
Leung, Isabel.....	B023
Leuzzi, Adriano.....	B105
Levay, Agata.....	B111
Leveque, Joseph	A016
Levitsky, Victor	B026
Levy, Michael L.....	A078
Levy, Olivier.....	A215
Levy, Ronald.....	B128
Lewis, Phoebe.....	B141
Lewis, Colleen.....	B176
Li, Aileen W.	B045
Li, Anita Kar Ying K.Y.	A087
Li, Bo	B077
Li, Chaoran.....	B065
Li, Dan Jun.....	A220
Li, Hanjie.....	B054
Li, Jinyang.....	A054
Li, Jun	B120
Li, Kaitao	PR8
Li, Li	B027, B119
Li, Lucy.....	A195
Li, Ming O.....	A181
Li, Qiang	B064
Li, Qiao.....	A014
Li, Shuai	A125
Li, Weihua	B091
Li, Yanli.....	A059
Li, Yanyun.....	A225
Li, Zeyang.....	B149
Li, Ziyi.....	A077, B077
Liang, Xiaoyan	A188
Liang, Zhengdong	B141
Libutti, Steven K.	B132
Liddy, Nathaniel	B001
Lieberman, Judy	A132, B057
Lillemoe, Kieth D.....	A115
Lim, Klothilda.....	A146
Lim, Michael	B165
Lim, Su Yin.....	A154
Lim, Wendell A.....	A031
Lim, Yong Taik	B126, B133
Lima, Vinicius Araujo Barbosa de	B070
Lin, Fang-Yu.....	B082
Lin, Hsiu-Ping.....	B172
Lin, Jia-Ren.....	A082
Lin, Ming	A014

AUTHOR INDEX

Lin, Shu-Yung	A221
Lin, Wen-Jye	B172
Linehan, Jonathan L.	PR16
Link, Alexand	B026
Lins, Debra C.....	A051
Lion, Eva.....	B137
Littman, Dan.....	B167, B198
Liu, Cailian.....	A225
Liu, Dan.....	B173
Liu, David	A082
Liu, Guoyu.....	B059
Liu, Haipeng	B143
Liu, Hao.....	A115
Liu, Hsin-Yu.....	A211
Liu, Jing	A208
Liu, Jun	B077
Liu, Ming-Chao	B082
Liu, Pingfang	B046
Liu, Xi.....	A059
Liu, Xiaole Shirley.	A077, A146, A176, B077
Liu, Xin (Cindy).....	A210
Liu, Xing.....	A132
Liu, Yuan.....	B176
Liu, Yunlong.....	A184
Llewellyn-Lacey, Sian	B007
Llorian Sopena, Miriam	A145
Lo, Sheng-fu L.....	B165
Lo, Yu-Hsun	A200
Lobb, Roy	A040
Lobel, Lior	B066
Lode, Holger.....	A013
Logtenberg, Meike Emma Willemijn.....	A143
Loibner, Hans	A013
Londin, Eric.....	A101
Lonetree, Cara-lin	A036
Long, Georgina V.....	A154
Long, Henry	A146
Lönnberg, Tapio	A134
Lopez-Moyado, Isaac F.	A178
Lorenzi, Philip	A059
Losic, Bojan	B071, B088
Loskog, Angelica	A119
Lotfi, Ramin	A043
Louie, Alexander	A170
Lowe, Jamie	A057
Lowne, David	B086
Lu, Hsin-Man	B082

Lubling, Yaniv	B054
Lucarini, Valeria.....	A091
Lucchesi, Carlo	PR3
Lucey, Vanessa M.....	A019, A022
Ludewig, Burkhard.....	A070
Lugano, Roberta	A128
Lukkes, Melanie M.	A164, A165, B117
Luo, Xuemei	A132
Luoma, Adrienne M.....	A082, A146
Luong, Tiffany.....	B109
Lyngaa, Rikke.....	B020
Lynn, Geoffrey M.	B108
Lyons, Jesse.....	A188

M

MacAry, Paul A.....	B189
Mackall, Crystal	A002, A007
MacKay, Joanna L.....	B183
Mackiewicz, Andrzej A.....	A144
Mackiewicz, Jacek	A144
Macri, Mary	A006, A022, B209
Maeda, Masatomo	A089
Maeder, Christina	B016
Maeng, Hoyoung.....	A004
Magen, Assaf.....	A201
Maggadóttir, Sólrun Melkorka.....	A035
Magistrelli, Giovanni.....	A088
Magri, Alessandro.....	B069
Mahajan, Milind.....	A005
Mahajan, Aayushi.....	B165
Mai, Nicole	B001
Maione, Federica.....	B069
Maiwald, Simone.....	B085
Majocchi, Stefano	A088
Mäkelä, Siru	A130, A134
Malhotra, Aryan.....	B174
Mallini, Paraskevi.....	B024
Mallow, Crystal.....	A068
Malu, Shruti.....	A082
Man, Stephen.....	B007
Manabe, Atsushi.....	A001
Mancini, Jacopo	A091
Mandeli, John.....	A005
Mandloi, Nitin.....	A112
Mane, Mayuresh M.....	A089
Manfredi, Mark G.	B008
Mangasarian, Aram	B206

AUTHOR INDEX

Mangsbo, Sara M.	A128, A137
Maniyar, Rachana.	B174
Manlove, Luke S.	B182
Manne, Saskinath.	A166, B012
Manning, Pamela T.	A147
Manoharan, Malini.	A112
Manos, Michael.	A216
Mansfield, Aaron	A210
Manz, Timo	A131
Marchuk, Kyle.	B148
Maresh, Grace	B027
Margolais, Claire.	A082
Margolin, David	B027
Marijt, Koen	B111
Markovic, Svetomir.	B097
Marks, Douglas K.	B005
Marnellos, George	B063
Maroto, Miguel.	A002
Marron, Thomas	A005
Marshall, Andrew.	B103
Marsoni, Silvia	B069
Martikainen, Miika	B175
Martikainen, Minttu-Maria	B175
Martin, William A.	B089
Martinez-Hague, Ruth	A214
Martínez-Ricarte, Francisco	A020
Martini, Dylan J.	B176
Martini, Rachel	A081, A090
Martins, Maria Solange	A083
Martirosyan, Anna	A182
Maruta, Masaki.	B031
Mascarenhas, John	B072
Masopust, David.	B182
Master, Alyssa	B029
Master, Viraj A.	B176
Masterman, Kelly-Anne	B125
Masternak, Krzysztof	A088
Mastri, Michalis	A084
Masuda, Takeshi	B081
Mathew, Divij.	A202
Mathis, Diane	B062, B065
Matsushita, Hirokazu	B081
Matsushita, Maiko	B177
Mattei, Fabrizio.	A091
Matthes, Jakob	B124
Matushansky, Igor	B131
Maurer, Dominik	A015, A020

Mazzone, Massimiliano.....	A083
McArdle, Stephanie E.B.	B118, B122
McCabe, Danielle	A022
McCarter, Martin D.	A117
McCauley, Scott.....	A016
McCormick, Kyle L.....	B165
McDonald, Sierra.....	A197
McDonald, Keely G.....	B146
McGillicuddy, Mary	B085
McGinness, Kathleen.....	A003
McGovern, Karen.....	B008
McIntosh, Richard.....	A161
McKinney, Michelle	A009
McLaren, James E.....	B007
Medina, Christopher.....	A098
Medrano, Ruan F.V.....	B134
Medyouf, Hind.....	A092
Medzhitov, Ruslan.....	B162
Meena, Kiran	B132
Mehdizadeh, Sadaf.....	A163
Mehta, Monika	A201
Mei, Shaolin	A082
Mei, Amy	A163
Meijers, Rob.....	B049
Melcher, Alan.....	A133, B101
Melenhorst, Joseph J.....	A123
Melms, Johannes M.....	A082
Mendonça, Samir A.....	B134
Mendoza, Alejandra	A203
Mendrzyk, Regina.....	A015, A020
Menzies, Alexander M.	A154
Merad, Miriam.....	A168
Merchan, Jaime	A018
Merchiers, Pascal	A192
Merghoub, Taha D.	A125, A225, 106
Merits, Andres.....	B175
Merkler, Doron	B131
Merritt, Chris	B006
Merritt, Elliot	B032
Mertz, Kirsten D.	B050
Mesa, Kai	B167
Mescher, Matthew F.	A051
Meseck, Marcia	A005, B032
Mestermann, Katrin.....	A037
Met, Özcan.....	B036
Metelitsa, Leonid S.....	A025
Metheringham, Rachael L.	B102, B104

AUTHOR INDEX

Meyer, Marten	A069
Meyer, Jochen.....	B075
Mezzadra, Riccardo.....	B188
Miao, Benchun	A082
Miao, Yuxuan.....	A093
Michaelson, James	A115
Michelakos, Theodoros	A115
Michels, Birgitta.....	A111
Miles, Dillon H.....	A162
Miller, Aaron M.....	B090
Milles, Brett A	A005
Miller, Brian C.....	A216
Mills, Lauren J.....	A051
Milner, Rowan J	A204
Miron, Michelle.....	B153
Misiukiewicz, Krysztof	A005
Mistry, Sejal.....	A073, A074
Mittman, Stephanie.....	A120
Mizuno, Shoichi	A001, A017
Mizushima, Emi	B007
Moch, Holger.....	A113
Modiano, Jaime F.....	A051
Modur, Vishnu.....	B083
Mohr, Christopher.....	B124
Mohrs, Markus.....	A062, A174
Moine, Valéry	A088
Moise, Leonard	B089
Mok, Stephen	A205
Molan, Amy.....	A133, B138
Molina, Ana M.....	B193
Molina Arcas, Miriam	A145
Moll, Tabea.....	A082
Momburg, Frank.....	A069
Momin, Noor	A206
Mommen, Geert P.M.	B086
Monkhorst, Kim	A185, B050
Monod, Anthea.....	B005
Montero Cuenca, Leslie.....	B090
Montler, Ryan.....	A186
Montone, Monica	B069
Moogk, Duane.....	PR8
Moon, James	B140
Moon, Sung S.....	B019
Mooney, David J.....	B043, B045, B053, B058, B119
Moraes Ribeiro, Emmanuelle.....	A140
Mordec, Kasia.....	A103
Moreira, Alvaro	B030

Moret, Ravan	B027
Mori, Masaki.....	B191
Moriarity, Branden S.....	A036
Morikawa, Naoto.....	A153
Morioka, Sho	A098
Moroz, Anna	A089
Moroz, Ekaterina	A089
Moroz, Maxim A.....	A089
Morris, John C.....	A004
Morton, Laura.....	A038
Moskalenko, Marina.....	A120
Motz, Greg	A003
Moudgil, Tarsem.....	A186
Moustaki, Ardiana.....	A189
Movahedian Attar, Farkhondeh.....	A113
Mu, Xin	A122
Mueller, Scott N.....	A208
Mugarza, Edurne.....	A145, A160
Muller, Alexander J.....	A101
Mumm, John B.	A016
Munshi, Nikhil.....	B100
Muntel, Jan	A066
Murad, Yanal.....	B059
Murgaski, Aleksandar	A083
Murphy, Janet E.	A115
Murthy, Ravi.....	A011
Mussolin, Benedetta	B069
Mustjoki, Satu	A065, A085, A130, A134
Myers, Darienne R.	A103
Myers, Jay T.....	A195
Myklebust, June Helen.....	A035

N

Nagareddy, Raveena.....	B028
Nagatomo, Kei.....	A101
Naik, Girish S.....	A216
Naing, Aung	A016
Nair, Sujit	A005
Nair, Shanti Kumar.....	B028
Najibi, Alex J.	B045
Nakagawa, Hidetoshi.....	A039
Nakajima, Kosei.....	A094
Nakamoto, Yasunari.....	A001
Nakamura, Mano.....	A095
Nakamura, Toru.....	A118
Nakanishi, Yoshitsugu	A118
Nakatsura, Tetsuya.....	A001, A017

AUTHOR INDEX

Nallagatla, SubbaRao	A136
Nambiar, Ashwathy	B116
Nanus, David M.	B193
Nastiuk, Kent L.	A084
Nathan, Carl.....	B201
Naxerova, Kamila.....	A115
Neale, Geoff.....	A189
Nelson, Christine E.	B182
Nemunaitis, John J.	A006
Nevler, Avinoam.....	A101
Nevmerzhitskaya, Aleksandra.....	A092
Newberry, Rodney D.	B146
Newell, Krista	B183
Newman, Lisa.....	A081, A090
Newman, Walter	A225
Newman, Michael J.	B178
Ng, Tony W.	A151
Nghiem, Paul.....	B020
Nguyen, Vinh	A163
Nguyen, Christine	B200
Nichols, Robert J.	A103
Nicosia, Alfredo.....	B105
Nie, Jia	A201
Niels, Halama	B206
Niesel, Katja.....	A111
Nikulina, Nadya	A073, A074
Nisén, Harry.....	A085
Nistico, Paola	A207
Nixon, Briana G.	A181
Noji, Takehiro	A118
Nolan, James.....	B008
Norry, Elliot.....	A002, A007
Norton, Thomas David.....	B121
Nosaka, Kazuto	A017
Nott, Alexander.....	A078
Nuijen, Bastiaan	B205
Nussenzweig, Michel C.	B113

O

O'Connell, Allison	A096
O'Connor, Carolyn	A078
O'Connor, Roddy S.....	B029
O'Donnell, Jake S.....	A208/PR2
O'Donnell, Timothy J.	A005, B032, B080
O'Donnell-Tormey, Jill.....	A019
O'Hara, Mark.....	A123
O'Hayer, Kevin	A101

Obermair, Franz-Josef.....	B078
Obers, Andreas.....	A079
Ochi, Toshiki	B031
Ock, Chan-Young	B084
Odunsi, Kunle O.	A006, A022, A070
Oeler, Daniel.....	B131
Oestrup, Olga.....	B070
Oft, Martin.....	A016
Oh, William K.....	A005
Oh, Dong Sun.....	A141
Ohue, Yoshihiro	B081
Oka, Mikio	B081
Okada, Hideo	A020
Okamura, Keisuke.....	A118
Olcina, Monica M.	A097
Olesch, Catherine	A209
Olinger, Grace	A220
Oliver, Amanda J.	A048
Ols, Michelle	A220
Olson, William.....	A174
Olweus, Johanna.....	A024
Onder, Lucas	A070
Ong, Giang.....	B006
Opyrchal, Mateusz.....	B203
Ordaz, Josue D.	A184
Orillion, Ashley	A184
Orlandi, Armando.....	B069
Orlänger, Klaus	A070, B131
Orme, Jacob J.	A210
Ørskov, Andreas D.	B129
Osborn, Mark J.	A036
Osborne, Edward	A034, B115
Osen, Wolfram.....	A067
Osman, Iman.....	PR8
Ostertag, Derek.....	A018
Ott, Patrick A.	A006, A010, A016, A082
Ottensmeier, Christian H.	A020, B139
Ottoson, Nadine C.....	A057
Querkaxi, Wushouer	B074
Ouyang, Zhengyu.....	A078
Owonikoko, Taofeek K.	B176

P

Pacheco Sanchez, Patricia	A120
Painter, Corrie	B085
Painter, Gavin.....	B103
Palermo, Belinda.....	A207

AUTHOR INDEX

Pamer, Eric G.	A170
Pan, Deng	A146, B077
Panda, Anshuman	B076
Panetta, Mariangela	A207
Pant, Shubham	A016
Papadimitrakopoulou, Vassiliki	A059
Papadopoulos, Kyriakos P.	A016
Papaioannou, Anne	A088
Parekh, Samir S.	A005
Park, Andrew	A006
Park, Chan Hee	B040, B041
Park, Changhee	B084
Park, Keunchil	A138
Park, Timothy	A157, A162
Parolini, Isabella	A091
Parts, Leopold	B145
Pasetto, Anna	A175
Pastan, Ira	A142
Paston, Samantha	A214
Patel, Ankur	B132
Patel, Avi	B027
Patel, Manish R.	A016
Patel, Priyanka	B193
Patrick, Harter	A111
Patton, Clay	A027
Pauzuolis, Mindaugas	B131
Pavesi, Andrea	A049
Pawelec, Graham	A135
Pearce, Laura	A019, B207
Pearson, Frances	B125
Pearson, Joshua R.D.	B122
Pecker, Iris	A076
Pedros, Christophe	A211
Peeper, Daniel S.	B033
Peeters, Koen C.M.J.	A063, B094
Peggs, Karl S.	A192
Pei, Jerry	A062
Pelanda, Roberta	A202
Peled, Amnon	A076
Pelin, Adrian	B101
Peltola, Katriina	A134
Peng, David	A059
Peng, Li	B034
Peng, Yibing	A030
Pennell, Christopher A.	B182
Pentelute, Bradley L.	A010
Peoples, George	A012

Pereg, Yaron.....	A076
Pereira, Daniel S.....	A147
Pereira, Lloyd A.....	A149
Perez-Quintero, Luis Alberto.....	B035
Perou, Charles.....	B185
Perrin, Priscillia.....	B149
Perry, Justin Shaun Arnold.....	A098
Pesonen, Sari	B123
Pestal, Kathleen	B179
Peters, Bjoern	B090
Peters, Dennis.....	B188
Petitprez, Florent.....	PR3
Petrova, Elissaveta	A099
Petryk, Julia.....	B101
Pezeshki, Abdul Mohammad.....	A011
Pham, Amber.....	A157
Phan, Anthony T.	B202
Philip, Mary	A215
Philips, Daisy	B022
Pieck, Jan-Carsten.....	A099
Pietrantonio, Filippo	B069
Piha-Paul, Sarina A.	A011
Pike, Kelly Anne	B035
Pikor, Larissa	B101
Pili, Roberto.....	A184
Pillai, Padmini Sushila.....	A148
Pillai, Rathi	B176
Pillarisetty, Venu G.....	A156
Pinho, Andreia V.	A100
Pinschewer, Daniel	B131
Pinter, Matthias.....	A115
Pintova, Sofya.....	B207
Piovesan, Dana	A162
Piraner, Dan Ilya.....	B037
Pires, Pedro R.L.....	B011, B180
Plate, Karlheinz.....	A111
Platten, Michael.....	PR15, A020, B075
Ploegh, Hidde L.....	B149
Pockley, Graham	A135, B118, B122
Poitevin, Yves.....	A088
Poli, Valeria.....	B105
Ponomarev, Vladimir	A089
Ponsaerts, Peter.....	B192
Ponsati, Berta	A020
Porcelli, Steven A.....	A151
Port, Elisa R.....	A005
Posch, Florian	A113

AUTHOR INDEX

Pöschke, Oliver.....	A099
Postow, Michael.....	A225
Poteet, Ethen	B141
Poulsen, Hans S.....	A020
Powe, Desmond George.....	B152
Powers, Jay P.....	A157, A162
Powlesland, Alex S.....	B086
Prado Martins, Rodrigo.....	B187
Preissl, Sebastian.....	A078
Premlal, Ashmitaa	B090
Prendergast, George C.	A101
Prestat, Emmanuel	A182
Preston, Andrew	B001
Price, David A.	B007
Prickett, Todd.....	A175
Priha, Petri	B123
Pritykin, Yuri.....	B038
Priyadarshini, Sushri	A112
Prokopi, Anastasia.....	A102
Pronk - van Montfoort, Nadine A.G.	B117
Prüfer, Ulrike.....	B206
Pulido, Jose S.	A133, B138
Puro, Robyn J.	A147
Pusch, Stefan	PR15
Putzel, Gregory	A075
Pyle, Anna M.	A187

Q

Qi, Jinjin.....	A225
Qiao, Guoliang.....	A212
Qin, Xiaodan.....	A213
Qing, Chen.....	A192
Qiu, Xiaohong	A057
Qiu, Xintao.....	A146
Quezada, Sergio A.	A192
Quijano Rubio, Alfredo	B023
Quintana, Elsa.....	PR15
Quintana, Francisco J.M.	A071
Quispe, Wilber.....	B132

R

Rabadan, Raul	B005
Rabasa, Ailem.....	B111
Rabasha, Bokang	A082
Rabsteijn, Armin	A131, A140, B124
Radford, Kristen J.	B125
Radic, Haja D.....	B154

Rafa, Vibeke Mindahl.....	B039
Rahman, Adeeb.....	A191
Rahman, Bushra	A187
Raina, Anjali.....	A011
Rajan, Anusha.....	B023
Rajan Unnithan, Afeesh	B040, B041
Ram, Zvi	A021
Ramachandra Kurup Sasikala, Arathyram	B040, B041
Ramachandran, Mohanraj	A128, A159, B110, B175, B181
Ramalingam, Suresh S.	B176
Ramesh, Navyashree A.....	B116
Ramkumar, Anjana.....	A169, B028, B116
Rammensee, Hans-Georg	A020, B124
Ramsay, Robert G.....	A149
Ramskov, Sofie	B036, B049, B092
Randon, Giovanni	B069
Ranger, Ann.....	A003
Ranki, Tuuli	B123
Ransohoff, Richard.....	A195
Rao, Prakash.....	A146
Rao, Anjana	A178
Rapin, Nicolas	B093
Rashid, Naureen.....	B193
Rataj, Felicitas	A043
Ratti, Navneet P.	A016
Raut, Chandrajit	B085
Ravichandran, Kodi.....	A098
Ravn, Ulla	A088
Raymond, Michael.....	A098
Reardon, Christopher	A220
Redelman-Sidi, Gil	B087
Regad, Tarik.....	B152
Regev, Aviv	A082
Reijmers, Rogier M.....	A044
Reilly, Christine.....	A068
Reinhardt, Carsten.....	A015
Reiter, Andrea.....	B131
Reiter, Lukas.....	A066
Reiter, Yoram.....	A142
Reker Hadrup, Sine	B015, B020, B036, B039, B049, B092, B129
Remst, Dennis F	A038
Ren, Bing.....	A078
Ren, Long	B126, B133
Rennert, Paul.....	A040
Restrepo, Paula	B088
Reuveni, Hadas.....	B127

AUTHOR INDEX

Ribas, Antoni.....	A068
Ribeiro, Ana.....	A214
Ribeiro Muniz-Bongers, Luciana	A104, A109
Ricciardi, Toni.....	A006, A022, B209
Richard, Françoise.....	A088
Richard, Guilhem	B089
Richardson, Celeste	A220
Riddell, Stanley R.....	B023
Ring, Aaron M.....	A051
Ring, Nan G	A051
Ring, Sandra.....	A070
Rippmann, Friedrich	A099
Ritz-Romeo, Janáe A.	A123
Rizk, Emanuelle.....	B005
Rizkallah, Pierre J.	B007
Rizos, Helen.....	A154
Rizvi, Naiyer	B207
Robbins, Paul F.....	A175
Roberts, Edward W.....	B185
Robertson, Tanner F.....	B183
Robins, Harlan	A034, B115
Robinson, William A.....	A117
Rodig, Scott J.....	A216
Rodman, Christopher	A082
Rodon, Jordi.....	A018
Rodriguez, Bertha Leticia.....	A059, A153
Rodrigues, Elaine G.	B134
Rodriguez, Ryan.....	A120
Rodriguez-Canales, Jaime	A059
Roedel, Franz	A111
Rogic, Anita.....	B156
Rohaan, Maartje	B205
Rojas-Moraleda, Rodrigo.....	A171
Rooman, Ilse.....	A100
Rosato, Pamela C.	B182
Rosen, Brandon R.....	A162
Rosen, Michael K.	B169
Rosén, Anna	A183
Rosenberg, Steven A.....	A175, B055
Rosenblatt-Rozen, Orit	A082
Rospo, Giuseppe.....	B069
Rossi, Jean-François	B208
Rotem, Asaf.....	A082
Roth, Edith.....	B152
Roth, Sara	A149
Rothaemel, Paula.....	A224
Rothenheber, Rebecca.....	A069

Rothlin, Carla Vanina.....	A092
Roudko, Vladimir	B072
Rouquet, Nicole.....	B208
Roy, Edward	A219
Roy, Nathan H.....	B183
Roy, Sobhan	PR16
Roybal, Kole T.....	B044
Ruan, Jianbin	A132
Ruano, Dina	B094
Rubinsteyn, Alex	A005, B032, B079, B080, B108
Rucinski, Marcin	A144
Rudensky, Alexander Y.	A190
Ruffin, Ayana T.....	A053
Ruhland, Megan K.	B184
Ruiz, Stormy.....	B109
Ryan, Aileen	A006, A022, B209
Ryan, David P.....	A115
Rybstein, Marissa.....	A150

S

Saadatpour, Assieh	A176
Saake, Marc	B030
Saavedra-Avila, Noemi A.	A151
Sabado, Rachel L.....	A005
Sabari, Joshua	B209
Šácha, Pavel.....	B147
Sachs, Jessica	A003
Sadanala, Keerthi Caroline.....	A109, A191
Saeed, Khalid	A065
Saenger, Yvonne	B005
Sage, Julien	A153
Sagiv, Yehudit J.	A076
Sagiv-Barfi, Idit	B128
Sahay, Bikash	A204
Sahin, Ugur	A020
Sahm, Felix	B075
Sahota, Sheena	A075
Sahu, Avinash	B077
Saikia, Ankur	B049
Saini, Sunil Kumar.....	B049, B129
Saitou, Takashi.....	B031
Salamero Boix, Anna	A111
Salazar, Nicole	A121
Salem, Mohamed Labib.	A106
Salimu, Josephine.....	A192
Salles, Thiago A.	B134
Salloum, Darin	A152

AUTHOR INDEX

Salmon, Ruth.....	A027
Salter, Alexander I.....	B023
Salute, Marc.....	A204
Sampson, John.....	A029
Sampurno, Shienny	A149
Sanchez, Violeta.....	A187
Sanchez Perez, Luis	A029
Santomasso, Bianca.....	A152
Sarén, Tina Anna.....	A041
Sarkissian, Aniee	A045
Sarkizova, Siranush	A010, B042
Sartore-Bianchi, Andrea	B069
Sasada, Tetsuro	A017
Sasso, Maria Stella.....	B130
Satagopan, Jaya.....	A089
Sather, Blythe D.	A027
Sato, Osamu.....	A118
Sautès-Fridman, Catherine	PR3
Savage, Peter A.....	A177
Savelyeva, Natalia	B139
Savoldo, Barbara.....	A025
Saw, Robyn P.M.	A154
Saxena, Mansi	A104, A109
Scaife, Sarah.....	B024
Scarselli, Elisa.....	B105
Sceneay, Jaclyn	B063
Schadendorf, Dirk	A082
Schadt, Eric E.	A005
Schaefer, Juergen	A013, B124
Schaeffer, Alexander.....	A111
Schaer, David	A225
Schäffner, Sandra.....	A099
Schane, Claire	A219
Schauder, David	B200
Scheinberg, David A.	B019
Schetters, Sjoerd.....	A110
Schiavoni, Giovanna.....	A091
Schietinger, Andrea.....	A215
Schilling, Bastian.....	A082
Schindler, Ulrike	A162
Schlachetzki, Johannes C.M.	A078
Schlegel, Patrick	A013, A131, A140
Schleicher, Sabine	A131
Schmess, Christian	B039
Schmid, Irene	A224
Schmid, Roland M.	B098
Schmidt, Patrick.....	A042

Schmidt, Sarah	A070, B131
Schneider, Dina A.....	B029
Schneider, Martin.....	A171
Schneider, Reva.....	A006
Schneider, Robert J.....	A222
Schober, Kilian.....	A043
Schoenberger, Stephen P.....	B090/PR12
Scholten, David	B021, B025
Schott, Sarah.....	A069, A086, A114
Schrand, Brett.....	B111
Schreiber, Robert D.....	A163
Schrimpf, Daniel.....	B075
Schroeder, Christopher	B124
Schuelke, Matthew	A133, B138
Schuler, Gerold	B030
Schulha, Sophie.....	B131
Schultze, Joachim L.....	A128
Schulz, Michael.....	A111
Schulze, Chris J.	A103
Schumacher, Ton N.M.....	B022, B050, B054, B188, B205
Schwarzenberger, Paul	A006, A022, B209
Schwinger, Wolfgang	A013
Scolyer, Richard A.	A154
Scott, Andrew C.....	A215
Scott-Browne, James P.....	A178
Scrivens, Maria.....	A068
Seder, Robert A.....	B108
Segal, Neil H.....	B207
Seidel, Ursula	A140
Seitz, Christian.....	A140
Seitz, Lisa	A124
Sekiya, Takashi.....	A178
Selby, Peter J.	A133
Selvanesan, Benson C.	B132
Sen, Debattama R.	A216
Sen, Shurjo.....	PR16
Sen, Triparna	A153
Senda, Takashi.....	B153
Senra, Joana.....	A002
Seo, Hyungseok	A178
Seo, Yongwoo David.	A156
Serganova, Inna.....	A089
Serneels, Jens	A083
Serreze, David V.....	A163
Sette, Allesandro	B090
Sevenich, Lisa	A111
Sfakianos, John P.....	B157

AUTHOR INDEX

Sha, Kai.....	A084
Shabto, Julie M.....	B176
Shah, Manish	A075
Shah, Nisarg	B043
Shah, Parin.....	A082
Shah, Sabaria	B104
Shaib, Walid	B176
Shaik, Jahangheer	PR16
Shakiba, Mojdeh.....	A217
Shalaby, Khalid	A089
Shalapour, Shabnam.....	B091
Shalek, Alex K.....	A082
Shamah, Steven.....	A220
Shan, Meimei.....	B032
Shang, Limin	A088
Shanti, Nair	B116
Shapira, Nati.....	A021
Shapiro, Mikhail G.....	B037
Sharif, Ehesan U.....	A162
Sharma, Shalu.....	A151
Sharma, Suresh C.....	A167
Sharona, Ben-Haim	A078
Sharpe, Arlene H.....	A216
Shastri, Prathap.....	B013
Sheehan, Kathleen C.F.....	A163
Shemesh, Avishai.....	B044
Shen, Cong	A016
Shenker, Larissa.....	A089
Shepard, Dale	A011
Shepherd, Jonathan.....	B185
Shi, Xiaoshan.....	A112
Shichinohe, Toshiaki.....	A118
Shieh, Jeng-Jer.....	B164
Shields, Nicholas J.....	B186
Shigeta, Kohei.....	A115
Shih-Chong, Tsai	A200
Shim, Kevin G	A133
Shimizu, Katsuhiko	B081
Shimizu, Yasuhiro	A017
Shimizu, Yoji	A051
Shimomura, Manami	A001
Shin, Il Woo	B126, B133
Shindo, Masahiro.....	A089
Shioda, Yoko	A001
Shirakawa, Toshiro.....	B114
Shisler, Joanna.....	A219
Shklovskaya, Elena	A154

Shmulevich, Ilya	B051
Shoda, Kayoko.....	A001, A017
Shohara, Lisa.....	A022
Shorr, Jolene S.	A018
Shukla, Sachet A.....	A010
Shuman, Stewart.....	B106
Siena, Salvatore.....	B069
Sierra, Jorge	A023, A028
Šilanskas, Mantas	A119
Silina, Karina.....	A113
Silk, Tarik	A125
Silke, Frenz	A037
Šimon, Petr	B147
Singh, Jaskirat	A073, A074
Singh, Mallika.....	A103
Singh, Hema	A124
Sirait-Fischer, Evelyn	A209
Sirard, Cynthia	A225
Siravegna, Giulia	B069
Skobe, Mihaela.....	B156
Skoulidis, Ferdinandos	A059
Slagter, Maarten	B022
Slaney, Clare Y.	A047/PR6, A048
Slomovitz, Brian.....	A022
Slotta-Huspenina, Julia.....	A092
Smeland, Erlend Bremertun	A035
Smits, Anja.....	A159
Smith, Derek E.....	A117
Smith, Ernest S.....	A068
Smith, Jan A.....	A103
Smith, Paul D.	A125
Smits, Evelien L.....	B137, B192
Smoragiewicz, Martin	B207
Smyth, Mark J.....	A208
Snyder, Kristin M.	A051
Snyder, Mark.....	B153
Sobral, Miguel C.	B045, B119
Soetopo, Devona	A092
Solomon, Isabelle	A192
Soltermann, Alex	A113
Song, Chanyoung	B126, B133
Song, Chen	B046
Song, Christina	B146
Sonnenberg, Gregory	A075
Sonner, Jana K.....	B075
Sonpavde, Guru P.	A008
Sorger, Peter K.	A082

AUTHOR INDEX

Soriano, Ferdie	A162
Spadaro, Francesca.....	A091
Spallanzani, Raul German.....	B065
Spataro, Clarissa	B003
Speak, Anneliese O.....	B145
Speiser, Daniel	A070
Spicer, James F.....	A095
Spiegelman, Bruce	B062
Springer, Sebastian	B049
Srinivasan, Srimathi	B063
Sroka, Ewa Maria.....	B187
Stacey, Andrea.....	A214
Stanger, Ben Z.....	A054
Stanton, Rick.....	A124
Starr, Renate.....	A045
Starrach, Victor	A086
Steen, Jeff.....	B013
Steiger, Katja.....	B098
Stein, Stefan	A111
Steinberg, Gary D.....	B089
Steinert, Elizabeth M.....	B067
Stemeseder, Felix	B131
Stenger, Dana	A043, A224
Stephens, Geoffrey.....	A015
Stern, Patrick.....	B047
Sternberg, Luise A.....	B090
Steuer, Conor	B176
Stevanovic, Stefan.....	A020, B124
Stief, Tanja.....	A043
Stoddard, Rachel	B085
Stoitzner, Patrizia.....	A102
Stolley, J.	B182
Stone, Everett	B008
Straten, Per Thor.....	A020, B020, B036
Stratford, Richard	B073
Stratton, Michael.....	B022
Strauch, Pamela	A202
Strauss, Bryan E.....	B134
Strecker, Maja.....	A111
Stroncek, David	A004
Strønen, Erlend.....	A024
Stump, Michael T.....	B026
Sturm, Marc	B124
Su, An	A155
Su, Lihe	A040
Su, Mei-Ju	A082
Su, Shicheng	A155

Suarez-Carmona, Meggy	A069, A086, A114, A171
Šubr, Vladimír.....	B147
Sullivan, Ryan J.	A082
Sullivan, Kevin M.	A156
Sun, Cheng-Ming	PR3
Sun, Chong	B188
Sun, Chuang	A025
Sun, Dexue.....	A220
Sun, Jing.....	A010
Sun, Jong-Mu.....	A138
Sun, Luo.....	B046
Sun, Xiang.....	A014
Sunkari, Vivekananda	A012
Surendran, Siju	A169
Suri, Vipin.....	A220
Sutanto-Ward, Erika	A101
Suter, Manuel Adrian.....	B189
Suzuki, Hiroyuki.....	B160
Svane, Inge Marie	A079, B015, B022, B039, B049, B092, B154
Swartz, Melody A.	AB130
Sweis, Randy F.	FB089
Symonds, Peter	B102, B104
Synder, Alexandra	A215
Szabo, Peter	B153
Szallasi, Zoltan.....	B092, B129
Sznol, Mario.....	A006
Szomolay, Barbara	B007

T

Tabatabai, Ghazaleh.....	A020
Tabi, Zsuzsanna.....	B007
Tackett, Alan	B048
Tada, Takuya.....	B121
Tagawa, Scott T.	B193
Tai, Yu-Tzu	B100
Takashi, Kojima.....	A017
Takenaka, Katsuto	B031
Talele, Nilesh P.	A115
Tamhane, Tripti.....	B039, B049
Tamir, Ami	A076
Tamoutounour, Samira	PR16
Tamura, Rodrigo	B134
Tamzalit, Fella	B190
Tan, Daniel	B161
Tan, Joanne B.L.....	A124, A157, A162
Tan, Lin.....	A059

AUTHOR INDEX

Tan, Nikki Yi Jie.....	B189
Tan, Xiaojun.....	A116
Tanay, Amos.....	B054
Tang, Bingtao.....	A219
Tang, Cha-Mei.....	A012
Tang, Dean.....	A084
Tang, Jun.....	A019
Tang, Matthew.....	B101
Tang, Patricia.....	B207
Tang, Qin.....	A218
Tang, Xudong.....	A180
Taniguchi, Ruth.....	A034, B115
Tanimoto, Kazushi.....	B031
Tannir, Nizar M.....	A016
Tap, William D.....	A002, A007
Tartour, Eric.....	A172
Tassa, Carlos.....	A188
Tatsumi, Maho.....	B114
Tavernier, Jan H.....	A158
Tay, Rong En.....	A146
Tchaicha, Jeremy.....	B008
Teng, Michele W.L.....	A208, B024
Terui, Ayu.....	B160
Tewari, Ashutosh.....	A005
Thapa, Puspa.....	B153
Theriot, Julie.....	B194
Thomas, Beena.....	B085
Thomas, Charlene.....	B193
Thomas, Gareth J.....	B139
Thomas, Paul.....	A189
Thommen, Daniela S.....	B050
Thompson, Jill.....	A029, A133, B138
Thompson, John F.....	A154
Thompson, Michael J.....	A097
Thorgrimsen, Stephan.....	B093
Thorsson, Vesteinn.....	B051
Thummalapalli, Rohit.....	A082
Thurston, Gavin.....	A062, A174
Thyagarajan, Bharat.....	A008
Tian, Feng.....	B013
Tiersten, Amy.....	A005
Tijera, Dalissa.....	A018
Timpson, Paul.....	A100
Tinari, Antonella.....	A091
Tipton, Barbara.....	B013
Tirado-Gonzalez, Irene.....	A092
Tirosh, Itay.....	A082

Tiwari, Raj K.	B174
Tobin, Richard P.	A117
Toebes, Mireille	B022
Tokita, Serina	B007, B018
Too, Chien Tei	B189
Torigoe, Toshihiko	B007, B018, B135
Torno, Sebold	A068
Torres, Raul M.	A202
Toth, Marta	B153
Toulmonde, Maud	PR3
Toy, Dean	A027
Trajanoski, Zlatko	A102
Tran, Bao	A201
Tran, Eric	B055
Tran, Karen	A220
Tran, Thi	A172
Tran-Quang, Christine	A092
Traugh, Nicole	A077, B077
Tremblay, Michel L.	B035
Trepel, Jane	A004
Tripathi, Shubhita	B189
Tripp, Christoph H.	A102
Trivedi, Trupti	A002, A007
Tsai, Hsing-Chen	A221
Tsai, Wan-Chen	B082
Tsang, Victoria	A160
Tsankova, Nadejda	B088
Tsoka, Sophia	A095
Tsoucas, Daphne	A146
Tsuchikawa, Takahiro	A118
Tu, Dongsheng	B207
Tucci, Fabio Giovanni	B105
Tuit, Sander	A128
Tullett, Kirsteen	B125
Tummers, Bart	A102
Tung, David	A011
Turner, Gemma	B145

U

Uehara, Tomoya	B160
Ueno, Takashi	A118
Uhlik, Mark	A057
Ulge, Umut Y.	B023
Ulges, Alexander	A015, A020
Ulrich, Alexis	A171
Unnikrishnan, Ashwin	B129
Uozaki, Ryo	B177

AUTHOR INDEX

- Urakawa, Shinya.....B191
Urton, AlisonB207

V

- Vaccaro, Alessandra.....A159
Vadakekolathu, Jayakumar.....B118, B152
Vaghela, Poonam.....B102, B104
Vaidyanathan, BharatB162
Valand, KarishmaA160
Valeta-Magara, Amanda.....A222
Valous, Nektarios A.....A114, A171
Van Acker, Heleen H.B137, B192
van Akkooi, Alexander C.J.B054
Van Allen, Eliezer M.A082
Van Bulck, MathiasA100
van Buuren, Marit M.B022
Van Calenbergh, SergeB136
Van Damme, HelenaA083
van den Berg, JoostB022, B205
van den Braber, Marlous.....B022, B050
van den Broek, Marlies.....A113
Van den Bulk, Jitske.....A186, B094
van der Breggen, Ruud.....A063, B094
van der Burg, Sjoerd S.H.....A020, B094, B117
van der Heijden, MichielA113
van der Lee, Dyantha I.A044
van der Leun, Anne.....B054
van der Steen, Dirk M.A044
Van Der Veeken, JorisA190
van Dijk, NickA113
van Eijck, Casper C.H.J.B117
Van Ginderachter, Jo A.A083
van Gulijk, Mandy L.....A164, A165
van Hall, Thorbald T.A164, A165, B111, B117
van Hooren, Luuk.....A128, A159
Van Kooyk, YvetteA110
Van Loenen, Marleen M.A038, A185
van Maldegem, FebeA145, A160
van Nimwegen, Menno M.....A164, A165, B117
van Rooij, NienkeB022
Van Tendeloo, Viggo F.B137, B192
Van Tine, Brian A.A007
van Unen, VincentA063
van Veelen, Peter A.A044
Van Winkle, Erin.....A002, A007
van Zon, MaaikeB205
Vande Walle, LieselotteA083

Vankemmelbeke, Mireille.....	A161
VanVlasselaer, Peter	A016
Varterasian, Mary	A011
Vaughan, Matthew J.....	B123
Vaynrub, Anna.....	B058
Veelken, Hendrik.....	A044
Velchetti, Vamsidhar	A225
Velds, Arno	B022
Vemuri, Kiranmayi	A089
Venhaus, Ralph.....	A006, A022, B209
Venkat, Shree.....	A018
Vennin, Claire.....	A100
Verbeke, Catia S.....	B045
Verbeke, Rein.....	B136
Verdegaal, Els M.E.....	A186, B094
Verma, Rakesh.....	A016
Versluis, Michel.....	B151
Versteven, Maarten	B137, B192
Vezys, Vaiva.....	B182
Viborg Petersen, Nadia.....	B036
Vickers, Michael.....	B207
Vignali, Dario A.A.....	A053
Vijayanand, Pandurangan	B090
Vile, Richard	A029, A133, B138
Villalobos, Pamela	A059
Villanueva, Augusto	B071
Villatoro, Tatiana	A101
Virkud, Yamini V.....	A216
Visser, Marten	B094
Vitale, Rosa.....	B105
Vitaly, Kochin	B018
Vlachostergios, Panagiotis J.....	B193
Voabil, Paula.....	B050
Volaric, Jana.....	B149
Volovitz, Ilan.....	A021
Volta, Viviana.....	A222
vom Baur, Elmar.....	B026
von Andrian, Ulrich H.....	B159
von Deimling, Andreas.....	PR15, A020, B075
von Scheidt, Bianca	A047
Vonderheide, Robert H.....	A054
Vorselen, Daan.....	B194
Vorwald, Victoria M.....	A117
Voskuilen, Charlotte.....	A113
Vowinckel, Jakob	B010
Vredevoogd, David W.....	B033
Vroman, Heleen H.	A164, A165, B117

AUTHOR INDEX

- Vuidepot, Annelise B001
Vujkovic-Cvijin, Ivan B068

W

- Wachtel, Carolin A092
Wada, Satoshi A017
Wada, Hisashi B191
Wagner, Beate A043
Waibel, Michaela A149
Wälchli, Sébastien A035
Walker, Nigel P.C. A124
Wallack, Marc B174
Walpole, Carina B125
Walter, Steffen A015
Walters, Matthew J. A157, A162
Walther, Tyler A215
Wang, Chuan B139
Wang, Chunlin B004
Wang, Dongrui A045
Wang, Guangchuan B095
Wang, Haiping A223
Wang, Hao A180
Wang, Hua B045, B053
Wang, Jiahu B106
Wang, Jing A059, A153
Wang, Lan A030
Wang, Mitchell S. B190
Wang, Ping-Huai A221
Wang, Shangzi A096
Wang, Shu A082
Wang, Sin-Ting B164
Wang, Yen-Chih B195
Wang, Yi A014
Wang, Yidao B139
Wang, Yifan B194
Wang, Yue A184, B130
Wang, Xiaoqing Shawn. A077
Wang, Xuchen B052
Wang-Gillam, Andrea A011
Wang-Rodriguez, Jessica A009
Warren, Sarah B006, B096
Webber, Beau R. A036
Weber, Jeffrey S. PR8, B207
Webster, Jamie A148
Wei, Kai-Lin A221
Weigand, Luise A214
Weigert, Andreas A209

Weight, Christopher J.	A008
Weinberg, Andrew D.	A186, B094
Weinberg, Samuel E.	B067
Weiner, Louis M.	A096
Weinkove, Robert	B103
Weiskopf, Kipp	A051
Weissman, Irving L.	A051
Weitmann, Maresa	A092
Welstead, Grant	A027
Wendel, Hans-Guido	A152
Weng, Lihong	A045
Weng, Nan Ping	A123
Wenthe, Jessica	A119
Whalley, Tom	B007
Wherry, E. John	A123, A166, A197, B012
White, Andrew	B006
Whiteley, Alexandra M.	B196
Wick, Wolfgang	PR15, A020
Wieder, Thomas	A080
Wijeyesinghe, Sathi	B182
Wildes, David	A103
Wilhelm, Jonas	A224
Wilky, Breelyn	A007
Williams, William V.	A012
Williams, Luke	B024
Willier, Semjon Manuel	A043, A224
Wilson, John T.	A187
Wilson, W. Casey	A147
Winder, Thomas	A113
Winter, Jordan M.	A101
Wiseman, Charles L.	A012
Wistuba, Ignasio	A059, A153
Withers, David	A075
Wolchock, Jedd D.	A006, A125, A225, B106
Wolf, Andrea S.	A005
Wolkers, Monika C.	A185
Wong, Deborah J.	A016
Wong, Kwok-Kin	A125
Wong, Phillip	A016, A225
Wong, Siew Cheng	A049
Wongthida, Phonphimon	A029, A133, B138
Wood, Lauren V.	A004
Woodham, Andrew W.	B149
Wortman, Jennifer	B063
Wouters, Anne K.	A038
Wright, Debbie	A214
Wright, Sarah	A045

AUTHOR INDEX

- Wu, Catherine J..... A010, B042
Wu, Christina..... A068, B176
Wu, Hao..... A132
Wu, Jianmin..... A100
Wu, Juan A030
Wu, Lan..... A040
Wu, Wei B188
Wu, Xiaopeng B200
Wu, Yi-Chieh A221
Wucherpfennig, Kai W. A082, A146, A176, B077

X

- Xavier, Pedro L.P. B011, B180
Xia, Leiming..... A014
Xia, Shiyu A132
Xia, Xiaofeng A026
Xia, Xiaoli B120
Xiang, Kehui B197
Xie, Tiancheng A210
Xin, Gang..... B200
Xing, Xiaofang A077
Xiong, Huizhong A120
Xu, Cheng..... B140
Xu, Hao B198
Xue, Wei B102, B104

Y

- Yadav, Bhagwan..... A130
Yakushijin, Yoshihiro B031
Yamaguchi, Hiroyuki B081
Yamazaki, Takahiro A150
Yamazaki, Takahiro B199
Yan, Wei..... B106
Yan, Yiyi..... B097/PR11
Yang, Lin..... A014
Yang, Ning B106
Yang, Weiwen A024
Yang, Xia A225
Yang, Xin A045
Yang, Yagai A120
Yao, Qizhi Cathy..... B141
Yasukawa, Masaki B031
Yates, Clayton A090
Yates, Kathleen B. A216
Ye, Lupeng B095
Yeo, Charles J. A101
Yeo, Theresa P. A101

Yeung, Raymond S.W.....	A156
Yi, Xiaohui.....	A059
Yin, FangFang.....	A124
Yin, Qian.....	B142
Ylosmaki, Erkko.....	B123
Yofe, Ido	B054
Yokoyama, Jason K.....	A032
Yong, Raymund.....	B088
Yoon, Charles H.....	A082
Yoshikawa, Toshiaki.....	A001, A017
Yoshimura, Akihiko.....	A178
Yossef, Rami	A175, B055
Young, Arabella.....	A163/PR7
Young, Katie A.....	B186
Young, Regina M.....	A123
Young, Sarah L.	B186
Youngblood, Ben	A189
Yu, Cheng-Chou	A200
Yu, Chong-Jen	A221
Yu, Chunsong.....	B143
Yu, Di	B110, B175
Yu, Shu-Han.....	A200
Yu, Wei.....	A031
Yu, Zhiyin	B141
Yuan, Guo-Cheng.....	A146, A176
Yuan, Zhou.....	PR8
Yuan, Ziqiang	B132

Z

Zacharias, Martin	B049
Zagaro, Elena.....	B003
Zamarin, Dmitriy	A022, A215
Zander, Ryan.....	B200
Zanetti, Cristiana.....	A091
Zang, Xingxing	A180
Zappasodi, Roberta	A225/PR1
Zauderer, Maurice.....	A068
Zekri, Latifa.....	A131
Zemmour, David.....	B065
Zeng, Xing.....	B062
Zervas, Dimitrios.....	A192
Zevin, Kristi.....	B006
Zhang, Conggang	A116
Zhang, David K.Y.....	B058
Zhang, Gao	A082
Zhang, Halle H.....	A011
Zhang, Kristen	A157

AUTHOR INDEX

Zhang, Li	B201
Zhang, Michelle	B008
Zhang, Shawn	B013
Zhang, Wandi	A010
Zhang, Wen	A174
Zhang, Wendy Ya Ling.....	B189
Zhang, Xin.....	B027
Zhang, Ying	B057
Zhao, Chen	B062
Zhao, Jingxia.....	A132
Zhao, Ronghua	B059
Zhao, Xiaoning	A124, A157
Zhao, Yongmei	A201
Zhao, Yunlong.....	A226
Zhong, Hong	A225
Zhong, Yi.....	A190
Zhu, Cheng	PR8
Zhu, Wei	A030
Zhu, Yu.....	A121
Ziccheddu, Giovanna.....	A091
Zidan, Mona F.	A106
Zidan, Abdel-Aziz A.	A106
Zimmer, Andrew	B085
Zippelius, Alfred.....	B050
Zoernig, Inka	A069, A086, A114, A171
Zuccolotto, Gaia.....	A046
Zurita, Juan	A089

INVITED SPEAKER INDEX

Name	Page No.
A	
Ahmed, Rafi	21
B	
Balachandran, Vinod P.	29
Bardelli, Alberto	26
Belkaid, Yasmine	32
Brown, Christine E.	25
G	
Gabrilovich, Dmitry I.	23
Greenbaum, Benjamin D.	29
Greenberg, Philip D.	25
H	
Hacohen, Nir	30
Haining, W. Nicholas	21
Hubbell, Jeffrey A.	23
Huh, 'Dan' Dongeun	30
Hwu, Patrick	26
I	
Irvine, Darrell J.	31
K	
Kochenderfer, James N.	24
M	
Mackall, Crystal L.	24
Melcher, Alan	28
Melero, Ignacio	24
Melief, Cornelis J.M.	27
Merad, Miriam	23
Metelitsa, Leonid S.	23
Moon, James J.	28
O	
Ottensmeier, Christian	21
P	
Pardoll, Drew M.	29
Porter, David L.	26

INVITED SPEAKER INDEX

Name	Page No.
R	
Restifo, Nicholas P.	21
Rizvi, Naiyer	29
Rosen, Antony	26
Rosenberg, Steven A.	24
S	
Sadelain, Michel	25
Sahin, Ugur	27
Savas, Peter	26
Schreiber, Robert D.	27
Schumacher, Ton N.	29
Seder, Robert	28
Sharma, Padmanee	22
T	
Turley, Shannon J.	23
W	
Wargo, Jennifer A.	31
Wu, Catherine J.	27
Z	
Zarour, Hassane M.	31

SUBJECT INDEX

2-Hydroxyglutarate	PR15
3D culture.....	A049
4-1BB.....	A183
4-1BB/4-1BBL.....	A076
4-1BBL	A119
$\gamma\delta$ T cells	A169

A

A2A receptor.....	A194
A2aR/A2bR	A162
AB928.....	A162
Abscopal antitumor effects	A136
Abscopal effects	A050
Abscopal response.....	A150
ACTR707	A003
Acute lymphoblastic leukemia	A106
Acute myeloid leukemia	A044
Adaptive immunity.....	A103
Adaptive T-cell therapy.....	A007
Adaptive thermogenesis	B062
Adeno-associated virus	A036
Adenosine	A162
Adenosine pathway	A157
Adenovirus.....	B052, B123, B134
Adipose tissue	B065
Adjuvant	A005, B103, B119
Adjuvant booster	B143
Adjuvant delivery.....	B017
Adoptive cell transfer	A015, B015, B039, B098, B205, PR5
Adoptive cell transfer immunotherapy	A093
Adoptive T-cell therapy	A002, A185
Adoptive T-cell transfer	A067, A219
Adoptive TIL therapy.....	A186
Adoptive transfer therapies.....	B035
Advanced prostate cancer	B193
Agonist.....	B026
Agonistic antibody	A126
Agonistic CD40 immunotherapy.....	A128
Allogeneic	A024, B117
Allogeneic dendritic cells	B110
Alloreactivity.....	A043
AM0010.....	A016
Androgen deprivation therapy	A084
Angiogenesis	A121
Angiosarcoma.....	B085

SUBJECT INDEX

Angiotensin	A115
Animal models.....	B187
Antibody.....	A147, A161, A183, B032, B113, B149, B152
Antibody effector functions	A095
Antibody mimetics.....	B147
Antibody therapy.....	A140
Antibody-drug conjugate	B149
Anticancer.....	B040, B041
Anti-CTLA-4	A125, A142, A205
AntiGD2	A013
Antigen	B078, B184
Antigen density sensing	A031
Antigen presentation.....	B058, B167
Antigen presenting cell.....	B149
Antigen processing	B018
Antigen-specific T cells.....	B014, B100, B110
Anti-inflammatory lipids.....	B064
Anti-LAG-3 antibody	A174
Anti-PD-1	A130, A138, A205, B081, B095, B107, B112
Anti-PD1 checkpoint	B178
Anti-PD-L1.....	A120
Anti-TNF	B154
Anti-tumor immunity.....	A209
Antiviral signaling	A122
APOBEC3	A133
APOBEC3B	B138
Apoptosis.....	A079, A102, B009, B120
Artificial antigen presenting cell	B039
Artificial intelligence	B028
Aryl hydrocarbon receptor (AHR).....	PR15
ATAC-seq.....	B012
Autoimmunity.....	A163/PR7
Autologous tumor cells vaccine.....	B112
Autologous vaccine.....	B208
Automation.....	B016
Autophagy	A150, B120
Autopsy	A048

B

B cell lymphoma	B099
B cells	A106, B113B196
B7H1	A210
Bacteria.....	B178
Bacteriolytic	A011
Barrett's esophagus	B144

Base editor.....	A036
BCG.....	B087
BI 1361849 vaccine	B209
Bifidobacterium.....	B114
Bile duct cancer	A118
Bioinformatics.....	B073
Bioinformatics pipeline	B079
Biomarker.....	B006, B010, B048, B070, B081, B096, B206
Biomaterial	B043, B058, B119
Biomaterial scaffolds.....	B045
Biomechanics.....	B194
Biophysics	B169
Bispecific antibody.....	A088, A140, B031
Bisphosphonate	A169
BITE.....	B013
Bladder cancer	A137, B087, B089, B157
BLT (bone marrow, liver, thymus) model.....	B165
Bortezomib.....	B158
Brain metastasis.....	A111
Brain tumor.....	A021, A045
Breast cancer	A012, A081, A090, B036, B112, B185
Breast cancer immune-modulation.....	B057
Broadly neutralizing antibodies	B109
Brown fat.....	B062

C

Calreticulin	A072
Calreticulin mutations	B072
Cancer	A097, A176, A197, B103, B127, B152, B172
Cancer and chronic infection mouse models	B038
Cancer immunology.....	A177
Cancer immunoprevention	B111
Cancer immunotherapy	A035, A069, A112, A169, A181, A223, B020, B027, B049, B095, B097/PR11, B116, B129, B133, B142
Cancer patients	A207
Cancer prevention	B135
Cancer stem cell.....	A093, A106
Cancer stem cell antigen	B135
Cancer stem/initiating cell	B007
Cancer therapy	A209
Cancer vaccine	A004, A010, A017, A070, A172, A204, B045, B053, B079, B090/PR12, B100, B105, B114, B115, B119, B128, B135, B139
Cancer vaccine design	B042

SUBJECT INDEX

- CAR T cell..... A003, A023, A026, A028, A029, A031, A032, A035, A040, A041, A042, A046, A047/PR6, A089, A152, A178, B029, PR5
- Cardiotoxicity..... B134
- CAR-pNK..... A014
- Cas9 A036
- Caspase-8 A083
- CD137..... A183
- CD19-CAR T cells A043
- CD1d..... A151
- CD25 A141, A192
- CD276 B7-H3 A131
- CD28 A207
- CD30 A028
- CD38 A059
- CD39 A138
- CD3-Folate..... B013
- CD4 help..... B200
- CD4 T cell..... A201, B102
- CD4 tumor-infiltrating lymphocyte..... A053
- CD40 A126, A159
- CD40L..... A119
- CD47 A051, A088, A147
- CD56 B192
- CD58 B188
- CD73 A157
- CD8 T cell..... A176, A186, A196, B066, B097/PR11, B162, B200
- CD8+ T cell..... A016, A124
- CD8+PD-1+ T cell..... A212
- CD80 A093
- Cell adhesion..... A195
- Cell recruitment..... A195
- Cell therapy A027, A040, B037
- Cell-based immunotherapy B110
- Cell-free reconstitution A226
- Cellular therapy A034
- cfDNA..... B207
- cGAS B189
- Checkpoint..... A180
- Checkpoint antibodies B128
- Checkpoint blockade..... A050, A052/PR4, A159, A202, A216, B122, B136, PR8
- Checkpoint inhibition B121
- Checkpoint inhibitor A208/PR2, B091, B096
- Checkpoint molecules A191

Chemokine.....	A081
Chemokine modulation.....	B203
Chemokine receptors	A081
Chemotherapy	A106, A135, B091
Childhood recall antigen	B132
Chimera receptors	B044
Chimeric antigen receptor	A025, A037, A045, B031
Chimeric virus	B098
Chlorin e6.....	A141
Chromatin accessibility and gene expression.....	B038
Chronic infection.....	A197
Chronic viral infection	B200
Circulating tumor cells (CTC).....	A012
Cis and trans interaction.....	A226
Citrulline	B102
Clinical biomarker.....	B030
Clinical outcomes.....	B176
Clinical trial	A004, A014
Clonality determination	B046
Clostridium	A011
CMTM6	B188
Coculture.....	B159
CODEX	A073, A074
Cohesin	B171
Coley's toxins	B178
Colitis-associated cancer.....	A075
Colon cancer	B120
Colorectal cancer.....	A022, A061, A066, A075, B027, B066, B094
Colorectal cancer immunity.....	A063
Combination.....	B063
Combination immunochemotherapy.....	B199
Combination immunotherapy	A206, B126, B135
Combination therapy.....	A124, B142
Combinatorial treatment	A082
Combined immunotherapy.....	B112
Commensal.....	B184, PR16
Community resource	B051
Complement.....	A097
Complex I	B067
Computational protein design.....	B023
Corticosteroids	A113, B154
CRISPR	A065, B095, B113, B145
CRISPR/Cas9	A043
CRISPR-Cas9 screen	A146
Cross-presentation	B186
Cross-reactivity	B060

SUBJECT INDEX

CTLA4.....	A149, A211, B083
CXCL12	B206
CXCR6	A172
CyTOF.....	A191
Cytokine multiplexes	A069
Cytokine release syndrome	A037
Cytokines.....	A117, A158, A206, B044
Cytolytic activity	B084
Cytotoxic innate lymphoid cells	A063
Cytotoxic T cell.....	A168
Cytotoxic T lymphocytes.....	B190

D

Damage-associated molecular patterns (DAMPs).....	A147, B199
Data exploration	B051
Deep profiling	A073, A074
Dendritic cell	A052/PR4, A056, A079, A102, A109, A110, A120, B119, B125, B137, B159, B173, B184
Dendritic cell manipulation.....	B053
Dendritic cell vaccination.....	A056, B117
Dendritic cell vaccine.....	B121
Destabilizing domain.....	A220
Developmental programming.....	B162
Diagnostics	B021, B096
Diversity.....	B153
DNA damage repair	A153
DNA vector	A042
DNA-barcoded multimers	B015
Dormancy.....	A144, A168
Driver oncogenes.....	B055
Drug resistance	B127
Dual signaling protein	A076
Durvalumab.....	A006, B209
DUSP22.....	B172

E

E2.....	B109
eATP	A173
EBV	B166
Efferocytosis.....	A098
EGFR.....	B172
EGFRt	A032
EL4	A039
Electroporation.....	A026
Elispot	B014

Endocytosis	B149
Endoplasmic reticulum (ER) stress	A056
Engineered heteroclitic peptide.....	B100
Engineered T-cell receptor.....	A027
Engineering non-native amino acids.....	B013
EOS100850	A194
Eosinophils.....	A091
EpCAM-aptamer conjugated small interfering RNAs.....	B057
Epigenetic immunotherapy	A184
Epigenetic modulation.....	B129
Epigenetic programs	A189
Epigenetic therapy	A221
Epigenetics	A197
Epigenomics.....	A078
Epithelial-mesenchymal transition (EMT)	B011, B180
Epitope.....	B007, B020
Epitope spreading	A010
Evasion.....	B145
Ex vivo models	B050
Exhaustion	A196, B012
Expansion.....	B016
Extracellular matrix	A206
Extracellular vesicles.....	A091

F

Fat	A086
Fc receptor	A126
FFPE	A066, A074
Fibroblast activation protein	A096
First-in-human clinical trial.....	A021
Flow cytometry	A154
Fluorescence imaging	A074
Foxp3.....	A190
Functional genomics	A176

G

Gamma delta T cell	B062
Gammacell 40 exactor	B204
Gas6/Axl.....	A092
Gasdermin D	A132
Gastric cancer	B191
Gastroesophageal reflux disease (GERD)	B144
Gastrointestinal tumor	A161
GD2	A025
GD3	A204
Gel dosimetry	B204

SUBJECT INDEX

Gene expression.....	B047
Gene knockout	A062
Gene therapy.....	A018, A044
Generalized linear model.....	B038
Genetic engineering.....	B113, PR5
Genomics	B085
Germinal center.....	A113
GITR agonism	A225/PR1, A060, A108, B088, B116, B168, B175
Glioblastoma multiforme.....	B082, B122
Glioma.....	A078, A159, A219, PR15
Glucocorticoids.....	A218, B162
Glycolysis.....	B164
GPCR	B173
Gut microbes.....	B167
GvHD	B043, B183

H

Haploidentical stem cell transplantation	A013
HDAC inhibitor.....	A184
Head and neck squamous cell carcinomas (HNSCC).....	A198
Heat shock protein 105.....	A017
Helios.....	A039
Hematopoietic stem cell transplant	B043
Hepatitis C virus (HCV).....	B109
Hepatocellular carcinoma	A030, B109
HER2	A004
Her2	A032
Herpes simplex virus type-1 (HSV-1).....	B059
Heteroclitic.....	B138
Heterogeneity	A045, A077, B200
HIFU	B151
High endothelial venules (HEV)	A137, B144
Histone methyl transferase inhibition.....	B011
HLA class I epitope presentation.....	B042
HLA class I mono-allelic profiling by mass spectrometry	B042
HLA class I peptide	B018
HLA class I presentation prediction	B042
HLA ligand	B019/PR13
HLA peptidomics	B086
Homocitrullination.....	B104
Human endogenous retroviruses.....	B129
Human melanoma cells.....	A109
Human pharmakokinetic	A157
Humanized mice	A151

Humanized mouse model	B165
Humanized orthotopic mouse model.....	B027
Hydrogel.....	A148, B041
Hydroxyapatite	B208
Hypermutated cancers.....	B207
Hyperthermia.....	B041
Hypoxia.....	A041, A097

I

IAP antagonists	A129
ICOS.....	A200
ICOSL.....	A200
IDH	PR15
IDH2	B170
IDO	A101, A155
IDO1	B008, A128
IFN γ	B033
Ig sequencing	B046
IgE	A095
IkappaBzeta.....	A109
IL-10.....	A016, A079
IL-12	A220
IL-12p70	A079
IL-15.....	A025, A188, A219, A220, B137, B192
IL-1 β	A083
IL-2	A192, B023
IL-27.....	B202
IL-33.....	A091
IL-6	B189
Imaging mass cytometry.....	A160
Imiquimod.....	B164
ImmTAC	A214, B001
ImmTAC TM molecule.....	B024
Immune checkpoint blockade	A077
Immune.....	B185
Immune adjuvant.....	B106/PR9, B136
Immune balance.....	A122
Immune cell content	A112
Immune cell infiltration	A094
Immune checkpoint	A076, A085, A096, B034, B074, B105
Immune checkpoint blockade	A153, A179, A218, B095
Immune checkpoint combination therapy.....	A068/PR10
Immune checkpoint inhibition.....	B050
Immune checkpoint inhibitor	A182, B075, B084, B114, B160, B199
Immune checkpoint molecules.....	A118

SUBJECT INDEX

Immune checkpoint receptors.....	A174
Immune checkpoint therapy	A149
Immune escape	A155
Immune evasion.....	A065
Immune monitoring	B014
Immune privilege.....	A168
Immune profiling	B073
Immune receptor	B026
Immune regulation.....	A164, A165
Immune resistance	A093
Immune responses	B141
Immune suppression.....	A092, A192
Immune surveillance.....	B036
Immune synapse.....	B190
Immune therapy.....	A152, B208
Immune tolerance.....	A163/PR7
Immune-related adverse events.....	A163/PR7, B032, B154
Immunity	B068
ImmunoBody	B122
Immunocytokines	A131
Immunoengineering.....	A148, B058
Immunofluorescence	A073, B005
Immunogenic cell death	A098, A147, B045, B134, B151, B164, B177, B181, B186
Immunogenicity prediction	B093
Immunogenomics	B071
Immunology	A145, A156
Immunome.....	B080
Immunometabolism.....	A223, B065
Immunomodulatory	B034
Immunomonitoring	A015, A020
Immuno-oncology	A018, A095, A194, B051, B084, B127
Immuno-oncology tools	B009
Immunopeptidomics.....	B080
Immunosuppression.....	A099, B133
Immunosuppressive cytokines	A191
Immunotherapeutic resistance.....	A208/PR2

Immunotherapy.....	A004, A005, A008, A009, A010, A011, A013, A018, A024, A037, A039, A048, A052/PR4, A054, A059, A111, A114, A123, A131, A134, A135, A137, A142, A143, A154, A156, A158, A164, A176, A180, A182, A183, A189, A196, A211, B003, B022, B024, B030, B040, B041, B048, B052, B055, B059, B063, B071, B077, B078, B083, B091, B094, B103, B107, B111, B117, B121, B123, B124, B132, B140, B152, B157, B161, B174, B175, B176, B180, B207, PR8
Immunotherapy resistance	A082
Immunotoxins	A142
Implantable scaffold	B126
Imprime	A057
In situ profiling.....	B006
In situ vaccination.....	B106/PR9, B128
In vitro preclinical testing.....	A214
In vitro tumor-killing.....	B154
Indoleamine 2,3-dioxygenase.....	A101
Inflammasome.....	A083, A132
Inflammation.....	A148
Inflammatory.....	A101
Inflammatory cell death.....	A161
Inflammatory signaling	B083
Inhibitory receptors.....	A202
Innate.....	A181, B146
Innate immunity	A122, B150, B195
Innate lymphoid cells	A075
Interaction test	B077
Interferon	A108, A158
Interferon-stimulated gene (ISG)	B163
Intestinal.....	A170
Intestine.....	B146
Intraepithelial lymphocytes (IEL)	B144
Intratumoral regulatory T cells	A223
Intrinsic immunity.....	A187
Invariant natural killer T cells	A151
IO target	B033

K

Killer immune cells	B192
KRAS.....	A145
KRAS.....	A175
KRAS mutant lung cancer.....	A125
Kynurenone.....	B008

SUBJECT INDEX

L

- LAG-3 B076
Landscape analysis A019
Larp1 B155
Lattice light-sheet microscopy B148
LDH-A A089
LDH-A knockdown A089
Lentiviral vectors B121
Leukemia A024, A092
LFA-1 B183
Library B138
Lineage-tracing A055
Lipid messenger A116
Lipids A202
Listeria A170
Listeria monocytogenes A151
Live unattenuated tumor cell vaccine A021
Local immunotherapy A206
longitudinal study A019
Long-term survival A117
Loop domain B099
Low mutation burden B094
LOX A060
LPA A202
LPS B197
Lung cancer A059, A145, A160,
A221, B161, B180, B202
Lymph node A164, A165
Lymph node targeting B053
Lymphangiogenesis A086
Lymphatic vessels B130
Lymphocyte A110
Lymphocytic choriomeningitis virus (LCMV) B131
Lymphodepletion A007
Lymphoid organ neogenesis A113
Lymphoma A003, B170, B196

M

- Macrophage A049, A055, A060, A114,
A127, A155, A165, B075,
B179, B194, B197, B201
Maraviroc A114
Mass spectrometry A066, B010, B019/PR13, B086
Matrix metalloproteinase-2 A109
Matrix metalloproteinase-2 (MMP2) A104
MCL B158
MDA5 A122

MDSC	A054, A117, B104, B191
Mechanopotentiation	B190
MEDI4736	A006
Medulloblastoma	A032
MEK inhibition	A125
Melanoma	A051, A070, A102, A104, A117, A119, A130, A134, A173, A204, B005, B015, B048, B054, B063, B068, B097/PR11, B108, B130, B156, B162, B174, B202, B205
Melanoma therapeutic vaccine	A144
Memory stem T cells	A023, A028
Memory T cell	A175, A205
Merkel cell carcinoma	B020
Mesenchymal stem cell	A087
Mesoporous silica nanoparticles	B140
Mesothelin	A088, B141
Metabolic sugar labeling	B053
Metabolism	A152, B067
Metastasis	A127
Methods	B029
Methylation	B084
MHC and antigen presentation	B091
MHC class I	A168, B011, B049
MHC multimers	B049
MHC-I	B180
MHC-I antigen presentation	B187
Microbiome	B060, B063, B066
Microbiota	A170, B066, B068, PR16
Microenvironment	A048, A077, B021
Microfluidics	A049
Microvilli	B148
Minimal residual disease	B046
MIRA	A034, B115
Mismatch repair	B069
Mitochondria	A173, B067
Modified vaccinia virus ankara	B106/PR9
Molecular vaccine	B143
Monoclonal	B152
Monoclonal antibodies	A095
Monocytes	A057, A108
Monte Carlo methods	B204
Mouse models	A160
MRI assessments	B030
mRNA vaccination	B136
mRNA vaccine	B116
mTOR	B155

SUBJECT INDEX

mTORC1	A222
MUC1	A014
Mucosal-associated invariant T (MAIT).....	PR16
Multiple myeloma	B100, B177
Multiplex imaging	B025
Muscle-invasive bladder cancer	A008
Mutation	B073, B092
Mutation load.....	B070
Mutational analysis.....	B093
Mutational burden.....	B069
Mutations	B022
Myb	A149
Myc-CaP.....	A089
MYCN.....	A213
Mycobacterium tuberculosis	B201
Myeloid.....	A078
Myeloid cells.....	A083
Myeloid suppression	A084
Myeloid suppressor cells.....	A017
Myeloid-derived suppressor cells	A099, A138, B003
Myeloma	B031
Myeloproliferative neoplasms.....	B072
Myofibroblasts	A100

N

Nano-adjuvants	B133
Nanofiber	B040
Nanoparticle.....	B116, B136
Nanoparticle delivery system.....	B017
NanoString.....	B096
Nanotechnology.....	A169
Natural killer cells	A039, A052/PR4, A065,
	A085, A096, A130, A135, A181, A191,
	A204, B044, B145, B153, B157
NCAM	B192
NCCV cocktail-1	A001
Necroptosis.....	B134
Neoadjuvant	A008
Neoadjuvant immunotherapy	A208/PR2
Neoantigen	A005, A010, A044, A175, A217,
	B018, B022, B060, B069, B073, B079, B080,
	B086, B090/PR12, B092, B094, B105, B108,
	B111, B115, B124, B187
Neoepitope	B019/PR13, B070, B071,
	B089, B093, B108
Neuroblastoma.....	A013, A025, A080, A087,
	A131, A140, A213

Neuroimmunology	B159
Neurotoxicity.....	A152
NF- κ B	B150
NGS analysis.....	B070
Nivolumab.....	A008, B052
NK92.....	A046
NKG2A	A198
NKT cell.....	A130
Nociceptors	B159
Noncoding RNA	B018
Non-human Great Apes (GAds) Adenovirus.....	B105
Non-small cell lung cancer.....	A055, A138, A182, A185, B010, B081, B209
Novel anti-neoplastic agent	B199
Novel immunotherapy.....	B034
NOX-A12.....	B206
Nr4a	A178
NT219	B127
NY-ESO-1.....	B031

O

Oncolytic	B123
Oncolytic adenovirus.....	A119
Oncolytic poxvirus.....	A219
Oncolytic virotherapy.....	B175
Oncolytic virus.....	A022, A029, A133, B059, B098, B101, B107, B181
OncoPeptTUME	A112
Oral cancer.....	A167
Ovarian cancer.....	A022, A056, A069, B013
OX40L.....	B106/PR9

P

PAMP	A057
Pancreatic adenocarcinoma	A156
Pancreatic cancer	A050, A054, A100, A115, A123, A129, B117, B141
Pancreatic ductal adenocarcinoma.....	A096
Pattern recognition receptor.....	B195
PD-1.....	A014, A103, A110, A196, A207, A210, B002, B097/PR11, B165
PD-1 blockade	A154, A225/PR1, B072
PD-1 combination trial.....	A019
PD-1 inhibitor.....	A184
PD-1 resistance	PR8
PD-1/PD-L1 immune checkpoint molecules	B027
PD-1/PD-L1-biology	A164
PD-1+/CD8+ ratio.....	B082

SUBJECT INDEX

PD-L1.....	A022, A118, A155, A210, B075, B168, B172, B188, B193
Pediatric hematology	A224
Pediatric oncology	B124
Pediatric solid tumors	A001
Pegilodecakin.....	A016
Pembrolizumab	B012, B161, B203, B206
Pepinemab.....	A068/PR10
Peptide transporter TAP.....	B111
Peptide vaccination	A001, A020, B124
Peptide-MHC.....	B039
Peptidome	B007
Peripheral T-cell lymphoma.....	A028
Personalized immunotherapy	A015, A020
Personalized vaccine	B080, B089, B140
PET imaging	B140
Phagocytosis.....	A051, A098, B194
Pharmacodynamics.....	A012
Pharmacokinetics	B160
Phase I trial	A001, A009, A020
Phenotypic screening	A099
PhIP-seq	B032
Phosphatases.....	B035
Photodynamic therapy.....	A141, B017
Photomodification.....	B147
Photothermal	B040
Pilot clinical study	B208
Pioneer translation products.....	B187
PKCeta.....	A211
Platinum chemotherapy	B193
PLX4032	B174
PMEL.....	A188
POLE/D1.....	B207
Poly(A) tail.....	B197
Postoperative	B191
Post-translational modification	B104
Post-translational modification of CD47	A143
Potency assay	B074
Poxvirus	B107
PPAR γ	B064
Precision immunotherapy	B090/PR12
Preclinical characterization.....	A157
Preclinical study	B059
Predictive biomarkers	A082, B193
Proliferation.....	B044
Prostate cancer	A009, A046, A084, B003, B118
Prostate cancer treatment	B007

Proteasome	B196
Protectin D1	B064
Protein design.....	B002
Protein engineering.....	B037
Proteomic.....	A066, B048, B064
Proximal signaling	PR8
Pseudoprogression.....	B161
PSMA	A046, B147
Pyroptosis	A132

Q

Qa-1.....	A039
QPCTL	A143

R

Radiation therapy	A150, B165
Radiation-induced ICD-based DC vaccine.....	B082
Radiochromic film	B204
Radiosensitivity gene signature.....	B168
Radiotherapy.....	A111
RAG chromatin scanning.....	B099
RAG tracking.....	B171
Raman spectroscopy.....	B028
Rapamycin	A222
Receptor occupancy.....	A124
Recovery of exhausted T cells (Trecov)	A166
Redirected T cell killing.....	A214
Regulatable degradation.....	B126
Regulation.....	A220
Regulatory T cell	A039, A141, A167, A177, A190, A192, A199, A203, A211, A222, A225/PR1, B065, B156
Renal cell carcinoma.....	B092
Residence.....	B153
Resident memory T cells	A172
Resistance	A059
Resistance to immunotherapy	A146
Retroviral replicating vector.....	A018
RIG-I.....	A187
Risk factors	A163/PR7
Rituximab.....	A003, B158
RNA FISH	B025
ROR γ t	B198

SUBJECT INDEX

S

- Scavenger receptors.....A017
Screening A065, B074
scRNAseq immune profiling.....A201
scRNAsequencing A055
Self-antigen specific CD8+ T cellsB142
SEMA4D..... A068/PR10
Semliki Forest virus.....B175
Senescence A080
Sepsis A132
Sequential treatment.....B176
Serum B032
Serum antibody against CT antigensB081
Shared oncogenic mutationsA175
Shared tumor neoantigensB072
SHP2 A103
Signaling.....B183
Single cell and imaging mass cytometry.....A063
Single-cell sequencingB024
Single-cell transcriptomicsA121
Single-cell.....A078
Single-cell RNA sequencingA134
Single-cell RNA-seqB054
SIRPa/CD47A076
SkinB068
SLIT-ROBO pathwayA100
Small-molecule inhibitors.....B035, B174
Small-cell lung cancerA153
Soft tissue sarcoma..... PR3
SoftwareB093
Solid tumor..... A006, A041, A047/PR6
Spatial analysisB005
Spherical nucleic acid.....A136
Sphingosine-1-phosphate.....A209
Stem cell.....A108
Stimuli-responsive delivery system.....B017
STINGA050, A061, A116, B150, B189
Stroma.....A115
SV-BR-1-GMA012
Switch.....B047
SynergyA161
Synovial sarcoma..... A002, A007
Synthetic biology.....A031
Synthetic immune nichesB133

T

T cell	A011, A024, A036, A070, A087, A102, A134, A140, A156, A165, A181, A187, A207, A217, B014, B020, B022, B029, B043, B049, B058, B078, B092, B118, B129, B170, B182, B183, B202
T cell coreceptor	A226
T cells transcriptome	A144
T regulatory cell	B067
T-ALL	A149
TAM receptors.....	A092
Target identification.....	B147
Targeted.....	B026
Targeted therapy.....	A129
TBK1	A116
T-cell activation.....	A128
T-cell costimulation	A129
T-cell differentiation.....	A123, A215
T-cell dysfunction	B038
T-cell engineering	A030
T-cell epigenetics.....	A216
T-cell exhaustion	A166, A173, A178, A182, A184, A189, A197, A208/PR2, A216, A221, A224, A225/PR1, B012,
T-cell immunology.....	A067, A185
T-cell infiltration	A171
T-cell monitoring.....	A171
T-cell polyfunctionality.....	A221
T-cell receptor.....	A002, A007, A030, A034, A039, A212, B004/PR14, B024, B086, B148, B205, PR5
T-cell receptor affinity	A217
T-cell receptor discovery	B075
T-cell receptor knockout.....	A043
T-cell receptor repertoire	A186
T-cell receptor sequencing	B046, B115
T-cell receptor transgenic mice	B065
T-cell receptor-based immunotherapy.....	A214
T-cell receptor-seq	B054
T-cell recognition	B036
T-cell therapy	A188, B023
T-cell tolerance	B019/PR13
TCGA.....	B076, B089, B168
TDO2	B008
Technology	B029
Temozolomide	B069
Tertiary lymphoid structure	PR3, A053, A113, A159

SUBJECT INDEX

- Th1-type immune response A136
Therapeutic antibody A062
Therapeutic monoclonal antibodies B009
Therapeutic resistance A133
Therapeutic vaccine A009
Three-dimensional imaging B025
TIGIT A124
TIM-3 A062, B157
TIPE2 B120
Tissue B153
Tissue homeostasis A203
Tissue imaging A073
Tissue resident memory CD8 T cells A170
TLR agonist B128, B143
T-lymphocyte A044
TNF A084, B033
TNFR1 signaling A094
TNF-Related Apoptosis Inducing Ligand B009
TNR2 A199
Tolerance B184
Toll-like receptor 9 agonist A136
Toll-like receptors (TLRs) A104, B178
Toxicity A126
Toxin peptide A045
TRAF2 B033
Trafficking A116
Transcription B155, B083
Transcriptome PR3
Transcriptomics B005
Translation A222, B155
Translational control B197
Translational regulation B163
Transparent tissue tomography (T3) B025
Transposon A026
Tremelimumab A006, B209
Triple-negative breast cancer (TNBC) A135, B057, B203
Tumor A217, B026
Tumor antigen discovery B142
Tumor antigens B074
Tumor cytotoxicity A091
Tumor endothelial cells A128
Tumor heterogeneity A040, B088
Tumor immunity A062
Tumor immunology A085, A160
Tumor immunotherapy A030, B102
Tumor lysates B186

Tumor microenvironment (TME).....	A017, A049, A054, A057, A067, A069, A070, A082, A086, A087, A097, A099, A100, A101, A104, A110, A111, A112, A115, A118, A137, A171, A216, A224, B003, B050, B126, B139, PR3
Tumor model.....	A171
Tumor mutation burden	B085
Tumor-reactive CD8 T cells.....	B015
Tumor reactivity	B054
Tumor vasculature	A121
Tumor-associated antigens	B036
Tumor-associated endothelial cells.....	A094
Tumor-associated leukocytes	A090
Tumor-associated macrophages.....	A017, A067, A103
Tumor-focused IO.....	B047
Tumor-infiltrating B cells	A053
Tumor-infiltrating lymphocytes (TIL)	A081, A085, A198, A201, B016, B039, B055, B082
Tumor-reactive	B016
Tumor-reactive T cells.....	A185, A186
Tumor-resident adaptive and innate lymphocytes	A063
Tumor-specific glycans	B034
Type I interferon (INF)	B189, B201

U

Ubiquitin.....	B196
Ultrasound	B037
Ultraspecific cancer targeting.....	B023
UV signature.....	B085
Uveal.....	B205
Uveal melanoma	B030

V

V(D)J recombination.....	B099, B171
Vaccination	A021, B103, B122
Vaccine.....	A005, A047/PR6, B104, B108, B118, B123, B125, B130, B131, B138, B141
Vaccinia.....	B101
VEGF-C	B130
Vesicular Stomatitis Virus (VSV).....	A133
Viperin.....	B163
Viral.....	B071
Viral particle	B139
Virus.....	A187
VX15/2503	A068/PR10

SUBJECT INDEX

W

- Web portal.....B051
Wilms' tumor 1.....B114
Wilms' tumor protein 1.....B137

Z

- Zebrafish.....A213